Covalent inhibitors of menin-MLL interaction for diabetes mellitus
Patent Information
- Application Number
- JP2024508318
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2022-03-07
- Filing Date
- 2022-08-10
- Publication Date
- 2024-11-11
- Estimated Expiration
- 2042-08-10
AI Technical Summary
Current treatments for diabetes mellitus, particularly type 2 diabetes, are inadequate in effectively reducing glycated hemoglobin (HbA1c) levels in patients, with approximately 50% of patients failing to reach the recommended target, leading to a significant unmet medical need.
Development of covalent inhibitors that target the menin-MLL interaction, specifically forming covalent bonds with the Cys329 residue in menin to inhibit the menin-MLL protein-protein interaction, which are designed to treat diabetes mellitus by modulating gene expression and improving glycemic control.
The covalent inhibitors demonstrate significant reductions in blood glucose levels, insulin levels, and glycated hemoglobin (HbA1c) in diabetic animal models, indicating potential therapeutic benefits for treating diabetes mellitus.
Smart Images

Figure 00000000_0000_ABST 
Figure 00000000_0001_ABST
Abstract
Description
[Technical field]
[0001] cross reference
[0001] This application claims the benefit of U.S. Provisional Application No. 63 / 232,154, filed August 11, 2021, No. 63 / 249,568, filed September 28, 2021, and No. 63 / 317,518, filed March 7, 2022, the contents of each of which are incorporated by reference in their entirety into this specification.
[0002] Field
[0002] Described herein are compounds that inhibit the activity of menin-MLL for the treatment of diabetes mellitus, methods for making such compounds, pharmaceutical compositions and medicaments containing such compounds, and methods of using such compounds and compositions. [Background technology]
[0003] background
[0003] Currently, the histone-lysine N-methyltransferase 2 (KMT2) family of proteins, which consists of at least five members, methylates lysine 4 on the histone H3 tail in key regulatory regions in the genome, thereby conferring important functions through the regulation of chromatin structure and DNA accessibility (Morera, Luebbert, and Jung., Clin.Epigenetics 8, 57- (2016)). These enzymes are known to play important roles in regulating gene expression during early development and hematopoiesis (Rao & Dou., Nat.Rev. Cancer 15, 334-346 (2015)).
[0004]
[0004] The human KMT2 family was originally named the mixed lineage leukemia (MLL) family because of the role of KMT2A, the first member discovered in the disease, and is still commonly referred to as MLL1 or MLL in routine clinical practice.
[0005]
[0005] KMT2A (MLL1) has been found to be frequently cytogenetically targeted in several types of leukemia (e.g., ALL and AML), and when balanced chromosomal translocations are found, these usually target KMT2A (MLL1) and one of the more than 80 translocation partner genes reported to date (Winters and Bernt, Front. Pediatr. 5, 4 (2017)). These chromosomal abnormalities often result in the formation of fusion genes that encode fusion proteins that are believed to be causally related to disease onset and / or progression. Inhibition of menin may be a promising strategy for treating MLL-related diseases, including diabetes.
[0006]
[0006] M-525 is a highly potent covalent small molecule inhibitor of menin-MLL protein-protein interaction. It forms a covalent bond with the Cys329 residue in menin. M-525 shows high cell specificity for non-MLL leukemia cells and is >30-fold more potent than the corresponding reversible inhibitors. See S. Xu et al. Angewandte Chemie International Ed. 57(6), 1601-1605 (2017).
[0007]
[0007] Diabetes mellitus, commonly referred to as diabetes, is a major global healthcare problem. As of 2019, an estimated 463 million people worldwide suffer from diabetes, with type 2 diabetes accounting for approximately 90% of cases. IDF Diabetes Atlas Ninth Edition, 2019. The proportion of women and men is roughly equal. Current proposed treatments include insulin (type 1 diabetes), as well as metformin, glucagon-like peptide 1 receptor agonists (GLP-1Ra), sulfonylureas, dipeptidyl peptidase 4 inhibitors (DDP-4I), thiazolidinediones, sodium-glucose cotransporter 2 (SGLT2 inhibitors), and insulin (type 2 diabetes). Despite these treatments, disease rates are rising, and the global economic cost of diabetes is estimated at US$727 billion in 2017. Despite the above-mentioned treatment options available for T2DM, approximately 50% of patients have glycated hemoglobin (HbA1c) levels above the recommended 7% target (CDC 2020), and thus, this condition remains an unmet medical need.
[0008]
[0008] New drugs are needed for the treatment of diabetes mellitus. Summary of the Invention [Means for solving the problem]
[0009] overview
[0009] Described herein are covalent inhibitors of the menin-MLL interaction for the treatment of diabetes mellitus. Also described herein are certain heterocyclic covalent inhibitors of the menin-MLL or MLL fusion protein interaction for the treatment of diabetes mellitus.
[0010]
[0010] Additionally, methods described herein include methods of synthesizing covalent inhibitors of menin-MLL or MLL fusion protein interaction, and methods of using such covalent inhibitors in the treatment of diseases, including diseases in which inhibition of menin-MLL interaction provides a therapeutic benefit to patients having the disease. Further described herein are pharmaceutical compositions comprising inhibitors of menin-MLL interaction. Specifically described herein are compounds that inhibit the interaction of menin with MLL oncoproteins (e.g., MLL1, MLL2, and / or MLL fusion oncoproteins) and methods of using the same.
[0011]
[0011] Specifically, described herein are covalent inhibitors of the menin-MLL interaction that form a covalent bond with a cysteine residue on menin. Further described herein are covalent inhibitors of the menin-MLL interaction that form a covalent bond with the Cys329 residue on menin. Also described herein are pharmaceutical formulations that include the covalent inhibitors of menin.
[0012] In some embodiments, there is provided a method for preventing, treating, or ameliorating a diabetic disease or condition in a mammal causally associated with aberrant activity of menin-MLL interaction in vivo, comprising administering to the mammal a therapeutically effective amount for the disease or condition of a compound according to formula (I), or a pharma- ceutically acceptable salt thereof, having the following structure: [ka] During the ceremony, A is carbon or nitrogen; Cy is a substituted or unsubstituted [ka] and; Q is nitrogen, -N(H)-, -O-, or -S-; Z is -CR 5a = or -N =; X is -NR 3a , -C(R 3b ) 2- or -O-; Y is a single bond, -NR 3a -, -C(R 3b ) 2 - or -O-; W is -C(O)-, -S(O)- or S(O) 2 - and; R 1 and R 2 One of them is Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6C ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6C ) and the other is hydrogen, C 1~6 Alkyl, C 1~6 haloalkyl, halo or CN; Cy 2 is an optionally substituted group selected from phenyl, pyridyl, or a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 3a and R 3b are independently hydrogen or C 1~6 is alkyl; Each R 4a and R 4b are independently hydrogen, halo, CN, OR, -N(R) 2 , -C(O)N(R) 2 , -NRC(O)R, -SO 2 R, -C(O)R, -CO 2 R or C 1~6 Alkyl, C 3~7 an optionally substituted group selected from cycloalkyl, a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R is independently hydrogen or C1~6 an optionally substituted group selected from aliphatic, phenyl, an 8-10 membered bicyclic aryl ring, a 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups on the same nitrogen together with their intervening atoms form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 5a is hydrogen, C 1~6 Alkyl, C 1~6 haloalkyl, halo or CN; Each R 6a and R 6b are independently hydrogen or C 1~6 is alkyl; or R 6a and R 6b come together to form a bond; R 6c is hydrogen or substituted or unsubstituted C 1~6 is alkyl; m is 1, 2 or 3; and n is 1, 2, 3 or 4.
[0013] In some embodiments, there is provided a compound according to formula (XXI) below, or a pharma ceutically acceptable salt thereof: [ka] During the ceremony, A, Cy, Cy 2 , R 4b , R 6a , R 6b , R 6c , m and n are as described for formula (I); 8 and R 9 are independently hydrogen, C 1~6 Alkyl, C 1~6 It is haloalkyl, halo or CN.
[0014] In some embodiments, X is -N(H)- and Y is -NH-, -C(H) 2 - or oxygen. In some embodiments, each of X and Y is -N(H)-.
[0015] In some embodiments, W is -S(O)- or S(O) 2 In certain embodiments, W is -C(O)-.
[0016] In some embodiments, -XWY- is -N(H)-C(O)-N(H)-, -N(H)-C(O)-CH 2 -, -CH 2 -C(O)-N(H)-, -N(H)-S(O)-N(H)-, -N(H)-S(O)-CH 2 -, -CH 2 -S(O)-N(H)-, -N(H)-S(O) 2 -N(H)-, -N(H)-S(O) 2 -CH 2 -, -CH 2 -S(O) 2 -N(H)- or -N(H)-C(O)-.
[0017] In some embodiments, the compound has formula (IIa), (IIb), (IIc) or (Ild): [ka] or a pharma- ceutically acceptable salt thereof.
[0018] In some embodiments, R 2 is hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0019] In some embodiments, the compound has formula (XV): [ka] or a pharma- ceutically acceptable salt thereof.
[0020] In some embodiments, the compound has formula (XVI): [ka] or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound is represented by formula (XVII): [ka] or a pharma- ceutically acceptable salt thereof.
[0021] In some embodiments, the active site is a cavity in which a compound or moiety described herein binds to the MLL site on menin. In some embodiments, the active site is menin at the MLL binding site.
[0022] In some embodiments, when using the compounds disclosed herein, the disease or condition being treated is diabetes mellitus. In some embodiments, the disease or condition is type 1 diabetes mellitus. In some embodiments, the disease or condition is type 2 diabetes mellitus. In some embodiments, the disease or condition is gestational diabetes mellitus. In some embodiments, the disease or condition is maturity-onset diabetes of the young. In some embodiments, the disease or condition is steroid-induced diabetes. In some embodiments, the disease or condition is double diabetes.
[0023]
[0023] In some embodiments, a pharmaceutical composition is provided comprising a therapeutically effective amount of a compound of formula (I) and a pharma- ceutically acceptable excipient. In some embodiments, a pharmaceutical composition comprising a compound of formula (I) is formulated for a route of administration selected from oral, parenteral, buccal, nasal, topical, or rectal administration. In some embodiments, a method is provided for treating a diabetic disease or condition disclosed herein, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I). In some embodiments, a method is provided for treating diabetes, comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I). In some embodiments, the diabetes is type 1 diabetes. In some embodiments, the diabetes is type 2 diabetes. In some embodiments, the diabetes is gestational diabetes.
[0024] Any combination (i.e., including several variables) of the above groups or embodiments is contemplated herein. It is understood that one skilled in the art can select substitutions and substitution patterns in the compounds provided herein to provide compounds that are chemically stable and can be synthesized by techniques known in the art and described herein.
[0025] In some embodiments, a pharmaceutical composition is provided that comprises a therapeutically effective amount of at least one of any of the compounds herein, or a pharma- ceutically acceptable salt, pharma- ceutically active metabolite, pharma- ceutically acceptable prodrug, or pharma- ceutically acceptable solvate. In certain embodiments, the compositions provided herein further comprise a pharma- ceutically acceptable diluent, excipient, and / or binder.
[0026]
[0026] Provided are pharmaceutical compositions formulated for administration by suitable routes and means that contain a high concentration of one or more compounds provided herein that deliver an amount effective for the treatment, prevention, or amelioration of one or more symptoms of a disease, disorder, or condition that is modulated or affected by, or in which menin-MLL activity is implicated. The effective amount and concentration is effective to ameliorate any of the symptoms of any of the diseases, disorders, or conditions disclosed herein.
[0027]
[0027] Provided herein in certain embodiments is a pharmaceutical composition containing: i) a physiologically acceptable carrier, diluent, and / or excipient; and ii) one or more compounds provided herein.
[0028] In some embodiments, provided herein is a method of treating a patient by administering a compound provided herein. In some embodiments, provided herein is a method of inhibiting menin-MLL activity in a patient, or treating a disease, disorder, or condition that would benefit from the inhibition of menin-MLL activity, comprising administering to the patient a therapeutically effective amount of at least one of any of the compounds herein, or a pharma- ceutically acceptable salt, pharma- ceutically active metabolite, pharma- ceutically acceptable prodrug, or pharma- ceutically acceptable solvate thereof.
[0029]
[0029] In some embodiments, provided herein is the use of the compounds disclosed herein for inhibiting menin-MLL activity or for the treatment of a disease, disorder or condition that would benefit from inhibition of menin-MLL activity.
[0030] In some embodiments, the compounds provided herein are administered to a human.
[0031] In some embodiments, the compounds provided herein are administered orally.
[0032] In some embodiments, the compounds provided herein are used in the formulation of a medicament for inhibiting menin-MLL activity. In some embodiments, the compounds provided herein are used in the formulation of a medicament for inhibiting menin-MLL activity.
[0033]
[0033] An article of manufacture is provided which includes packaging material, a compound or composition provided herein that is effective for inhibiting menin-MLL activity, or a pharma- ceutically acceptable derivative thereof, within the packaging material, and a label indicating that the compound or composition, or a pharma- ceutically acceptable salt thereof, a pharma- ceutically acceptable metabolite, a pharma- ceutically acceptable prodrug or a pharma- ceutically acceptable solvate thereof, is used to inhibit the activity of menin-MLL.
[0034]
[0034] Within any of the foregoing embodiments, there are several embodiments in which administration is enteral, parenteral, or both, in which (a) an effective amount of a provided compound is administered systemically to a mammal; (b) an effective amount of a provided compound is administered orally to a mammal; (c) an effective amount of a provided compound is administered intravenously to a mammal; (d) an effective amount of a provided compound is administered by inhalation; (e) an effective amount of a provided compound is administered intranasally; (f) an effective amount of a provided compound is administered to a mammal by injection; (g) an effective amount of a provided compound is administered topically (dermally) to a mammal; (h) an effective amount of a provided compound is administered ophthalmically; or (i) an effective amount of a provided compound is administered rectally to a mammal.
[0035]
[0035] Within any of the foregoing embodiments, there are several embodiments that include a single administration of an effective amount of a provided compound, for example, (i) a provided compound is administered once; (ii) a provided compound is administered to a mammal multiple times per day; (iii) repeatedly; or (iv) administered continuously.
[0036]
[0036] In any of the above embodiments, there are some embodiments that include multiple administrations of an effective amount of a provided compound, for example, (i) a provided compound is administered in a single dose; (ii) the multiple administrations are spaced apart every 6 hours; or (iii) a provided compound is administered to a mammal every 8 hours. In some embodiments, the method includes a drug holiday during which administration of the compound is temporarily suspended or the dose of the administered compound is temporarily reduced, and administration of the compound is resumed at the end of the drug holiday. The length of the drug holiday can vary from 2 days to 1 year.
[0037]
[0037] In any of the aforementioned embodiments involving the treatment of diabetes, there are some embodiments which include administering insulin and at least one additional agent selected from the group consisting of metformin, GLP-1Ra, sulfonylurea, dipeptidyl peptidase 4 inhibitors, thiazolidinediones, and SGLT2 inhibitors.
[0038]
[0038] The term "covalent menin inhibitor," as used herein, refers to an inhibitor of menin that can form a covalent bond with an amino acid residue of menin. In certain embodiments, the inhibitor is irreversible.
[0039] In some embodiments, the compounds of Formula (I)-(XLIIIc) are covalent inhibitors of menin-MLL activity. In certain embodiments, such covalent inhibitors have an IC of less than 10 μM in an enzyme assay. 50 In some embodiments, the menin-MLL inhibitor has an IC of less than 1 μM. 50 and in some embodiments has an IC of less than 0.25 μM 50 has.
[0040]
[0040] Other objects, features and advantages of the methods and compositions described herein will become apparent from the following detailed description. However, it should be understood that the detailed description and specific examples, while showing specific embodiments, are given by way of example only, since various changes and modifications within the spirit and scope of the present disclosure will become apparent to those skilled in the art from this detailed description. The headings of the sections used herein are for organizational purposes only and should not be construed as limiting the subject matter described. All documents or portions of documents cited in this application, including but not limited to patents, patent application publications, papers, books, manuals and papers, are expressly incorporated herein by reference in their entirety for any purpose. [Brief description of the drawings]
[0041] BRIEF DESCRIPTION OF THE DRAWINGS [Figure 1A] FIG. 1A provides glucose in the non-fasted state in Zucker Diabetic Fatty (ZDF) rats following administration of Compound 10, vehicle or control. [Figure 1B] FIG. 1B provides glucose in the fasted state in Zucker Diabetic Fatty (ZDF) rats following administration of Compound 10, vehicle or control. [Figure 2A]
[0042] FIG. 2A provides insulin in the non-fasted state in ZDF rats on days 1, 8 and 14 following administration of Compound 10, vehicle and control. [Figure 2B] FIG. 2B provides insulin in the non-fasted state in ZDF rats on days 1, 8 and 14 following administration of Compound 10, vehicle and control. [Figure 3A]
[0043] FIG. 3A shows Compound 10 in the HOMA-IR or homeostasis model assessment of insulin resistance, showing results in non-fasted ZDF rats on days 1, 8 and 14 after administration of Compound 10, vehicle and control. [Figure 3B]FIG. 3B shows Compound 10 in the HOMA-IR or homeostasis model assessment of insulin resistance, showing results in fasted state in ZDF rats on days 1, 8 and 14 after administration of Compound 10, vehicle and control. [Figure 4A]
[0044] Figure 4A provides the results of an oral glucose tolerance test in ZDF rats after 14 days of treatment with Compound 10, vehicle and control. Figure 4A provides blood glucose. [Figure 4B]
[0044] Figure 4B provides the oral glucose tolerance test results in ZDF rats after 14 days of treatment with Compound 10, vehicle and control. Figure 4B provides the blood glucose area under the curve data. [Figure 5A]
[0045] Figure 5A provides the results of an oral glucose tolerance test in ZDF rats after 29 days of treatment with Compound 10, vehicle and control. Figure 5A provides blood glucose. [Figure 5B]
[0045] Figure 5A provides the results of an oral glucose tolerance test in ZDF rats after 29 days of treatment with Compound 10, vehicle and control. Figure 5B provides the blood glucose area under the curve data. [Figure 6A]
[0046] FIG. 6A provides 4-hour fasted insulin in ZDF rats on days 17 and 31 (approximately 2 weeks after treatment) with Compound 10, vehicle and control. [Figure 6B] FIG. 6B provides 4-hour fasted glucose in ZDF rats on days 17 and 31 (approximately 2 weeks after treatment) with Compound 10, vehicle and control. [Figure 7]
[0047] FIG. 7 provides C-peptide levels in ZDF rats on days 17 and 31 (approximately 2 weeks after treatment) with Compound 10, vehicle and control. [Figure 8]
[0048] FIG. 8 provides non-fasting blood glucose levels in a streptozotocin-induced diabetes model before and after treatment with Compound 10, vehicle and control. [Figure 9]
[0049] FIG. 9 provides non-fasted insulin levels in a streptozotocin-induced diabetic model 1 and 8 days after treatment with Compound 10, vehicle and control. [Figure 10A]
[0050] FIG. 10A provides non-fasting insulin levels in a streptozotocin-induced diabetic model at 1, 8 and 14 days after treatment with Compound 10, vehicle and control. [Figure 10B] FIG. 10B provides 4-hour fasted insulin levels in a streptozotocin-induced diabetic model on day 17 after treatment with Compound 10, vehicle and control. [Figure 11A]
[0051] Figure 11A provides the results of an oral glucose tolerance test in streptozotocin-induced diabetic rats 15 days after treatment with Compound 10, vehicle and control. Figure 11A provides blood glucose. [Figure 11B]
[0051] Figure 11B provides the results of an oral glucose tolerance test in streptozotocin-induced diabetic rats 15 days after treatment with Compound 10, vehicle and control. Figure 11B provides the blood glucose area under the curve data. [Figure 12]
[0052] 12 provides HbA1c levels in ZDF rats administered vehicle, Compound 10 and liraglutide for 28 days. Levels are reported on days 1, 8, 15, 21, 29 and 43. [Figure 13A]
[0053] Figure 13 shows that Compound 10 significantly reduces blood glucose levels and significantly changes serum insulin and C-peptide levels in ZDF rats. ZDF rats treated with Compound 10, pioglitazone or vehicle for 16 days were evaluated at various time points. Statistical significance of treatment groups was calculated compared to vehicle control. Figure 13A shows the OGTT results on day 15 as time course and AUC. [Figure 13B] FIG. 13B shows fasting blood glucose levels on day 17. [Figure 13C]FIG. 13C shows fasting insulin on day 17. [Figure 13D] FIG. 13D shows fasting C-peptide on day 17. [Figure 13E] Non-fasting blood glucose was measured weekly on days -3, 1, 8 and 14. [Figure 14A]
[0054] Figure 14 shows that Compound 10 maintains a significant effect on blood glucose, insulin and C-peptide levels during drug washout (2 weeks after the last dose). Blood glucose levels of ZDF rats treated with Compound 10, pioglitazone or vehicle control for 16 days were monitored by OGTT on day 29, approximately 2 weeks after the last dose, and showed a 40% AUC reduction (p<0.05). Statistical significance of treatment groups was calculated compared to vehicle control. [Figure 14B] On day 31, blood glucose levels were monitored during a 4-hour fast. [Figure 14C] On day 31, serum insulin levels were monitored during a 4-hour fast. [Figure 14D]
[0054] On day 31, C-peptide levels were monitored during a 4-hour fast. [Figure 15A]
[0055] Figure 15 shows that compound 10 strongly reduces blood glucose levels in STZ-induced rats. STZ rats pretreated with streptozotocin for 14 days (see Methods) were treated with compound 10, pioglitazone or vehicle control for 16 days. Blood glucose was measured by OGTT on day 15, and only rats treated with compound 10 showed a 41% AUC decrease (p<0.05), with no change in the pioglitazone treatment group. [Figure 15B]
[0055] Non-fasting glucose levels were measured daily during model establishment (STZ treatment) and weekly during treatment with Compound 10, pioglitazone or vehicle control, and rats treated with Compound 10 showed reduced glucose levels throughout the treatment period. [Figure 16A]
[0056] Figure 16 provides measurements of HOMA-IR in rats treated for 16 days with Compound 10. Fasting HOMA-IR was analyzed on day 17 in ZDF rats treated with Compound 10, pioglitazone or vehicle, and values were compared to vehicle controls to calculate statistical significance. [Figure 16B]
[0056] Non-fasting HOMA-IR on day 17 in ZDF rats treated with Compound 10, pioglitazone or vehicle was analyzed and values were compared to vehicle controls to calculate statistical significance. [Figure 17A]
[0057] Figure 17 provides measurements of cholesterol, triglycerides and body weight in ZDF rats treated with Compound 10 for 16 days. All groups were treated with vehicle, Compound 10 or pioglitazone and compared to vehicle for statistical analysis. Animals continued to consume a high fat diet until day 29. Cholesterol was measured on day 17. [Figure 17B]
[0057] Triglycerides were measured on the 17th day. [Figure 17C] Body weight was measured daily during treatment and continuously monitored for two weeks after treatment. [Figure 18]
[0058] Figure 18 provides the body weights of ZDF rats during 28 days of treatment with Compound 10, liraglutide or vehicle control. Data represent the mean SEM of dose groups. [Figure 19A]
[0059] Figure 19 shows the reduction of fasting blood glucose and HbA1c levels in ZDF rats treated with compound 10. Statistical significance was calculated for blood glucose or HbA1c changes compared to vehicle control. Glucose was monitored during a 4-hour fast in rats treated with the indicated doses of compound 10, liraglutide or vehicle control. [Figure 19B]
[0059] HbA1c was calculated for treated animals every week during the 28 day treatment period. [Figure 20A]
[0060] Figure 20 shows that Compound 10 exerts strong glycemic control over a 28-day treatment period in ZDF rats. OGTTs were performed on day 25 in rats treated with the indicated doses of Compound 10, liraglutide or vehicle control by measuring blood glucose at 15-minute and 30-minute intervals for up to 2 hours. [Figure 20B] Fasting insulin levels were measured weekly for 28 days in rats treated with the indicated doses of Compound 10, liraglutide, or vehicle control. Insulin levels were also measured on day 43 (15 days after administration of the last dose). [Figure 20C]
[0060] C-peptide levels were measured weekly for 28 days in rats treated with the indicated doses of Compound 10, liraglutide, or vehicle control. C-peptide levels were also measured on day 43 (15 days after administration of the last dose). [Figure 21]
[0061] Figure 21 provides HbA1c levels measured in ZDF rats 2 weeks after administration of the final dose. HbA1c levels of rats treated with the indicated doses of Compound 10, liraglutide or vehicle control for 28 days were monitored on days 1 and 15 after administration. Statistical significance is calculated by two-way ANOVA comparing drug-treated groups with vehicle control. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0042] Detailed Description Specific Terms
[0062] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the claimed subject matter belongs. In the event of multiple definitions for terms herein, the definitions in this section prevail. When a URL or other such identifier or address is referenced, it is understood that such identifiers may change and specific information on the Internet may come and go, but that equivalent information may be found by searching the Internet. Reference thereto evidences that such information is available and publicly distributed.
[0043]
[0063] It should be understood that the foregoing general description and the following detailed description are merely exemplary and explanatory and are not intended to limit the claimed subject matter. In this application, the use of the singular includes the plural unless expressly stated otherwise. It should be noted that, as used in this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. The use of the term "including," as well as other forms such as "include," "includes," and "included," is not limiting. Standard definitions of chemical terms can be found in Carey and Sundberg "ADVANCED ORGANIC CHEMISTRY 4 thED." Vols. A (2000) and B (2001), Plenum Press, New York. Unless otherwise indicated, conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology within the skill of the art will be used. Unless specific definitions are provided, the nomenclature and the laboratory procedures and techniques used in connection with analytical chemistry, synthetic organic chemistry and medicinal chemistry described herein are those known in the art. Standard techniques can be used for chemical synthesis, chemical analysis, pharmaceutical preparation, formulation and delivery, and treatment of patients. Standard techniques can be used for recombinant DNA, oligonucleotide synthesis, and tissue culture and transformation (e.g., electroporation, lipofection). Reactions and purification techniques can be performed, for example, using kits including manufacturer's specifications, or as commonly performed in the art, or as described herein. The foregoing techniques and procedures can generally be performed by conventional methods well known in the art and as described in the various general and more specific references cited and discussed throughout this specification.
[0044]
[0064] It is understood that the methods and compositions described herein are not limited to the particular methodology, protocols, cell lines, constructs, and reagents described herein, and as such may vary. It is also understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the methods and compositions described in the specification or the appended claims.
[0045]
[0065] All publications and patents mentioned herein are incorporated herein by reference in their entirety for the purpose of describing and disclosing, for example, the constructs and methodologies described therein that can be used in connection with the methods, compositions and compounds described herein. The publications discussed herein are provided solely for their disclosure prior to the filing date of this application. Nothing herein should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior disclosure or for any other reason.
[0046]
[0066] "Alkyl," as used herein, refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, and having from 1 to 15 carbon atoms (e.g., C 1 ~C 15 In certain embodiments, alkyl comprises 1 to 13 carbon atoms (e.g., C 1 ~C 13 In certain embodiments, alkyl comprises 1 to 8 carbon atoms (e.g., C 1 ~C 8 In certain embodiments, alkyl contains 1 to 6 carbon atoms (e.g., C 1 ~C 6 In some embodiments, the alkyl group contains 5 to 15 carbon atoms (e.g., C 5 ~C 15 In certain embodiments, the alkyl group contains 5 to 8 carbon atoms (e.g., C 5 ~C 8 Alkyl. Alkyl, such as methyl (Me), ethyl (Et), n-propyl (n-pr), 1-methylethyl (iso-propyl or i-Pr), n-butyl (n-Bu), n-pentyl, 1,1-dimethylethyl (t-butyl or t-Bu), 3-methylhexyl, 2-methylhexyl, and the like, is attached to the remainder of the molecule by a single bond. Unless otherwise stated herein, alkyl groups are optionally substituted as defined and described elsewhere herein.
[0047]
[0067] In certain embodiments, the alkyl group can also be a "lower alkyl" having 1 to 6 carbon atoms (e.g., C 1 ~C 6 alkyl).
[0048]
[0068] As used herein, "C 1 ~C x " is C 1 ~C 2 , C 1 ~C 3 ...C 1 ~C x (wherein x is an integer from 1 to 50).
[0049]
[0069] "Alkenyl," as used herein, refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one double bond, and having 2 to 12 carbon atoms. In certain embodiments, an alkenyl contains 2 to 8 carbon atoms. In some embodiments, an alkenyl contains 2 to 4 carbon atoms. An alkenyl, such as ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, etc., is attached to the remainder of the molecule by a single bond. Unless otherwise stated herein, an alkenyl group is optionally substituted as defined and described elsewhere herein.
[0050]
[0070] "Alkynyl," as used herein, refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one triple bond, and having from 2 to 12 carbon atoms. In certain embodiments, alkynyls contain from 2 to 8 carbon atoms. In some embodiments, alkynyls have from 2 to 4 carbon atoms. Alkynyls, such as ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like, are attached to the remainder of the molecule by a single bond. Unless stated otherwise herein, alkynyl groups are optionally substituted as defined and described elsewhere herein.
[0051]
[0071] "Alkylene" or "alkylene chain", as used herein, refers to a straight or branched divalent hydrocarbon chain that connects the remainder of the molecule to a radical group, consists only of carbon and hydrogen, contains no unsaturation, and has 1 to 12 carbon atoms, such as methylene (-CH 2 -), -CH 2 CH 2 -, -CH 2 CH 2 CH 2 -, -CH 2 CH 2 CH 2 CH 2 -, etc. The alkylene chain is attached to the rest of the molecule through each radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain. Unless stated otherwise in the specification, the alkylene chain is optionally substituted as defined and described elsewhere herein.
[0052]
[0072] As used herein, "alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain that connects the rest of the molecule to a radical group, consists solely of carbon and hydrogen, contains at least one double bond, and has 2 to 12 carbon atoms, e.g., ethenylene, propenylene, n-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through each radical group by a double bond or a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or through any two carbons within the chain. Unless stated otherwise herein, the alkylene chain is optionally substituted as defined and described elsewhere herein.
[0053]
[0073] As used herein, "aryl" refers to a group derived from an aromatic monocyclic or polycyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom. The aromatic monocyclic or polycyclic hydrocarbon ring system contains only hydrogen and carbon (i.e., 6-18 carbon atoms) and at least one of the rings in the ring system is fully unsaturated (i.e., contains a cyclic delocalized (4n+2) pi-electron system according to Hückel's theory). Aryl groups include, but are not limited to, groups such as phenyl (Ph), fluorenyl, and naphthyl. Unless otherwise stated herein, the term "aryl" or the prefix "ar-" (e.g., as in "aralkyl") is meant to include aryl groups that are optionally substituted, as defined and described elsewhere herein.
[0054]
[0074] As used herein, “aralkyl” refers to a group of the formula -R c -aryl (wherein R c is an alkylene chain as defined above, e.g., benzyl, diphenylmethyl, etc. The alkylene chain part of the aralkyl group is optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl group is optionally substituted as described above for an aryl group.
[0055]
[0075] As used herein, an “aralkenyl” refers to a group of the formula —R d - an aryl group, where R d is an alkenylene chain as defined above. The aryl part of the aralkenyl group is optionally substituted as defined above for an aryl group. The alkenylene chain part of the aralkenyl group is optionally substituted as defined above for an alkenylene group.
[0056]
[0076] As used herein, an “aralkynyl” refers to a group of the formula —R e - an aryl group, where R eis an alkynylene chain as defined above. The aryl part of the aralkynyl group is optionally substituted as defined above for an aryl group. The alkynylene chain part of the aralkynyl group is optionally substituted as defined above for an alkynylene chain.
[0057]
[0077] As used herein, "carbocyclyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon group consisting solely of carbon and hydrogen atoms, including fused or bridged ring systems, having 3 to 15 carbon atoms. In certain embodiments, a carbocyclyl contains 3 to 10 carbon atoms. In some embodiments, a carbocyclyl contains 5 to 7 carbon atoms. A carbocyclyl is attached to the remainder of the molecule by a single bond. A carbocyclyl is optionally saturated (i.e., contains only single C-C bonds) or unsaturated (i.e., contains one or more double or triple bonds). Fully saturated carbocyclyl groups are also referred to as "cycloalkyls." Examples of monocyclic cycloalkyls include cyclopropyl, ... [ka] , cyclobutyl [ka] , cyclopentyl [ka] , cyclohexyl [ka] , cycloheptyl [ka] and cyclooctyl [ka] Unsaturated carbocyclyls are also referred to as "cycloalkenyls". Examples of monocyclic cycloalkenyls include cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Polycyclic carbocyclyl groups include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated herein, the term "carbocyclyl" is meant to include carbocyclyl groups that are optionally substituted, as defined and described elsewhere herein.
[0058]
[0078] As used herein, "halo" or "halogen" refers to a bromo (Br), chloro (Cl), fluoro (F) or iodo (I) substituent.
[0059]
[0079] The terms "haloalkyl", "haloalkenyl", "haloalkynyl" and "haloalkoxy" include alkyl, alkenyl, alkynyl and alkoxy (see below) structures in which at least one hydrogen has been replaced with a halogen atom. In certain embodiments in which two or more hydrogen atoms have been replaced with halogen atoms, the halogen atoms are all the same. In some embodiments in which two or more hydrogen atoms have been replaced with halogen atoms, the halogen atoms are not all the same.
[0060]
[0080] As used herein, "fluoroalkyl" refers to an alkyl group, as defined above, that is substituted by one or more fluoro groups, as defined above, e.g., trifluoromethyl, difluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, etc. The alkyl portion of the fluoroalkyl group is optionally substituted as defined above for an alkyl group.
[0061]
[0081] As used herein, the term "non-aromatic heterocycle", "heterocycloalkyl" or "heteroalicyclic" refers to a non-aromatic ring in which one or more of the atoms forming the ring are heteroatoms. A "non-aromatic heterocycle" or "heterocycloalkyl" group refers to a cycloalkyl group containing at least one heteroatom selected from nitrogen, oxygen and sulfur. The group may be fused with an aryl or heteroaryl. A heterocycloalkyl ring can be formed by 3 to 14 ring atoms, such as 3, 4, 5, 6, 7, 8, 9, or more than 9 atoms. A heterocycloalkyl ring can be optionally substituted. In certain embodiments, a non-aromatic heterocycle contains one or more carbonyl or thiocarbonyl groups, such as oxo (C=O or carbonyl) and thio-containing groups. Examples of heterocycloalkyls include lactams, lactones, cyclic imides, cyclic thioimides, cyclic carbamates, tetrahydrothiopyrans, 4H-pyrans, tetrahydropyrans, piperidines, 1,3-dioxines, 1,3-dioxanes, 1,4-dioxanes, 1,4-dioxanes, piperazines, 1,3-oxathianes, 1,4-oxathiines, 1,4-oxathianes, tetrahydro-1,4-thiazines, 2H-1,2-oxazines, maleimides, succinimides, barbituric acids, thiobarbituric acids, dioxopiperazines, hydantoins, Examples of heterocycloalkyl groups include, but are not limited to, dihydrouracil, morpholine, trioxane, hexahydro-1,3,5-triazine, tetrahydrothiophene, tetrahydrofuran, pyrroline, pyrrolidine, pyrrolidone, pyrrolidione, pyrazoline, pyrazolidine, imidazoline, imidazolidine, 1,3-dioxole, 1,3-dioxolane, 1,3-dithiole, 1,3-dithiolane, isoxazoline, isoxazolidine, oxazoline, oxazolidine, oxazolidinone, thiazoline, thiazolidine, and 1,3-oxathiolane. Illustrative examples of heterocycloalkyl groups, also referred to as non-aromatic heterocycles, include: [ka] and the like. The term heteroalicyclic also includes all ring forms of carbohydrates, including, but not limited to, monosaccharides, disaccharides, and oligosaccharides. Depending on the structure, a heterocycloalkyl group can be a monoradical or a diradical (i.e., a heterocycloalkylene group).
[0062]
[0082] "Heteroaryl" refers to a group derived from a 3-18 membered aromatic ring group containing 2-17 carbon atoms and 1-6 heteroatoms selected from nitrogen, oxygen and sulfur. As used herein, a heteroaryl group is a monocyclic, bicyclic, tricyclic or tetracyclic ring system, where at least one of the rings in the ring system is fully unsaturated (i.e., contains a cyclic delocalized (4n+2) pi-electron system according to Hückel's theory). Heteroaryl includes fused or bridged ring systems. In some embodiments, a heteroaryl ring has 5, 6, 7, 8, 9 or more than 9 ring atoms. The heteroatoms in a heteroaryl group are optionally oxidized. One or more nitrogen atoms, if present, are optionally quaternized. A heteroaryl is attached to the remainder of the molecule through any atom of the ring. Examples of heteroaryl include azepinyl, agridinyl, benzimidazolyl, benzindolyl, 1,3-benzodioxolyl, benzfuranyl, benzoxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4, 6]imidazo[1,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyrimidinyl, 5,6,7,8,9,10-hexahydrocycloocta[d]pyridazinyl, 5,6,7,8,9,10-Hexahydrocycloocta[d]pyridinyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, 5,8-methano-5,6,7,8-tetrahydroquinazolinyl, naphthyridinyl, 1,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepi oxoazepinyl, oxazolyl, oxiranyl, 5,6,6a,7,8,9,10,10a-octahydrobenzo[h]quinazolinyl, 1-phenyl-1H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl rimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[ Examples of heteroaryl include, but are not limited to, 4,5]thieno[2,3-d]pyrimidinyl, 5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, thieno[2,3-d]pyrimidinyl, thieno[3,2-d]pyrimidinyl, thieno[2,3-c]pyridinyl, and thiophenyl (i.e., thienyl). Unless otherwise stated herein, the term "heteroaryl" is meant to include heteroaryl groups as defined above, optionally substituted as defined and described elsewhere herein.
[0063]
[0083] As used herein, "N-heteroaryl" refers to a heteroaryl group as defined above that contains at least one nitrogen and the point of attachment of the heteroaryl group to the remainder of the molecule is through a nitrogen atom in the heteroaryl group. The N-heteroaryl group is optionally substituted as described above for heteroaryl groups.
[0064]
[0084] As used herein, "C-heteroaryl" refers to a heteroaryl group as defined above, where the point of attachment of the heteroaryl group to the remainder of the molecule is through a carbon atom in the heteroaryl group. The C-heteroaryl group is optionally substituted as described above for heteroaryl groups.
[0065]
[0085] As used herein, a "heteroarylalkyl" refers to a group of the formula -R f -heteroaryl (wherein R f is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the heteroaryl is optionally attached to the alkyl group at the nitrogen atom. The alkylene chain of the heteroarylalkyl group is optionally substituted as defined above for an alkylene chain. The heteroaryl portion of the heteroarylalkyl group is optionally substituted as defined above for a heteroaryl group.
[0066]
[0086] As used herein, "sulfanyl" refers to the group --S--.
[0067]
[0087] As used herein, "sulfinyl" refers to the group -S(=O)-.
[0068]
[0088] As used herein, "sulfonyl" refers to -S(=O) 2 Refers to the base.
[0069]
[0089] As used herein, "amino" refers to -NH 2 Refers to the base.
[0070]
[0090] As used herein, "cyano" refers to the group --CN.
[0071]
[0091] As used herein, "nitro" refers to -NO 2 Refers to the base.
[0072]
[0092] As used herein, "oxa" refers to an --O-- group.
[0073]
[0093] As used herein, "oxo" refers to =O or a carbonyl group.
[0074]
[0094] As used herein, "imino" refers to the group ═NH.
[0075]
[0095] As used herein, "thioxo" refers to the group ═S.
[0076]
[0096] An "alkoxy" group refers to an (alkyl)O- group, where alkyl is as defined herein. For example, CH 3 CH 2 -O corresponds to ethoxy
[0077]
[0097] An "aryloxy" group refers to an (aryl)O- group, where aryl is as defined herein. For example, [ka] corresponds to phenoxy.
[0078]
[0098] As used herein, "carbocyclylalkyl" refers to an alkyl group, as defined herein, substituted with a carbocyclyl group. As used herein, "cycloalkylalkyl" refers to an alkyl group, as defined herein, substituted with a cycloalkyl group. Non-limiting cycloalkylalkyl groups include cyclopropylmethyl, cyclobutylmethyl, cyclopentylmethyl, cyclohexylmethyl, and the like.
[0079]
[0099] As used herein, the terms "heteroalkyl," "heteroalkenyl," and "heteroalkynyl" include optionally substituted alkyl, alkenyl, and alkynyl groups in which one or more skeletal atoms is a heteroatom, such as oxygen, nitrogen, sulfur, silicon, phosphorus, or combinations thereof. The heteroatom can be placed at any position within the heteroalkyl group or at the position at which the heteroalkyl group is attached to the remainder of the molecule. Examples include -CH 2 -O-CH 3 , -CH 2 -CH 2 -O-CH 3 , -CH 2 -NH-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -N(CH 3 )-CH 3 , -CH 2 -CH 2 -NH-CH 3 , -CH 2 -CH 2 -N(CH 3 )-CH 3 , -CH 2 -S-CH 2 -CH 3 , -CH 2 -CH 2 ,-S(O)-CH 3 , -CH 2 -CH 2 -S(O) 2 -CH 3 , -CH=CH-O-CH 3 , -Si(CH 3 ) 3 , -CH 2 -CH=N-OCH 3 and -CH=CH-N(CH 3 )-CH 3 In addition, -CH 2 -NH-OCH 3 and C.H. 2 -O-Si(CH 3 ) 3 Up to two heteroatoms may be consecutive, such as:
[0080]
[0100] The term "heteroatom" as used herein refers to an atom other than carbon or hydrogen. Heteroatoms are typically independently selected from among oxygen, sulfur, nitrogen, silicon and phosphorus, but are not limited to these heteroatoms. In embodiments where there are two or more heteroatoms, the two or more heteroatoms may all be the same as each other, or some or all of the two or more heteroatoms may each be different from each other.
[0081]
[0101] The term "bond," "direct bond," or "single bond," as used herein, refers to a chemical bond between two atoms, or between two moieties when the atoms joined by the bond are considered to be part of a larger chemical substructure.
[0082]
[0102] As used herein, an "isocyanato" group refers to a --NCO group.
[0083]
[0103] As used herein, an "isothiocyanato" group refers to a -NCS group.
[0084]
[0104] The term "moiety" as used herein refers to a specific segment or functional group of a molecule. A chemical moiety is often recognized as a chemical entity embedded within or appended to a molecule.
[0085]
[0105] As used herein, a "thioalkoxy" or "alkylthio" group refers to an --S-alkyl group.
[0086]
[0106] As used herein, an "alkylthioalkyl" group refers to an alkyl group substituted with an --S-alkyl group.
[0087]
[0107] As used herein, the term "acyloxy" refers to a group of the formula RC(=O)O-.
[0088]
[0108] As used herein, "carboxy" refers to a -C(O)OH group.
[0089]
[0109] As used herein, the term "acetyl" is a group having the chemical formula -C(=O)CH3.
[0090]
[0110] As used herein, "acyl" refers to the group -C(O)R.
[0091]
[0111] As used herein, the term "trihalomethanesulfonyl" refers to a compound of the formula X 3 CS(=O) 2 (wherein X is a halogen).
[0092]
[0112] As used herein, "cyanoalkyl" refers to an alkyl group, as defined herein, that is substituted with at least one cyano group.
[0093]
[0113] As used herein, the term "N-sulfonamido" or "sulfonylamino" refers to a compound of the formula RS(=O) 2 It refers to a group having an NH- group.
[0094]
[0114] As used herein, the term "O-carbamyl" refers to a group having the formula -OC(=O)NR 2 It refers to a group having the formula:
[0095]
[0115] As used herein, the term "N-carbamyl" refers to a group having the formula ROC(=O)NH-.
[0096]
[0116] As used herein, the term "O-thiocarbamyl" refers to a compound having the formula -OC(=S)NR 2 It refers to a group having the formula:
[0097]
[0117] As used herein, the term "N-thiocarbamyl" refers to a group having the formula ROC(=S)NH-.
[0098]
[0118] As used herein, the term "C-amide" refers to a compound having the formula C(=O)NR 2 It refers to a group having the formula:
[0099]
[0119] As used herein, "aminocarbonyl" refers to -CONH 2 Refers to radicals.
[0100]
[0120] As used herein, the term "N-amide" refers to a group having the formula RC(=O)NH-.
[0101]
[0121] As used herein, "hydroxyalkyl" refers to an alkyl radical, as defined herein, substituted with at least one hydroxy group. Non-limiting examples of hydroxyalkyl include, but are not limited to, hydroxymethyl, 2-hydroxyethyl, 2-hydroxypropyl, 3-hydroxypropyl, 1-(hydroxymethyl)-2-methylpropyl, 2-hydroxybutyl, 3-hydroxybutyl, 4-hydroxybutyl, 2,3-dihydroxypropyl, 1-(hydroxymethyl)-2-hydroxyethyl, 2,3-dihydroxybutyl, 3,4-dihydroxybutyl, and 2-(hydroxymethyl)-3-hydroxypropyl.
[0102]
[0122] As used herein, "alkoxyalkyl" refers to an alkyl group, as defined herein, substituted with an alkoxy group, as defined herein.
[0103]
[0123] As used herein, an "alkenyloxy" group refers to an (alkenyl)O- group, where alkenyl is as defined herein.
[0104]
[0124] As used herein, the term "alkylamine" refers to an -N(alkyl) x H yrefers to a group in which x and y are selected from among x=1, y=1; and x=2, y=0. When x=2, the alkyl groups, together with the nitrogen atom to which they are attached, can optionally form a cyclic ring system.
[0105]
[0125] As used herein, "alkylaminoalkyl" refers to an alkyl group, as defined herein, substituted with an alkylamine, as defined herein.
[0106]
[0126] An "amide" as used herein is, for example, a chemical moiety having the formula -C(O)NHR or NHC(O)R, where R is selected from among alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon) and heteroalicyclic (bonded through a ring carbon). The amide moiety may form a bond between an amino acid or peptide molecule and a compound described herein, thereby forming, for example, a prodrug. Any amine or carboxyl side chain of a compound described herein can be amidated. Procedures and specific groups for making such amides are known to those of skill in the art and are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., 1999, 143:1311-1323, 1999. rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety.
[0107]
[0127] The term "ester" as used herein refers to a chemical moiety having the formula -COOR, where R is selected from among alkyl, cycloalkyl, aryl, heteroaryl (bonded through a ring carbon), and heteroalicyclic (bonded through a ring carbon). Any hydroxy or carboxyl side chain of the compounds described herein can be esterified. Procedures and specific groups for making such esters are known to those of skill in the art and are described in Greene and Wuts, Protective Groups in Organic Synthesis, 3rd ed., 1999, pp. 111-114, 1999.rd Ed., John Wiley & Sons, New York, NY, 1999, which is incorporated herein by reference in its entirety.
[0108]
[0128] As used herein, the term "ring" refers to any covalently closed ring structure. Rings include, for example, carbocycles (e.g., aryl and cycloalkyl), heterocycles (e.g., heteroaryl and non-aromatic heterocycles), aromatic (e.g., aryl and heteroaryl), and non-aromatic (e.g., cycloalkyl and non-aromatic heterocycles). Rings can be optionally substituted. Rings can be monocyclic or polycyclic.
[0109]
[0129] As used herein, the term "ring system" refers to one or more rings.
[0110]
[0130] The term "membered ring" as used herein can include any ring structure. The term "membered" is meant to indicate the number of skeletal atoms that constitute the ring. Thus, for example, cyclohexyl, pyridine, pyran, and thiopyran are 6-membered rings, and cyclopentyl, pyrrole, furan, and thiophene are 5-membered rings.
[0111]
[0131] As used herein, the term "fused" refers to a structure in which two or more rings share one or more bonds.
[0112]
[0132] As described herein, the compounds of the present disclosure may be "optionally substituted". In general, the term "substituted", whether preceded by the term "optionally" or not, means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise indicated, an "optionally substituted" group may have a suitable substituent at each chemically substitutable position of the group, and if more than one position in any given chemical structure may be substituted with more than one substituent selected from a specified group, the chemical substituents may be the same or different at all positions. The combinations of substituents envisioned by the present disclosure are those that result in the formation of stable compounds or chemically feasible compounds. As used herein, the term "stable" refers to compounds that are substantially unchanged when subjected to conditions that allow for their production, detection, and in certain embodiments, their recovery, purification, and use for one or more of the purposes disclosed herein.
[0113]
[0133] Suitable monovalent substituents on a substitutable carbon atom of an "optionally substituted" group are independently halogen; (CH 2 ) 0~4 R 0 ;-(CH 2 ) 0~4 OR 0 ;-O(CH 2 ) 0~4 R 0 ;-O-(CH 2 ) 0~4 C(O)OR 0 ;-(CH 2 ) 0~4 CH(OR 0 ) 2 ;-(CH 2 ) 0~4 S.R. 0 ;R 0 may be substituted with -(CH 2 ) 0~4 Ph;R 0 may be substituted with -(CH 2 ) 0~4 O(CH 2 ) 0~1 Ph;R0 -CH=CHPh; R 0 may be substituted with -(CH 2 ) 0~4 O(CH 2 ) 0~1 -Pyridyl; -NO 2 ;-CN;-N 3 ;-(CH 2 ) 0~4 N(R 0 ) 2 ;-(CH 2 ) 0~4 N(R 0 )C(O)R 0 ;-N(R 0 )C(S)R 0 ;-(CH 2 ) 0~4 N(R 0 )C(O)NR 0 2 ;-N(R 0 )C(S)NR 0 2 ;-(CH 2 ) 0~4 N(R 0 )C(O)OR 0 ;-N(R 0 )N(R 0 )C(O)R 0 ;-N(R 0 )N(R 0 )C(O)NR 0 2 ;-N(R 0 )N(R 0 )C(O)OR 0 ;-(CH 2 ) 0~4 C(O)R 0 ;-C(S)R 0 ;-(CH 2 ) 0~4 C(O)OR 0 ;-(CH 2 ) 0~4 C(O)SR 0 ;-(CH 2 ) 0~4 C(O)OSiR 0 3 ;-(CH 2 ) 0~4 O.C.(O)R 0;-OC(O)(CH 2 ) 0~4 SR 0 -、-SC(S)SR 0 ;-(CH 2 ) 0~4 SC(O)R 0 ;-(CH 2 ) 0~4 C(O)NR 0 2 ;-C(S)NR 0 2 ;-C(S)SR 0 ;-(CH 2 ) 0~4 OC(O)NR 0 2 ;-C(O)N(OR 0 )R 0 ;-C(O)C(O)R 0 ;-C(O)CH 2 C(O)R 0 ;-C(NOR 0 )R 0 ;-(CH 2 ) 0~4 SSR 0 ;-(CH 2 ) 0~4 S(O) 2 R 0 ;-(CH 2 ) 0~4 S(O) 2 OR 0 ;-(CH 2 ) 0~4 OS(O) 2 R 0 ;-S(O) 2 NR 0 2 ;-(CH 2 ) 0~4 S(O)R 0 ;-N(R 0 )S(O) 2 NR 0 2 ;-N(R 0 )S(O) 2 R 0 ;-N(OR 0 )R 0 ;-C(NH)NR 0 2 ;-P(O) 2 R 0;-P(O)R 0 2 ;-OP(O)R 0 2 ;-OP(O)(OR 0 ) 2 ;SiR 0 3 ;-(C 1~4 Linear or branched alkylene)ON(R 0 ) 2 ;or-(C 1~4 Linear or branched alkylene)C(O)ON(R 0 ) 2 (In the formula, each R 0 are optionally substituted as defined herein and independently represent hydrogen, C 1~6 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, -CH 2 -(5- to 6-membered heteroaryl ring), or a 5- to 6-membered saturated, partially unsaturated, or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or, notwithstanding the above definitions, R 0 two independent occurrences of together with their intervening atoms form a 3-12 membered saturated, partially unsaturated or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, which may be substituted as defined below.
[0114]
[0134] R 0 (or two independent occurrences of R 0 Preferred monovalent substituents on the ring formed by (with their intervening atoms) are independently halogen, -(CH 2 ) 0~2 R 0 , -(Halo R 0 ), -(CH 2 ) 0~2 OH 、 -(CH 2 ) 0~2 OR 0 , -(CH 2 ) 0~2 CH(OR 0 ) 2, -O(HaloR 0 ), -CN, -N 3 , -(CH 2 ) 0~2 C(O)R 0 , -(CH 2 ) 0~2 C(O)OH, -(CH 2 ) 0~2 C(O)OR 0 , -(CH 2 ) 0~2 S.R. 0 , -(CH 2 ) 0~2 SH 、 -(CH 2 ) 0~2 NH 2 , -(CH 2 ) 0~2 NHR 0 , -(CH 2 ) 0~2 NR 0 2 , -NO 2 , -SiR 0 3 , -OSiR 0 3 , -C(O)SR 0 , -(C 1~4 Linear or branched alkylene)C(O)OR 0 , or SSR 0 where each R 0 is unsubstituted or, when preceded by "halo" (e.g., -(haloR 0 ) is substituted with one or more halogens only (e.g., -(halo), -(halo) 2 , or - (halo) 3 ), independently, C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 R is selected from Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. 0 Suitable divalent substituents on a saturated carbon atom of include =O (ie, carbonyl) and =S (ie, thiocarbonyl).
[0115]
[0135] Suitable divalent substituents on a saturated carbon atom of an "optionally substituted" group include: =O (i.e., carbonyl), =S (i.e., thiocarbonyl), =NNR * 2 , =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O) 2 R * , =NR * , =NOR * , -O(C(R * 2 )) 2~3 O- or -S(C(R * 2 )) 2~3 S-(in the formula, each R * are independently defined for each occurrence as hydrogen, C 1~6 (Optionally substituted) groups are selected from alkyl, which may be aliphatic or substituted as defined below, or unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur. Preferred divalent substituents attached to adjacent substitutable carbons of the "optionally substituted" group include -O(CR * 2 ) 2~3 O-(in the formula, each R * are independently defined for each occurrence as hydrogen, C 1~6 aliphatic or alkyl, which may be substituted as defined below, or unsubstituted 5-6 membered saturated, partially unsaturated or aryl rings having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0116]
[0136] R * Suitable substituents on the aliphatic group include halogen, -R 0 , -(Halo R 0 ), -OH, -OR 0 , -O(HaloR 0 ), -CN, -C(O)OH, -C(O)OR 0 , -NH 2 , -NHR 0 , -NR 0 2 Or NO2 (In the formula, each R 0 is unsubstituted or, if preceded by "halo" (above), is substituted with only one or more halogens, and independently represents C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0117]
[0137] Suitable substituents on a substitutable nitrogen of an "optionally substituted" group include -R † , -NR † 2 , -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH 2 C(O)R † , -S(O) 2 R † , -S(O) 2 NR † 2 , -C(S)NR † 2 , -C(NH)NR † 2 or N(R † )S(O) 2 R † where each R † are independently hydrogen, optionally substituted as defined below, 1~6 an aliphatic, unsubstituted -OPh, or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur; or, notwithstanding the above definitions, R † two independent occurrences of together with their intervening atoms form an unsubstituted 3-12 membered saturated, partially unsaturated or aryl mono- or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0118]
[0138] R† Suitable substituents on the aliphatic groups are independently halogen, R 0 , -(Halo R 0 ), -OH, -OR 0 , -O(HaloR 0 ), -CN, -C(O)OH, -C(O)OR 0 , -NH 2 , -NHR 0 , -NR 0 2 or NO 2 (In the formula, each R 0 is unsubstituted or, if preceded by "halo" (above), is substituted with only one or more halogens, and independently represents C 1~4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0~1 Ph, or a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0119]
[0139] The term "nucleophile" or "nucleophile" as used herein refers to an electron-rich compound or chemical moiety thereof.
[0120]
[0140] The term "electrophile" or "electrophile" as used herein refers to an electron-poor or electron-deficient molecule or chemical moiety thereof. Examples of electrophiles include, but are not limited to, Michael acceptor moieties (e.g., α,β-unsaturated carbonyls).
[0121]
[0141] The term "acceptable" or "pharmaceutical acceptable" as used herein with respect to a formulation, composition or ingredient used herein means that it does not have a lasting adverse effect on the general health of the subject being treated or that it does not negate the biological activity or properties of the compound, and has relatively low toxicity.
[0122]
[0142] As used herein, "amelioration" of symptoms of a particular disease, disorder or condition by administration of a particular compound or pharmaceutical composition refers to a decrease in severity, delay in onset, slowing of progression, or shortening of duration, whether permanent or temporary, ongoing or transient, that can result from or be associated with the administration of a compound or composition described herein.
[0123]
[0143] "Bioavailability" as used herein refers to the percentage of the weight of a compound disclosed herein, e.g., any compound of Formula (I)-(XLIIIc), that is administered or delivered to the systemic circulation of the animal or human being being tested. (0-∞) ) is typically defined as 100% bioavailability (F%). As used herein, "oral bioavailability" refers to the extent to which a compound disclosed herein, such as any compound of Formulae (I)-(XLIIIc), is absorbed into the systemic circulation when a pharmaceutical composition is taken orally, as compared to intravenous injection.
[0124]
[0144] As used herein, "plasma concentration" refers to the concentration of a compound disclosed herein, e.g., a compound of any of Formulae (I)-(XLIIIc), in the plasma component of a subject's blood. It is understood that the plasma concentration of a compound of any of Formulae (I)-(XLIIIc) may vary significantly between subjects due to metabolic variability and / or possible interactions with other therapeutic agents. According to some embodiments disclosed herein, the plasma concentration of a compound of any of Formulae (I)-(XLIIIc) may vary from subject to subject. Similarly, the maximum plasma concentration (C max ), or the time to reach maximum plasma concentration (T max ), or the total area under the plasma concentration-time curve (AUC( 0-∞ )) may vary from subject to subject. Because of this variability, the amount necessary to achieve a "therapeutically effective amount" of a compound of any of Formulas (I)-(XLIIIc) may vary from subject to subject.
[0125]
[0145] Terms like "co-administration," as used herein, are meant to encompass administration of the selected therapeutic agents described to a single patient, and are intended to include therapeutic regimens in which the agents are administered by the same or different routes of administration or at the same or different times.
[0126]
[0146] The term "effective amount" or "therapeutically effective amount" as used herein refers to an amount of a described agent or compound administered sufficient to relieve to some extent one or more symptoms of the disease or condition being treated. The result may be reduction and / or alleviation of the signs, symptoms and causes of the disease, or any other desired change in a biological system. For example, an "effective amount" for therapeutic use is the amount of a composition containing a compound disclosed herein that is required to provide a clinically significant reduction in disease symptoms without undue adverse side effects. An appropriate "effective amount" in any individual case may be determined using techniques such as dose escalation studies. The term "therapeutically effective amount" includes, for example, a prophylactically effective amount. An "effective amount" of a compound disclosed herein is an amount effective to achieve a desired pharmacological effect or therapeutic improvement without undue adverse side effects. It is understood that an "effective amount" or "therapeutically effective amount" may vary from subject to subject due to variability in metabolism of any of the compounds of formula (I)-(XLIIIc), the age, weight, general condition of the subject, the condition being treated, the severity of the condition being treated, and the judgment of the prescribing physician. By way of example only, a therapeutically effective amount may be determined by routine experimentation, including, but not limited to, a dose escalation clinical trial.
[0127]
[0147] As used herein, the term "enhance" or "enhancing" means to increase or extend the potency or duration of a desired effect. By way of example, "enhancing" the effect of a therapeutic agent refers to the ability to increase or extend, in potency or duration, the effect of the therapeutic agent during the treatment of a disease, disorder or condition. An "enhancing-effective amount," as used herein, refers to an amount sufficient to enhance the effect of the therapeutic agent in the treatment of a disease, disorder or condition. When used in a patient, the amount effective for this use will depend on the severity and course of the disease, disorder or condition, previous treatments, the patient's health condition and response to the drug, and the judgment of the treating physician.
[0128]
[0148] The term "identical" as used herein refers to two or more sequences or subsequences that are the same. Additionally, the term "substantially identical" as used herein refers to two or more sequences that have a percentage of sequential units that are identical when compared and aligned to show maximum correspondence over a comparison window, or designated region, as measured using a comparison algorithm, or by manual alignment and visual inspection. By way of example only, two or more sequences may be "substantially identical" if the sequential units are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95% identical over a particular region. Such percentages represent the "percent identity" of two or more sequences. Sequence identity may exist over a region that is at least about 75-100 sequential units in length, over a region that is about 50 sequential units in length, or over the entire sequence if not specified. This definition also refers to the complement of a test sequence. By way of example only, two or more polypeptide sequences are identical if the amino acid residues are the same, and furthermore, two or more polypeptide sequences are "substantially identical" if the amino acid residues are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95% identical over a particular region. Identity can exist over a region of at least about 75-100 amino acids in length, over a region of about 50 amino acids in length, or, if not specified, over the entire sequence of the polypeptide sequence. Further, by way of example only, two or more polynucleotide sequences are identical if the nucleic acid residues are the same, and furthermore, two or more polynucleotide sequences are "substantially identical" if the nucleic acid residues are about 60% identical, about 65% identical, about 70% identical, about 75% identical, about 80% identical, about 85% identical, about 90% identical, or about 95% identical over a particular region. The identity can exist over a region that is at least about 75-100 nucleic acids in length, over a region that is about 50 nucleic acids in length, or, if not specified, over the entire sequence of the polynucleotide sequence.
[0129]
[0149] The term "isolated" as used herein refers to the separation and removal of a component of interest from (naturally occurring) components that are not the component of interest. An isolated material may be in a dry or semi-dry state, or in a solution, including but not limited to an aqueous solution. An isolated component may be in a homogenous state, or an isolated component may be part of a pharmaceutical composition that includes additional pharma- ceutically acceptable carriers and / or excipients. By way of example only, a nucleic acid or protein is "isolated" if such nucleic acid or protein is free of at least some of the cellular components with which it is naturally associated, or if the nucleic acid or protein is concentrated to a level higher than its in vivo or in vitro production concentration. Also by way of example, a gene is isolated if it is separated from open reading frames adjacent to the gene and encoding proteins other than the gene of interest.
[0130]
[0150] As used herein, a "metabolite" of a compound disclosed herein is a derivative of that compound that is formed when the compound is metabolized. As used herein, the term "active metabolite" refers to a biologically active derivative of a compound that is formed when the compound is metabolized. As used herein, the term "metabolized" refers to the sum of processes (including, but not limited to, hydrolysis reactions and reactions catalyzed by enzymes, such as oxidation reactions) by which a particular substance is changed by an organism. Thus, enzymes can produce specific structural changes to a compound. For example, cytochrome P450 catalyzes various oxidation and reduction reactions, and uridine diphosphate glucuronyltransferase catalyzes the transfer of activated glucuronic acid molecules to aromatic alcohols, aliphatic alcohols, carboxylic acids, amines, and free sulfhydryl groups. Further information on metabolism can be obtained from The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill (1996). Metabolites of the compounds disclosed herein can be identified by administering the (parent) compound to a host and analyzing tissue samples from the host, or by incubating the (parent) compound with hepatocytes in vitro and analyzing the resulting compound. Both methods are well known in the art. In some embodiments, metabolites of the (parent) compound are formed by oxidation processes and correspond to the corresponding hydroxy-containing compounds. In some embodiments, the (parent) compound is metabolized to a pharmacologically active metabolite.
[0131]
[0151] The term "modulate," as used herein, means to interact directly or indirectly with a target to alter the activity of the target, for example, by way of example only, to enhance, inhibit, limit, or prolong the activity of the target.
[0132]
[0152] As used herein, the term "modulator" refers to a compound that alters the activity of a molecule. For example, a modulator can increase or decrease the magnitude of a particular activity of a molecule compared to the magnitude of the activity in the absence of the modulator. In certain embodiments, a modulator is an inhibitor that decreases the magnitude of one or more activities of a molecule. In certain embodiments, an inhibitor completely prevents one or more activities of a molecule. In certain embodiments, a modulator is an activator that increases the magnitude of at least one activity of a molecule. In certain embodiments, the presence of a modulator results in an activity that does not occur in the absence of the modulator.
[0133]
[0153] The term "covalent inhibitor" as used herein refers to a compound that, upon contact with a target protein (e.g., menin), causes the formation of new covalent bonds with or within the protein, thereby altering, decreasing or eliminating one or more biological activities (e.g., phosphotransferase activity) of the target protein, regardless of the subsequent presence or absence of the covalent or irreversible inhibitor. In certain embodiments, the covalent inhibitor is irreversible. In contrast, a non-covalent inhibitor compound, upon contact with a target protein, does not cause the formation of new covalent bonds with or within the protein, and thus can associate with and dissociate from the target protein.
[0134]
[0154] The term "covalent inhibitor of menin-MLL protein-protein interaction" as used herein refers to an inhibitor of menin capable of forming a covalent bond with an amino acid residue of menin. In one embodiment, a covalent or irreversible inhibitor of menin is capable of forming a covalent bond with a Cys residue of menin, and in certain embodiments, a covalent inhibitor is capable of forming a covalent bond with the Cys329 residue (or a homolog thereof) of menin. In certain embodiments, the covalent inhibitor is irreversible.
[0135]
[0155] The term "prophylactically effective amount," as used herein, refers to an amount of a composition applied to a patient that will relieve to some extent one or more symptoms of the disease, condition, or disorder being treated. In such prophylactic applications, such amounts may depend on the patient's health condition, weight, and the like. It is considered well within the skill of one of ordinary skill in the art to determine such prophylactically effective amounts by routine experimentation, including but not limited to dose escalation clinical trials.
[0136]
[0156] As used herein, the term "selective binding compound" refers to a compound that selectively binds to any portion of one or more target proteins.
[0137]
[0157] As used herein, the term "selectively binds" refers to the ability of a selective binding compound to bind to a target protein, such as menin, with greater affinity than it binds to a non-target protein. In certain embodiments, specific binding refers to binding to a target with an affinity that is at least 10-fold, 50-fold, 100-fold, 250-fold, 500-fold, 1000-fold, or more, greater than the affinity for a non-target.
[0138]
[0158] As used herein, the term "selective modulator" refers to a compound that selectively modulates a target activity relative to a non-target activity. In certain embodiments, a specific modulator refers to modulating a target activity at least 10-fold, 50-fold, 100-fold, 250-fold, 500-fold, 1000-fold greater than the non-target activity.
[0139]
[0159] The term "substantially purified" as used herein refers to a component of interest that may be substantially or essentially free of other (natural) components that typically accompany or interact with the component of interest prior to purification. By way of example only, a component of interest may be "substantially purified" if a preparation of the component of interest contains less than about 30%, less than about 25%, less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% (by dry weight) of contaminating components. Thus, a "substantially purified" component of interest may have a purity level of about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 96%, about 97%, about 98%, about 99% or more.
[0140]
[0160] The term "subject" or "patient" as used herein refers to an animal who is the object of treatment, observation, or experiment. By way of example only, a subject can be, but is not limited to, an animal, such as, but not limited to, a human.
[0141]
[0161] As used herein, the term "target activity" refers to a biological activity that can be modulated by a selective modulator. Certain exemplary target activities include, but are not limited to, binding affinity, signal transduction, enzyme activity, tumor growth, inflammation or inflammation-related processes, and amelioration of one or more symptoms associated with a disease or condition (e.g., diabetes mellitus).
[0142]
[0162] As used herein, the term "target protein" refers to a molecule or portion of a protein that can be bound by a selective binding compound. In certain embodiments, the target protein is menin.
[0143]
[0163] The terms "treat", "treating" or "treatment" as used herein include alleviating, reducing or ameliorating the symptoms of a disease or condition, preventing further symptoms, ameliorating or preventing the underlying metabolic cause of the symptoms, inhibiting a disease or condition, e.g., arresting the progression of a disease or condition, relieving a disease or condition, regressing a disease or condition, reducing pathology caused by a disease or condition, or arresting the symptoms of a disease or condition. The terms "treat", "treating" or "treatment" as used herein include, but are not limited to, prophylactic and / or therapeutic treatment.
[0144]
[0164] As used herein, IC 50 refers to the amount, concentration or dosage of a particular test compound that achieves 50% inhibition of a maximal response, for example inhibition of menin-MLL, in an assay that measures such response.
[0145]
[0165] As used herein, EC 50 refers to the dose, concentration or amount of a particular test compound that elicits a dose-dependent response that is 50% of the maximal expression of the particular response induced, elicited or enhanced by the particular test compound.
[0146]
[0166] The methods described herein include administering to a subject in need thereof (e.g., a subject suffering from diabetes mellitus) a composition described herein containing a therapeutically effective amount of one or more menin-MLL inhibitor compounds described herein.
[0147]
[0167] In some embodiments, the methods described herein can be used to treat diabetes mellitus, including, but not limited to, type 1 diabetes, type 2 diabetes, gestational diabetes, maturity-onset diabetes of the young, steroid diabetes, and double diabetes.
[0148]
[0168] Symptoms, diagnostic tests and prognostic tests for each of the above conditions are known to those skilled in the art. See, for example, Hartling L, et al., "Screening and diagnosing gestational diabetes mellitus," Evid Rep Technol Assess, 2012, 1-327; PMID: 24423035; Kaur G, et al., "Diagnostic accuracy of tests for type 2 diabetes and prediabetes: A systematic review and meta-analysis," PLoS One, 2020, 15(1 l):e0242415, PMID: 33216783; and Gan WZ, et al., "Omics-based biomarkers in the diagnosis of diabetes," J Basic Clin Physiol Pharmacol, 2019, 31(2), PMID: 31730525.
[0149]
[0169] A number of animal models are useful for establishing the therapeutically effective dose range of the menin-MLL inhibitor compounds described herein for treating any of the aforementioned diseases.
[0150]
[0170] For example, administration of menin-MLL inhibitor compounds described herein to treat diabetes mellitus can be evaluated in mouse models of diabetes mellitus using, for example, mice with ob, db, ob / ob, db / db, or ob / db mutations.
[0151]
[0171] The therapeutic effect of the provided compounds for one of the aforementioned diseases can be optimized during the course of treatment. For example, a subject being treated can undergo a diagnostic evaluation that correlates the alleviation of symptoms or pathology of the disease with the inhibition of menin-MLL activity in vivo achieved by administering a given dose of a menin-MLL inhibitor described herein.
[0152] compound
[0172] In the following description of menin-MLL inhibitor compounds suitable for use in the methods described herein, definitions of standard chemical terms referred to can be found in references, such as Carey and Sundberg "Advanced Organic Chemistry 4th Ed." Vols. A (2000) and B (2001), Plenum Press, New York (unless otherwise defined herein). Unless otherwise indicated, conventional methods of mass spectrometry, NMR, HPLC, protein chemistry, biochemistry, recombinant DNA techniques and pharmacology within the skill of the art are employed. Unless specific definitions are provided, the nomenclature used in connection with, and the laboratory procedures and techniques of, analytical chemistry, synthetic organic chemistry, and medicinal and pharmaceutical chemistry described herein are known to those of skill in the art. Standard techniques can be used for chemical syntheses, chemical analyses, pharmaceutical preparation, formulation and delivery, and treatment of patients.
[0153]
[0173] Menin-MLL inhibitor compounds may be used in the manufacture of a medicament for the treatment of any of the aforementioned conditions (eg diabetes mellitus).
[0154]
[0174] In some embodiments, the menin-MLL inhibitor compound used in the methods described herein has a concentration of less than about 10 μM (e.g., less than about 1 μM, less than about 0.5 μM, less than about 0.4 μM, less than about 0.3 μM, less than about 0.1 μM, less than about 0.08 μM, less than about 0.06 μM, less than about 0.05 μM, less than about 0.04 μM, less than about 0.03 μM, less than about 0.02 μM, less than about 0.01 μM, less than about 0.008 μM, less than about 0.006 μM, in vitro IC of less than about 0.005 μM, less than about 0.004 μM, less than about 0.003 μM, less than about 0.002 μM, less than about 0.001 μM, less than about 0.00099 μM, less than about 0.00098 μM, less than about 0.00097 μM, less than about 0.00096 μM, less than about 0.00095 μM, less than about 0.00094 μM, less than about 0.00093 μM, less than about 0.00092 μM, or less than about 0.00090 μM 50inhibits menin-MLL activity.
[0155]
[0175] In some embodiments, the menin-MLL inhibitor compound selectively inhibits the activated form of its target menin.
[0156]
[0176] Also described herein are methods of synthesizing such covalent inhibitors, and methods of using such covalent inhibitors in the treatment of diseases, including diseases in which inhibition of the menin-MLL interaction provides a therapeutic benefit to patients having the disease. Additionally, pharmaceutical compositions comprising inhibitors of the menin-MLL interaction are described.
[0157]
[0177] Specifically, described herein are covalent inhibitors of the menin-MLL interaction that form a covalent bond with a cysteine residue on menin. Further described herein are covalent inhibitors of the menin-MLL interaction that form a covalent bond with the Cys329 residue on menin. Also described are pharmaceutical formulations that include the covalent inhibitors of menin.
[0158]
[0178] The menin inhibitor compounds described herein are selective for menin that have a cysteine residue at an amino acid sequence position in the menin protein that is homologous to the amino acid sequence position of cysteine 329 in menin. The covalent inhibitor compounds described herein contain a Michael acceptor moiety.
[0159]
[0179] Generally, the menin non-covalent or covalent inhibitor compounds used in the methods described herein are identified or characterized in an in vitro assay, such as a cell-free biochemical assay or a functional cellular assay. Such assays include in vitro IC of non-covalent or covalent menin inhibitor compounds. 50 This is useful for determining
[0160]
[0180] Furthermore, covalent complex formation between menin and a candidate covalent menin inhibitor is a useful indicator of covalent inhibition of menin, which can be readily determined by many methods known in the art (e.g., mass spectrometry). For example, some covalent menin inhibitor compounds can form a covalent bond with Cys329 of menin (e.g., via a Michael reaction). See S. Xu et al. Angewandte Chemie International Ed.57(6), 1601-1605 (2017) (incorporated by reference in its entirety).
[0161]
[0181] Compounds of any of formulas (I)-(XLIIIc) are described herein. Pharmaceutically acceptable salts, pharma- ceutically acceptable solvates, pharma- ceutically active metabolites, and pharma- ceutically acceptable prodrugs of such compounds are also described herein. Pharmaceutical compositions are provided that include at least one such compound, or a pharma- ceutically acceptable salt, pharma- ceutically acceptable solvate, pharma- ceutically active metabolite, or pharma- ceutically acceptable prodrug of such a compound. In some embodiments, when a compound disclosed herein contains an oxidizable nitrogen atom, the nitrogen atom can be converted to an N-oxide by methods well known to those skilled in the art. In certain embodiments, isomers and chemically protected forms of compounds having a structure represented by any of formulas (I)-(XLIIIc) are also provided.
[0162]
[0182] In some embodiments, provided herein are menin-MLL covalent inhibitors according to compounds of Formulas (I)-(XLIIIc).
[0163]
[0183] In some embodiments, there is provided a compound of Formula (I) having the following structure, or a pharma- ceutically acceptable salt thereof: [ka] During the ceremony, A is carbon or nitrogen; Cy is a substituted or unsubstituted [ka] and; Q is nitrogen, -N(H)-, -O-, or -S-; Z is -CR 5a = or -N =; X is -NR 3a , -C(R 3b ) 2 - or -O-; Y is a single bond, -NR 3a -, -C(R 3b ) 2 - or -O-; W is -C(O)-, -S(O)- or S(O) 2 - and; R 1 and R 2 One of them is Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6C ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6C ) and the other is hydrogen, C 1~6 Alkyl, C 1~6 haloalkyl, halo or CN; Cy 2 is an optionally substituted group selected from phenyl, pyridyl, or a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 3a and R 3b are independently hydrogen or C 1~6 is alkyl; Each R 4a and R 4b are independently hydrogen, halo, CN, OR, -N(R) 2 , -C(O)N(R) 2 , -NRC(O)R, -SO 2 R, -C(O)R, -CO 2 R or C1~6 Alkyl, C 3~7 an optionally substituted group selected from cycloalkyl, a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8-10 membered bicyclic aryl ring, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R is independently hydrogen or C 1~6 an optionally substituted group selected from aliphatic, phenyl, an 8-10 membered bicyclic aryl ring, a 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups on the same nitrogen together with their intervening atoms form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 5a is hydrogen, C 1~6 Alkyl, C 1~6 haloalkyl, halo or CN; Each R 6a and R 6b are independently hydrogen or C 1~6 is alkyl; or R 6a and R 6b come together to form a bond; R 6c is hydrogen or substituted or unsubstituted C 1~6 is alkyl; m is 1, 2 or 3; and n is 1, 2, 3 or 4.
[0164]
[0184] In some embodiments, W is -S(O)- or S(O) 2 -It is.
[0165]
[0185] In some embodiments, W is -C(O)-.
[0166]
[0186] In some embodiments, X is -NR 3a and Y is -C(R 3b ) 2 -, -NR 3b -or -O-.
[0167]
[0187] In some embodiments, Y is a single bond or NR 3a - and X is -C(R 3b ) 2 -, -NR 3b -or -O-.
[0168]
[0188] In some embodiments, each of X and Y is independently -NR 3a -It is.
[0169]
[0189] In some embodiments, R 3a is hydrogen.
[0170]
[0190] In some embodiments, R 3b is hydrogen or methyl.
[0171]
[0191] In some embodiments, each of X and Y is -N(H)-.
[0172]
[0192] In some embodiments, -XWY- is -N(H)-C(O)-N(H)-, -N(H)-C(O)-CH 2 -, -CH 2 -C(O)-N(H)-, -N(H)-S(O)-N(H)-, -N(H)-S(O)-CH 2 -, -CH 2 -S(O)-N(H)-, -N(H)-S(O) 2 -N(H)-, -N(H)-S(O) 2 -CH 2 -, -CH 2 -S(O) 2 -N(H)- or -N(H)-C(O)-.
[0173]
[0193] In some embodiments, R 1 Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ), or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) and R 2 is hydrogen, halo, hydroxyl, CN, substituted or unsubstituted C 1~6 It is alkyl, substituted or unsubstituted amino, or substituted or unsubstituted alkoxy.
[0174]
[0194] In some embodiments, R 1 Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) and R 2 is hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0175]
[0195] In some embodiments, R 1 Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ), or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) and R 2 is hydrogen.
[0176]
[0196] In some embodiments, R 2 Cy 2 -N(H)C(O)-C(R6a )=C(R 6b )(R 6c ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) and R 1 is hydrogen, halo, hydroxyl, CN, substituted or unsubstituted C 1~6 It is alkyl, substituted or unsubstituted amino, or substituted or unsubstituted alkoxy.
[0177]
[0197] In some embodiments, R 2 Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) and R 1 is hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0178]
[0198] In some embodiments, R 2 Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c ) and R 1 is hydrogen.
[0179]
[0199] -XWY is -N(H)-C(O)-; R 1 -CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6c) and R 2 is hydrogen.
[0180]
[0200] In some embodiments, the compound is according to formula (XXI) or a pharma- ceutically acceptable salt thereof: [ka] During the ceremony: A, Cy, Cy 2 , R 4b , R 6a , R 6b , R 6c , m and n are as described for formula (I); 8 and R 9 are independently hydrogen, C 1~6 Alkyl, C 1~6 It is haloalkyl, halo or CN.
[0181]
[0201] In some embodiments, R 8 and R 9 One of the groups is hydrogen, halo, hydroxyl, CN, substituted or unsubstituted C 1~6 alkyl, substituted or unsubstituted amino, or substituted or unsubstituted alkoxy; the other is hydrogen.
[0182]
[0202] In some embodiments, each R 8 and R 9 is hydrogen or methyl.
[0183]
[0203] In some embodiments, each R 8 and R 9 is hydrogen.
[0184]
[0204] In some embodiments, A is nitrogen.
[0185]
[0205] In some embodiments, A is carbon.
[0186]
[0206] In some embodiments, m is 1 or 2.
[0187]
[0207] In some embodiments, n is 1 or 2.
[0188]
[0208] In some embodiments, each R 4a are independently hydrogen, halo, hydroxyl, CN, substituted or unsubstituted C 1~6 It is alkyl, substituted or unsubstituted amino, or substituted or unsubstituted alkoxy.
[0189]
[0209] In some embodiments, each R 4a are independently hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0190]
[0210] In some embodiments, each R 4a is hydrogen.
[0191]
[0211] In some embodiments, each R 4b are independently hydrogen, halo, hydroxyl, CN, substituted or unsubstituted C 1~6 It is alkyl, substituted or unsubstituted amino, or substituted or unsubstituted alkoxy.
[0192]
[0212] In some embodiments, each R 4b are independently hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0193]
[0213] In some embodiments, each R 4b is hydrogen.
[0194]
[0214] In some embodiments, the compound is according to Formula (IIa), (IIb), (IIc) or (IId), or a pharma- ceutically acceptable salt thereof. [ka]
[0195]
[0215] In some embodiments, R 2 is hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0196]
[0216] In some embodiments, R 2 is hydrogen.
[0197]
[0217] In some embodiments, the compound is according to formula (XXIIa) or (XXIIb), or a pharma- ceutically acceptable salt thereof: [ka] During the ceremony: Cy, Cy 2 , R 6a , R 6b or R 6c is as described for formula (I).
[0198]
[0218] In some embodiments, the compound is according to Formula (IIIa), (IIIb), (IIIe) or (IIId), or a pharma- ceutically acceptable salt thereof. [ka]
[0199]
[0219] In some embodiments, the compound is according to formula (XXXIIa), (XXXIIb), (XXXIIc), (XXXIId), (XXXIIe) or (XXXIIf), or a pharma- ceutically acceptable salt thereof. [ka]
[0200]
[0220] In some embodiments, R 1 is hydrogen, Me, Et, i-Pr, CF 3 , F, Cl, OMe, OEt or CN.
[0201]
[0221] In some embodiments, R 1 is hydrogen.
[0202]
[0222] In some embodiments, the compound is according to Formula (XXXIIIa), (XXXIIIb), (XXXIIIc), (XXXIIId), (XXXIIIe) or (XXXIIIf), or a pharma- ceutically acceptable salt thereof. [ka]
[0203]
[0223] In some embodiments, Cy 2 is substituted or unsubstituted phenyl, pyridyl, azetidinyl, pyrrolidinyl, piperidinyl or azepinyl.
[0204]
[0224] In some embodiments, the compound is according to Formula (IVa) or (IVb), or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2, or 3. [ka]
[0205]
[0225] In some embodiments, the compound is according to Formula (XXIIIa) or (XXIIIb), or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2, or 3. [ka]
[0206]
[0226] In some embodiments, Cy is substituted or unsubstituted [ka] It is.
[0207]
[0227] In some embodiments, Cy is substituted or unsubstituted [ka] It is.
[0208]
[0228] In some embodiments, Q is -N(H)-.
[0209]
[0229] In some embodiments, Q is --O--.
[0210]
[0230] In some embodiments, Q is -S-.
[0211]
[0231] In some embodiments, Z is -N=.
[0212]
[0232] In some embodiments, Z is -CR 5a = is
[0213]
[0233] In some embodiments, R 5a is hydrogen, Me, Et, i-Pr, Cl, F, CF 3 Or CN.
[0214]
[0234] In some embodiments, R 5a is hydrogen, Me or F.
[0215]
[0235] In some embodiments, R 5a is hydrogen.
[0216]
[0236] In some embodiments, Z is -C(H)=.
[0217]
[0237] In some embodiments, Cy is [ka] (In the formula, R 7is an optionally substituted group selected from a 4- to 7-membered heterocycloalkyl ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl, an 8- to 10-membered bicyclic aryl ring, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. It is.
[0218]
[0238] In some embodiments, Cy is substituted or unsubstituted [ka] (In the formula, R 7 is an optionally substituted group selected from a 4- to 7-membered heterocycloalkyl ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a phenyl, an 8- to 10-membered bicyclic aryl ring, and a 5- to 6-membered heteroaryl ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. It is.
[0219]
[0239] In some embodiments, the compound has formula (Va) or (Vb): [ka] or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3; R 7 is an optionally substituted group selected from a 4- to 7-membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8- to 10-membered bicyclic aryl ring, and a 5- to 6-membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0220]
[0240] In some embodiments, the compound has formula (XXIVa) or (XXIVb) [ka] or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3; R 7 is an optionally substituted group selected from a 4- to 7-membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, phenyl, an 8- to 10-membered bicyclic aryl ring, and a 5- to 6-membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0221]
[0241] In some embodiments, the compound has formula (XXXIVa) or (XXXIVb): [ka] or a pharma- ceutically acceptable salt thereof.
[0222]
[0242] In some embodiments, the compound has the formula (XXXVa) or (XXXVb): [ka] or a pharma- ceutically acceptable salt thereof.
[0223]
[0243] In some embodiments, the compound has formula (XXXVIa) or (XXXVIb): [ka] or a pharma- ceutically acceptable salt thereof.
[0224]
[0244] In some embodiments, R 7 is a 4-7 membered heterocycloalkyl ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, where nitrogen is optionally substituted with Me, Et or i-Pr.
[0225]
[0245] In some embodiments, R 7is pyrrolidinyl, piperidinyl, piperazinyl or morpholinyl.
[0226]
[0246] In some embodiments, R 7 is morpholinyl.
[0227]
[0247] In some embodiments, R 7 is a substituted or unsubstituted heteroaryl.
[0228]
[0248] In some embodiments, R 7 is substituted or unsubstituted pyridyl or pyrimidyl.
[0229]
[0249] In some embodiments, R 7 is unsubstituted pyridyl.
[0230]
[0250] In some embodiments, R 7 is halo, hydroxyl, CN, substituted or unsubstituted C 1~6 It is pyridyl substituted with alkyl, substituted or unsubstituted amino, or substituted or unsubstituted alkoxy.
[0231]
[0251] In some embodiments, R 7 is Me, Et, i-Pr, OH, Cl, F, CF 3 , CN or NH 2 and pyridyl substituted with
[0232]
[0252] In some embodiments, R 7 is Me, Et, i-Pr, Cl, F, CF 3 or pyridyl substituted with CN.
[0233]
[0253] In some embodiments, R 7 is substituted or unsubstituted pyrrolyl, pyrazolyl, imidazolyl, oxazolyl, triazolyl, thiazolyl, oxadiazolyl or thiadiazolyl.
[0234]
[0254] In some embodiments, R 7 is a substituted or unsubstituted imidazolyl.
[0235]
[0255] In some embodiments, R 7 is Me, Et, i-Pr, Cl, F, CF 3 or imidazoyl substituted with CN.
[0236]
[0256] In some embodiments, R 7 is a methyl substituted imidazoyl.
[0237]
[0257] In some embodiments, the compound has formula (VIa) or (VIb) [ka] or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3.
[0238]
[0258] In some embodiments, the compound has formula (XXVa) or (XXVb): [ka] or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3.
[0239]
[0259] In some embodiments, p is 0, 1, or 2.
[0240]
[0260] In some embodiments, R 2 is hydrogen or F.
[0241]
[0261] In some embodiments, R 2 is hydrogen.
[0242]
[0262] In some embodiments, the compound has formula (VIIa), (VIIb), or (VIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0243]
[0263] In some embodiments, the compound has formula (VIIIa), (VIIIb), or (VIIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0244]
[0264] In some embodiments, the compound has formula (XXVIa), (XXVIb) or (XXVIc) [ka] or a pharma- ceutically acceptable salt thereof.
[0245]
[0265] In some embodiments, the compound has formula (XXXVIIa) or (XXXVIIb) [ka] or a pharma- ceutically acceptable salt thereof.
[0246]
[0266] In some embodiments, the compound has formula (XXXVIIIa) or (XXXVIIIb) [ka] or a pharma- ceutically acceptable salt thereof.
[0247]
[0267] In some embodiments, the compound has formula (XXXIXa) or (XXXIXb) [ka] or a pharma- ceutically acceptable salt thereof.
[0248]
[0268] In some embodiments, R 6a , R 6b and R 6c Each of is hydrogen.
[0249]
[0269] In some embodiments, R 6a and R 6b is hydrogen, and R 6c is substituted or unsubstituted alkyl.
[0250]
[0270] In some embodiments, R 6a and R 6b is hydrogen, and R 6c is unsubstituted alkyl.
[0251]
[0271] In some embodiments, R 6a and R 6b is hydrogen, and R 6c is methyl or ethyl.
[0252]
[0272] In some embodiments, R 6a and R 6b is hydrogen, and R 6c is alkyl substituted with amino, alkylamino or dialkylamino.
[0253]
[0273] In some embodiments, R 6a and R 6b is hydrogen, and R 6c is an alkyl substituted with dimethylamino.
[0254]
[0274] In some embodiments, R 6a and R 6b is hydrogen, and R 6c -CH 2 NMe 2 It is.
[0255]
[0275] In some embodiments, R 6a and R 6b forms a bond, R6c is hydrogen or substituted or unsubstituted alkyl.
[0256]
[0276] In some embodiments, R 6a and R 6b forms a bond; R 6c is methyl.
[0257]
[0277] In some embodiments, the compound has formula (IXa), (IXb) or (IXc): [ka] or a pharma- ceutically acceptable salt thereof.
[0258]
[0278] In some embodiments, the compound has formula (Xa), (Xb), or (Xc): [ka] or a pharma- ceutically acceptable salt thereof.
[0259]
[0279] In some embodiments, the compound has formula (XIa), (XIb), or (XIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0260]
[0280] In some embodiments, the compound has formula (XIIa), (XIIb), or (XIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0261]
[0281] In some embodiments, the compound has formula (XIIIa), (XIIIb), or (XIIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0262]
[0282] In some embodiments, the compound has formula (XIVa), (XIVb), or (XIVc): [ka] or a pharma- ceutically acceptable salt thereof.
[0263]
[0283] In some embodiments, the compound has formula (XV): [ka] or a pharma- ceutically acceptable salt thereof.
[0264]
[0284] In some embodiments, the compound has formula (XVI): [ka] or a pharma- ceutically acceptable salt thereof.
[0265]
[0285] In some embodiments, the compound has formula (XVII): [ka] or a pharma- ceutically acceptable salt thereof.
[0266]
[0286] In some embodiments, the compound has formula (XXVIIa), (XXVIIb), or (XXVIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0267]
[0287] In some embodiments, the compound has formula (XXVIIIa), (XXVIIIb), or (XXVIIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0268]
[0288] In some embodiments, the compound has formula (XXIXa), (XXIXb) or (XXIXc): [ka] or a pharma- ceutically acceptable salt thereof.
[0269]
[0289] In some embodiments, the compound has formula (XLa), (XLb) or (XLc): [ka] or a pharma- ceutically acceptable salt thereof.
[0270]
[0290] In some embodiments, the compound has formula (XLIa), (XLIb) or (XLIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0271]
[0291] In some embodiments, the compound has formula (XLIa), (XLIb) or (XLIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0272]
[0292] In some embodiments, the compound has formula (XLIIa), (XLIIb) or (XLIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0273]
[0293] In some embodiments, the compound has formula (XLIIIa), (XLIIIb) or (XLIIIc): [ka] or a pharma- ceutically acceptable salt thereof.
[0274]
[0294] In certain embodiments, the compound is selected from compounds 1-26 and 101-112 provided herein. In certain embodiments, the compound is compound 10. In certain embodiments, the compound is compound 10. [ka] It is a racemic mixture of
[0275]
[0295] In one particular embodiment, the compound is compound 10 [ka] It is the (R) isomer of
[0276]
[0296] In one particular embodiment, the compound is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3d]pyrimidin-6-yl]phenyl]-4-[[3(R)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2 pyridinecarboxamide, or a pharma- ceutically acceptable salt thereof. In one particular embodiment, the compound is compound 10. [ka] It is the (S) isomer of
[0277]
[0297] In one particular embodiment, the compound is N-[4-[4-(4-morpholinyl)-7H-pyrrolo[2,3d]pyrimidin-6-yl]phenyl]-4-[[3(S)-[(1-oxo-2-propen-1-yl)amino]-1-piperidinyl]methyl]-2pyridinecarboxamide, or a pharma- ceutically acceptable salt thereof.
[0278]
[0298] In some embodiments, the compound is according to formula (XLIIa).
[0279]
[0299] In some embodiments, the compound is according to Formula (XLIIIa).
[0280]
[0300] Embodiments of compounds of formula (I) have low IC values of less than 1 nM or less than 0.1 nM when administered in vivo (e.g., in rats) at low doses of less than 5 mg / kg (e.g., 3 mg / kg or less). 50 values indicating improved potency against menin-MLL and / or high occupancy of the menin active site (eg, greater than 50%, greater than 70% or greater than 90% occupancy).
[0281]
[0301] In some embodiments, a pharmaceutical composition comprising a compound according to formula (I) is provided.
[0282]
[0302] In some embodiments, a pharmaceutical composition is provided that comprises a therapeutically effective amount of a compound of formula (I) and a pharma- ceutically acceptable excipient.
[0283]
[0303] In certain aspects, methods of treating diabetes are provided comprising administering to a subject in need thereof (e.g., a subject suffering from diabetes mellitus) a composition comprising a therapeutically effective amount of one or more menin-MLL inhibitor compounds described herein.
[0284]
[0304] In a particular embodiment, the menin-MLL inhibitor is compound 10. In a more particular embodiment, the menin-MLL inhibitor is the (R)-isomer of compound 10.
[0285]
[0305] In certain embodiments, the menin-MLL inhibitor is KO-539 or Zifomenib. [ka] It is.
[0286]
[0306] In certain embodiments, the menin-MLL inhibitor is SNDX-5613 or revumenib [ka] It is.
[0287]
[0307] In some embodiments, the pharmaceutical composition is formulated for a route of administration selected from oral, parenteral, buccal, nasal, topical, or rectal administration.
[0288]
[0308] In some embodiments, methods are provided for treating a diabetic disease or condition comprising administering to a patient in need thereof a pharmaceutical composition described herein. In some embodiments, the disease or condition is type 1 diabetes. In some embodiments, the disease or condition is type 2 diabetes. In some embodiments, the disease or condition is gestational diabetes. In some embodiments, the disease or condition is maturity-onset diabetes of the young. In some embodiments, the disease or condition is steroid diabetes. In some embodiments, the disease or condition is double diabetes.
[0289]
[0309] In some embodiments, a pharmaceutical composition is provided that includes a pharma- ceutically acceptable carrier and a pharma- ceutically effective amount of a compound according to any one of the formulae described herein, in some embodiments, the compound is according to any one of formulae (I)-(XLIIIc).
[0290]
[0310] In some embodiments, the pharmaceutical composition is formulated for a route of administration selected from oral, parenteral, buccal, nasal, topical, or rectal administration.
[0291]
[0311] In some embodiments, the carrier is a parenteral carrier.
[0292]
[0312] In some embodiments, the carrier is an oral carrier.
[0293]
[0313] In some embodiments, the carrier is a topical carrier.
[0294]
[0314] Any combination of the groups or embodiments described above for the various variables is contemplated herein. It is understood that one of ordinary skill in the art can select substitutions and substitution patterns in the compounds provided herein to provide compounds that are chemically stable and can be synthesized by techniques known in the art and described herein.
[0295]
[0315] Further representative embodiments of the compounds of formula (I) include the compounds listed in Table 1, or a solvate or pharma- ceutically acceptable salt thereof.
[0296]
[0316] Throughout the specification, chemical groups and substituents thereof can be chosen by one skilled in the art to provide stable chemical moieties and compounds.
[0297]
[0317] In some embodiments, the compounds of Formulae (I)-(XLIIIc) inhibit menin-MLL, hi some embodiments, the compounds of Formulae (I)-(XLIIIc) are used to treat patients suffering from menin-MLL dependent or menin-MLL interaction mediated conditions or diseases, including but not limited to diabetes mellitus.
[0298]
[0318] In some embodiments, the compounds of Formulae (I)-(XLIIIc) inhibit menin-MLL interaction. In some embodiments, the compounds of Formulae (I)-(XLIIIc) are used to treat a patient suffering from a menin-MLL interaction dependent or mediated condition or disease, including but not limited to diabetes mellitus.
[0299] Preparation of compounds
[0319] The compounds of any of formulae (I)-(XLIIIc) can be synthesized using standard synthetic reactions known to those of skill in the art or using methods known in the art. The reactions can be used in a linear sequence to provide the compounds or the reactions can be used to synthesize fragments which are then coupled by methods known in the art.
[0300]
[0320] Described herein are compounds that inhibit the activity of menin-MLL and methods for their preparation. Also described herein are pharma-ceutically acceptable salts, pharma-ceutically acceptable solvates, pharma-ceutically active metabolites, and pharma-ceutically acceptable prodrugs of such compounds. Provided are pharmaceutical compositions comprising at least one such compound, or a pharma-ceutically acceptable salt, pharma-ceutically acceptable solvate, pharma-ceutically active metabolite, or pharma-ceutically acceptable prodrug of such a compound.
[0301]
[0321] Starting materials used in the synthesis of the compounds described herein may be synthesized or obtained from commercial sources such as, but not limited to, Aldrich Chemical Co. (Milwaukee, Wisconsin), Bachem (Torrance, California), or Sigma Chemical Co. (St. Louis, Mo.). The compounds described herein, as well as other related compounds with different substituents, can be prepared, for example, by March, ADVANCED ORGANIC CHEMISTRY 4 th Ed., (Wiley 1992);Carey and Sundberg, ADVANCED ORGANICCHEMISTRY 4 th Ed., Vols. A and B (Plenum 2000, 2001);Green and Wuts, PROTECTIVE GROUPS IN ORGANICSYNTHESIS 3 rdEd., (Wiley 1999); Fieser and Fieser's Reagents for Organic Synthesis, Volumes 1-17 (John Wiley and Sons, 1991); Rodd's Chemistry of Carbon Compounds, Volumes 1-5 and Supplementals (Elsevier Science Publishers, 1989); Organic Reactions, Volumes 1-40 (John Wiley and Sons, 1991); and Larock's Comprehensive Organic Transformations (VCH Publishers Inc., 1989), all of which are incorporated herein by reference in their entireties. Further methods for synthesizing the compounds described herein can be found in WO 2020 / 142559 and WO 2020 / 142557, Arnold et al. Bioorganic & Medicinal Chemistry Letters 10 (2000) 2167-2170; and Burchat et al. Bioorganic & Medicinal Chemistry Letters 12 (2002) 1687-1690. The general methods for preparing the compounds disclosed herein can be derived from reactions known in the art, and the reactions can be modified using appropriate reagents and conditions that will be recognized by those skilled in the art for the introduction of various chemical moieties found in the formulas provided herein.
[0302]
[0322] The products of the reactions can be isolated and purified, if desired, using conventional techniques, such as, but not limited to, filtration, distillation, crystallization, chromatography, etc. Such materials can be characterized using conventional means, including physical constants and spectral data.
[0303]
[0323] The compounds described herein may be prepared as a single isomer or a mixture of isomers.
[0304]
[0324] In some embodiments, representative compounds of formula (I) are prepared according to the synthetic schemes provided herein.
[0305] Further forms of the compound
[0325] The compounds disclosed herein have the structure of formulas (I)-(XLIIIc). When referring to compounds described herein, it is understood that unless otherwise indicated, it is intended to include any compound of formula (I)-(XLIIIc), as well as all of the specific compounds falling within the scope of these general formulas.
[0306]
[0326] The compounds described herein may have one or more stereocenters, and each center may exist in either the (R)- or (S)-configuration. The compounds described herein include all diastereomeric, enantiomeric and epimeric forms, as well as the appropriate mixtures thereof. Stereoisomers can be obtained, if desired, by methods known in the art, for example, separation of stereoisomers by chiral chromatographic columns.
[0307]
[0327] Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by known methods, such as, for example, chromatography and / or fractional crystallization. In some embodiments, enantiomers can be separated by chiral chromatographic columns. In some embodiments, enantiomers can be separated by converting the enantiomeric mixture to a diastereomeric mixture by reaction with a suitable optically active compound (e.g., a chiral alcohol or amine), separating the diastereomers, and converting the individual diastereomers to the corresponding pure enantiomers (e.g., by hydrolysis). All such isomers, including diastereomers, enantiomers, and mixtures thereof, are considered part of the compositions described herein.
[0308]
[0328] The compounds disclosed herein may, in one aspect, be in purified form, and compositions comprising the compounds in purified form are disclosed herein. In certain embodiments, a composition of a substantially pure compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of impurities. An impurity may be a compound in a stereochemical form different from the desired stereochemical form. For example, a composition of a substantially pure (S) compound means that the composition contains no more than 15%, no more than 10%, no more than 5%, no more than 3%, or no more than 1% of the (R) form of the compound. Alternatively, as used herein, "enantiomeric excess (ee)" refers to a dimensionless molar ratio that represents the purity of, for example, a chiral substance containing a single stereocenter. For example, an enantiomeric excess of zero indicates a racemate (e.g., a 50:50 mixture of enantiomers, or no excess of one enantiomer over the other). As a further example, an enantiomeric excess of 99 indicates a nearly stereochemically pure enantiomer compound (ie, a large excess of one enantiomer over the other). Enantiomeric excess, ee%=([(R) compound]-[(S) compound] / ([(R) compound]+[(S) compound])×100 (where (R) compound>(S) compound); or ee%=([(S) compound]-[(R) compound] / ([(S) compound]+[(R) compound])×100 (where (S) compound>(R) compound). Furthermore, as used herein, "diastereomeric excess (de)" refers to a dimensionless molar ratio that represents the purity of a chiral substance that contains two or more stereocenters. For example, a diastereomeric excess of zero indicates an equimolar mixture of diastereoisomers. As a further example, a diastereomeric excess of 99 indicates a nearly stereochemically pure diastereomeric compound (i.e., one diastereomer is in greater excess than the other). Diastereomeric excess can be calculated by methods similar to ee. As will be appreciated by those skilled in the art, de is usually reported as de percent (de%). de% can be calculated by methods similar to ee%.
[0309]
[0329] The methods and formulations described herein include the use of N-oxides, crystalline forms (also known as polymorphs), or pharma- ceutically acceptable salts of the compounds described herein, as well as active metabolites of these compounds having the same type of activity. In some cases, compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein. In addition, the compounds described herein can exist in unsolvated forms as well as solvated forms with pharma- ceutically acceptable solvents such as water, ethanol, etc. The solvated forms of the compounds presented herein are also considered to be disclosed herein.
[0310]
[0330] The non-oxidized form of any of the compounds of formulae (I)-(XLIIIc) can be prepared from the N-oxide of any of the compounds of formulae (I)-(XLIIIc) by treatment with a reducing agent, such as, but not limited to, sulfur, sulfur dioxide, triphenylphosphine, lithium borohydride, sodium borohydride, phosphorus trichloride, tribromide, in a suitable inert organic solvent, such as, but not limited to, acetonitrile, ethanol, aqueous dioxane, at 0° C. to 80° C.
[0311]
[0331] In some embodiments, the compounds described herein are prepared as prodrugs. As used herein, "prodrug" refers to a modified drug that is converted to the parent drug in vivo. Prodrugs are often useful because in some cases they may be easier to administer than the parent drug. For example, the prodrug may be absorbed and utilized by the body, for example, by oral administration, whereas the parent may not. The prodrug may also have better solubility in pharmaceutical compositions than the parent drug. A non-limiting example of a prodrug is a compound described herein that is administered as an ester (i.e., a "prodrug") to facilitate passage through cell membranes where water solubility is detrimental to transport, but is then metabolically hydrolyzed to a carboxylic acid, and the active (parent) entity enters cells where water solubility is beneficial. A further example of a prodrug may be a short peptide (i.e., a polyamino acid) bonded to an acid group, where the peptide is metabolized to expose the active (parent) moiety. In certain embodiments, the prodrug, when administered in vivo, is chemically converted to a biologically, pharma- ceutical, or therapeutically active form of the compound. In certain embodiments, a prodrug is enzymatically metabolized by one or more steps or processes into a biologically, pharma- ceutical or therapeutically active form of the compound. To generate a prodrug, a pharma- ceutical active (parent) compound is modified such that, upon administration in vivo, the active compound is regenerated. Prodrugs can be designed to alter the metabolic stability or transport properties of the (parent) drug, to mask side effects or toxicity, to improve the taste of the (parent) drug, or to alter other properties or characteristics of the (parent) drug.Given a pharmacodynamic compound, one of skill in the art can design a prodrug of the compound given its pharmacodynamic processes and drug metabolism in vivo (see, e.g., Nogrady (1985) Medicinal Chemistry A Biochemical Approach, Oxford University Press, New York, pages 388-392; Silverman (1992), The Organic Chemistry of Drug Design and Drug Action, Academic Press, Inc., San Diego, pages 352-401, and / or Saulnier et al., (1994), Bioorganic and Medicinal Chemistry Letters, Vol. 4, p. 1985).
[0312]
[0332] Prodrug forms of the compounds described herein (wherein the prodrug is metabolized in vivo to produce a derivative described herein) are included within the scope of the appended claimed subject matter. In some instances, some of the compounds described herein may be prodrugs of another derivative or active compound.
[0313]
[0333] Prodrugs can be designed as reversible drug derivatives for use as modifiers to enhance drug transport to site-specific tissues. In some embodiments, the design of the prodrug enhances effective water solubility (e.g., Fedorak et al., Am. J. Physiol., 269:G210-218 (1995); McLoed et al., Gastroenterol, 106:405-413 (1994); Hochhaus et al., Biomed. Chrom., 6:283-286 (1992); J. Larsen and H. Bundgaard, Int. J. Pharmaceutics, 37, 87 (1987); J. Larsen et al., Int. J. Pharmaceutics, 47, 103 (1988); Sinkula et al., J. Pharm. Sci., 64:181-210(1975); T. Higuchi and V. Stella, Pro-drugs as Novel Delivery Systems, Vol. 14 of the ACS Symposium Series; and Edward B. Roche, Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987 (all references hereby incorporated in their entireties).
[0314]
[0334] Sites on the aromatic ring moiety of any of the compounds of formula (I)-(XLIIIc) are susceptible to a variety of metabolic reactions, therefore, introduction of appropriate substituents, such as halogens, on the aromatic ring structure can reduce, minimize or eliminate this metabolic pathway.
[0315]
[0335] The compounds described herein include compounds that are identical to those listed in the various formulas and chemical structures presented herein, but are isotopically labeled due to the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, sulfur, fluorine and chlorine, e.g., 2 H, 3 H, 13 C. 14 C. 15 N, 18 O. 17 O. 35 S, 18 F and 36 Certain isotopically labeled compounds described herein include, for example, 3 H and 14 Incorporating a radioactive isotope, such as C, is useful in drug and / or substrate tissue distribution assays. 2 Substitution with isotopes such as H may afford certain therapeutic advantages resulting from increased metabolic stability, such as increased in vivo half-life or reduced dosage requirements.
[0316]
[0336] In certain embodiments, the compounds described herein, when administered to an organism in need, are metabolized to produce metabolic products that are then used to produce a desired effect, e.g., a desired therapeutic effect.
[0317]
[0337] The compounds described herein can be formed as and / or used as pharma- ceutically acceptable salts. Types of pharma-ceutically acceptable salts include: (1) salts of the compounds in free base form with pharma- ceutically acceptable inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, metaphosphoric acid, and the like, or with inorganic acids, such as acetic acid, propionic acid, hexanoic acid, cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric acid, trifluoroacetic acid, tartaric acid, citric acid, benzoic acid, 3-(4-hydroxybenzoyl)benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanedisulfonic acid, 1,2-ethanedisulfonic acid, 2-hydroxyethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, 2-naphthalenesulfonic acid, 4-methylbicyclo[2.2.2]oct-2- ... (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion, such as an alkali metal ion (e.g., lithium, sodium, potassium), an alkaline earth ion (e.g., magnesium or calcium), or an aluminum ion, or is ionically coordinated with an organic base. Acceptable organic bases include ethanolamine, diethanolamine, triethanolamine, tromethamine, N-methylglucamine, and the like. Acceptable inorganic bases include aluminum hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide, and the like.
[0318]
[0338] The corresponding counter ions of pharma- ceutically acceptable salts can be analyzed and identified using a variety of methods, including but not limited to, ion exchange chromatography, ion chromatography, capillary electrophoresis, inductively coupled plasma, atomic absorption spectrometry, mass spectrometry, or any combination thereof.
[0319]
[0339] The salts are recovered by using at least one of the following techniques: filtration, precipitation with a non-solvent followed by filtration, evaporation of the solvent, or lyophilization (in the case of aqueous solutions).
[0320]
[0340] Reference to a pharmaceutically acceptable salt should be understood to include its solvent addition forms or crystal forms, particularly solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric amounts of solvent and can be formed during the process of crystallization with pharmaceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of the compounds described herein can be conveniently prepared or formed during the processes described herein. Furthermore, the compounds provided herein can exist in unsolvated and solvated forms. In general, solvated forms are considered equivalent to unsolvated forms for the purposes of the compounds and methods provided herein.
[0321]
[0341] It should be understood that a reference to a salt includes its solvent addition forms or crystal forms, particularly solvates or polymorphs. Solvates contain stoichiometric or non-stoichiometric amounts of solvent and are often formed during the process of crystallization with pharma- ceutically acceptable solvents such as water, ethanol, etc. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Polymorphs include different crystal packing arrangements of the same elemental composition of a compound. Polymorphs may have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability, and solubility. Various factors, such as recrystallization solvent, crystallization rate, and storage temperature, may result in the predominance of a single crystal form.
[0322]
[0342] The compounds described herein may be in various forms, including but not limited to amorphous, pulverized and nanoparticle forms. Additionally, the compounds described herein include crystalline forms, also known as polymorphs. Polymorphs include different crystal packing arrangements of the same elemental composition of a compound. Polymorphs usually have different X-ray diffraction patterns, infrared spectra, melting points, density, hardness, crystal shape, optical and electrical properties, stability and solubility. Various factors, such as recrystallization solvent, crystallization rate and storage temperature, may cause a single crystalline form to predominate.
[0323]
[0343] Screening and characterization of pharma- ceutically acceptable salts, polymorphs and / or solvates can be accomplished using a variety of techniques, including, but not limited to, thermal analysis, x-ray diffraction, spectroscopy, vapor sorption, and microscopy. Thermal analysis methods address thermochemical decomposition or thermophysical processes, including, but not limited to, polymorphic transitions, and such methods are used to analyze the relationship between polymorphic forms, determine weight loss, find glass transition temperatures, or for excipient compatibility testing. Such methods include, but are not limited to, differential scanning calorimetry (DSC), modulated differential scanning calorimetry (MDCS), thermogravimetric analysis (TGA), and thermogravimetric infrared analysis (TG / IR). X-ray diffraction methods include, but are not limited to, single crystal and powder diffractometers and synchrotron sources. Various spectroscopic techniques used include, but are not limited to, Raman, FTIR, UVIS, and NMR (liquid and solid state). Various microscopy techniques include, but are not limited to, polarized light microscopy, scanning electron microscopy (SEM) with energy dispersive X-ray spectroscopy (EDX), ring-controlled scanning electron microscopy with EDX (in a gas or water vapor atmosphere), IR microscopy, and Raman microscopy.
[0324]
[0344] Throughout the specification, groups and substituents thereof can be chosen by one skilled in the art to provide stable chemical moieties and compounds.
[0325] Pharmaceutical Compositions / Formulations
[0345] Pharmaceutical compositions can be formulated in a conventional manner using one or more physiologically acceptable carriers, including excipients and auxiliaries that facilitate the processing of active compounds into medicament that can be used pharmaceuticals.The appropriate formulation depends on the route of administration selected.Any of the well-known techniques, carriers and excipients can be used appropriately as understood in the art. Summary summaries of pharmaceutical compositions described herein can be found, for example, in Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999), each of which is incorporated herein by reference in its entirety.
[0326]
[0346] A pharmaceutical composition, as used herein, refers to a mixture of a compound described herein, such as any of the compounds of formula (I)-(XLIIIc), with other chemical components, such as carriers, stabilizers, diluents, dispersants, suspending agents, thickeners, and / or excipients. A pharmaceutical composition facilitates administration of a compound to an organism. In carrying out the methods of treatment or use provided herein, a therapeutically effective amount of a compound described herein is administered as a pharmaceutical composition to a mammal having the disease, disorder, or condition to be treated. In certain embodiments, the mammal is a human. The therapeutically effective amount can vary widely depending on the severity of the disease, the age and relative health of the subject, the potency of the compound used, and other factors. The compounds can be used alone or in combination with one or more therapeutic agents as components of a mixture.
[0327]
[0347] In certain embodiments, the compositions may also include one or more pH adjusting or buffering agents, including acids such as acetic acid, boric acid, citric acid, lactic acid, phosphoric acid, and hydrochloric acid, bases such as sodium hydroxide, lithium hydroxide, potassium hydroxide, and trishydroxymethylaminomethane, and buffers such as citrate / dextrose, sodium bicarbonate, and ammonium chloride. Such acids, bases, and buffers are included in amounts necessary to maintain the pH of the composition in an acceptable range.
[0328]
[0348] In some embodiments, the composition may also contain one or more salts in an amount necessary to bring the osmolality of the composition into an acceptable range. Such salts include salts having sodium, potassium or ammonium cations and chloride, citrate, ascorbate, borate, phosphate, bicarbonate, sulfate, thiosulfate or bisulfite anions, with suitable salts including sodium chloride, potassium chloride, sodium thiosulfate, sodium bisulfite and ammonium sulfate.
[0329]
[0349] The term "pharmaceutical combination" as used herein means a product resulting from the mixing or combination of two or more active ingredients, and includes both fixed and non-fixed combinations of active ingredients. The term "fixed combination" as used herein means that the active ingredients, e.g., the compounds described herein and the co-agents, are administered simultaneously in the form of a single entity or dosage. The term "non-fixed combination" as used herein means that the active ingredients, e.g., the compounds described herein and the co-agents, are administered to a patient as separate entities simultaneously, concurrently, or successively without a specific time interval, such that such administration provides an effective concentration of the two compounds in the patient's body. The latter also applies to cocktail therapy, e.g., the administration of three or more active ingredients.
[0330]
[0350] The pharmaceutical compositions described herein can be administered to a subject by multiple routes of administration, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous, intramuscular), intranasal, buccal, topical, rectal, or transdermal routes of administration. Pharmaceutical compositions described herein include, but are not limited to, aqueous dispersions, self-emulsifying dispersions, solid solutions, liposomal dispersions, aerosols, solids, powders, immediate release formulations, controlled release formulations, fast dissolving formulations, tablets, capsules, pills, delayed release formulations, sustained release formulations, pulsatile release formulations, multiparticulate formulations, and immediate and controlled release combination formulations.
[0331]
[0351] Pharmaceutical compositions containing a compound described herein can be manufactured in a conventional manner, such as by using conventional mixing, dissolving, granulating, dragee-making, levigating, emulsifying, encapsulating, entrapping or compressing processes.
[0332]
[0352] The pharmaceutical compositions include at least one compound described herein, such as any of the compounds of formulae (I)-(XLIIIc), as an active ingredient, in the form of a free acid or free base, or in the form of a pharma- ceutically acceptable salt. In addition, the methods and pharmaceutical compositions described herein include the use of N-oxides, crystalline forms (also known as polymorphs), and active metabolites of these compounds having the same type of activity. In some cases, the compounds may exist as tautomers. All tautomers are included within the scope of the compounds presented herein. In addition, the compounds described herein can exist in unsolvated forms as well as solvated forms with pharma- ceutically acceptable solvents, such as water, ethanol, and the like. Solvated forms of the compounds presented herein are also contemplated herein.
[0333]
[0353] As used herein, an "antifoaming agent" reduces the formation of bubbles during processing that can lead to coagulation of the aqueous dispersion, air bubbles in the produced film, or general adverse effects on processing. Exemplary antifoaming agents include silicone emulsions or sorbitan sesquioleate.
[0334]
[0354] As used herein, "antioxidants" include, for example, butylated hydroxytoluene (BHT), sodium ascorbate, ascorbic acid, sodium metabisulfite, and tocopherol. In certain embodiments, antioxidants enhance chemical stability as needed.
[0335]
[0355] In certain embodiments, the compositions provided herein may include one or more preservatives that inhibit microbial activity. Suitable preservatives include mercury-containing substances such as merfen and thiomersal, stabilized chlorine dioxide, and quaternary ammonium compounds such as benzalkonium chloride, cetyltrimethylammonium bromide, and cetylpyridinium chloride.
[0336]
[0356] The formulations described herein may benefit from antioxidants, metal chelators, thiol-containing compounds, and other common stabilizers. Examples of such stabilizers include: (a) about 0.5% to about 2% w / v glycerol, (b) about 0.1% to about 1% w / v methionine, (c) about 0.1% to about 2% w / v monothioglycerol, (d) about 1 mM to about 10 mM EDTA, (e) about 0.01% to about 2% w / v ascorbic acid, (f) 0.003% to about 0.02% w / v tetrahydrofuran, (g) about 1 mM to about 10 mM tetrahydrofuran, (h) about 1 mM to about 10 mM tetrahydrofuran, (i) about 1 mM to about 10 mM tetrahydrofuran, (j) about 1 mM to about 10 mM tetrahydrofuran, (k) about 1 mM to about 10 mM tetrahydrofuran, (l ... % polysorbate 80, (g) 0.001% to about 0.05% w / v polysorbate 20, (h) arginine, (i) heparin, (G) dextran sulfate, (k) cyclodextrin, (1) pentosan polysulfate and other heparinoids, (m) divalent cations such as magnesium and zinc, or (n) mixtures thereof.
[0337]
[0357] "Binders" as used herein provide cohesiveness and include, for example, alginic acid and its salts; cellulose derivatives such as carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropylmethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose (e.g., Klucel®), ethylcellulose (e.g., Ethocel®) and microcrystalline cellulose (e.g., Avicel®); microcrystalline dextrose; amylase; magnesium aluminum silicate; polysaccharide acids; bentonite; gelatin; polyvinylpyrrolidone / vinyl acetate copolymer; crospovidone; povidone; starch; pregelatinized starch; dextrin; sugars such as sucrose (e.g., Dipac®), glucose, dextrose, mannitol, sorbitol, xylitol (e.g., Xylitab®) and lactose; natural or synthetic gums such as acacia, tragacanth, ghatti gum, psyllium husk (isapol Examples of suitable antibacterial and antifungal agents include husk mucilage, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10), larch arabogalactan, Veegum®, polyethylene glycol, waxes, sodium alginate, and the like.
[0338]
[0358] As used herein, "carrier" or "carrier material" includes excipients commonly used in pharmaceuticals and should be selected based on compatibility with the compounds disclosed herein, such as any of the compounds of formulae (I)-(XLIIIc), and the release profile characteristics of the desired dosage form. Exemplary carrier materials include, for example, binders, suspending agents, disintegrants, fillers, surfactants, solubilizers, stabilizers, lubricants, wetting agents, diluents, and the like. As used herein, "pharmacologically compatible carrier materials" may include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, polyvinylpyrrolidone (PVP), cholesterol, cholesterol esters, sodium caseinate, soy lecithin, taurocholic acid, phosphotidylcholine, sodium chloride, tricalcium phosphate, dipotassium phosphate, cellulose and cellulose conjugates, sugar, sodium stearoyl lactylate, carrageenan, monoglycerides, diglycerides, pregelatinized starch, and the like. See, e.g., Remington: The Science and Practice of Pharmacy, Nineteenth Ed (Easton, Pa.: Mack Publishing Company, 1995); Hoover, John E., Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, Pennsylvania 1975; Liberman, HA and Lachman, L., Eds., Pharmaceutical Dosage Forms, Marcel Decker, New York, NY, 1980; and Pharmaceutical Dosage Forms and Drug Delivery Systems, Seventh Ed. (Lippincott Williams & Wilkins 1999).
[0339]
[0359] As used herein, "dispersing agents" and / or "viscosity modifiers" include materials that control the diffusion and homogeneity of the drug through a liquid medium or through granulation or blending processes. In some embodiments, these agents also promote the effectiveness of the coating or erosion matrix. Exemplary diffusion enhancers / dispersing agents include, for example, hydrophilic polymers, electrolytes, Tween® 60 or 80, polyethylene glycol (PEG), polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and carbohydrate-based dispersing agents, such as hydroxypropylcellulose (e.g., HPC, HPC-SL, and HPC-L), hydroxypropylmethylcellulose (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate (HPMCAS), amorphous cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinylpyrrolidone / vinyl acetate copolymer (S630), 4(1,1,3,3-tetramethylbutyl)-phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, F88®, and Fl08®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from the sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Corporation, Parsippany, NJ.), polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25 or polyvinylpyrrolidone K30, polyvinylpyrrolidone / vinyl acetate copolymer (S-630), polyethylene glycol (for example, the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 5400 to about 7000), sodium carboxymethylcellulose, methylcellulose, polysorbate 80, sodium alginate, gums such as gum tragacanth and gum acacia, guar gum, xanthan including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, polyethoxylated sorbitan monolaurate, povidone, carbomer, polyvinyl alcohol (PVA), alginates, chitosan, and combinations thereof. Plasticizers such as cellulose or triethylcellulose can also be used as dispersants. Particularly useful dispersing agents for liposomal and self-emulsifying dispersions are dimyristoyl phosphatidylcholine, natural phosphatidylcholine from eggs, natural phosphatidylglycerol from eggs, cholesterol and isopropyl myristate.
[0340]
[0360] Combinations of one or more erosion facilitators and one or more diffusion facilitators can also be used in the compositions described herein.
[0341]
[0361] The term "diluent" as used herein refers to a compound that is used to dilute the compound of interest before delivery. Diluents can also be used to stabilize the compound, since they can provide a more stable environment. Salts dissolved in buffer solutions (which can also provide pH control or maintenance) are also utilized as diluents in the art, including, but not limited to, phosphate buffered saline. In certain embodiments, diluents increase the bulk of the composition to facilitate compression or create sufficient bulk for homogeneous blending for capsule filling. Such compounds include, for example, lactose, starch, mannitol, sorbitol, dextrose, microcrystalline cellulose such as Avicel®, dibasic calcium phosphate, dicalcium phosphate dihydrate, tricalcium phosphate, calcium phosphate, anhydrous lactose, spray dried lactose, pregelatinized starch, compressible sugars such as Di-Pac® (Amstar), mannitol, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate stearate, sucrose-based diluents, powdered sugar, calcium sulfate monobasic monohydrate, calcium sulfate dihydrate, calcium lactate trihydrate, dextrates, hydrolyzed grain solids, amylase, powdered cellulose, calcium carbonate, glycine, kaolin, mannitol, sodium chloride, inositol, bentonite, and the like.
[0342]
[0362] The term "disintegrate" as used herein includes both dissolution and dispersion of the dosage form upon contact with gastrointestinal fluids. A "disintegration agent" or "disintegrant" as used herein promotes the breakup or disintegration of a substance. Examples of disintegrants include starches, e.g., natural starches such as corn starch or potato starch, pregelatinized starches such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®, celluloses such as wood products, methyl crystalline celluloses, e.g., Avicel®, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® P100, Emcocel®, Ming, etc. Examples include Tia®, Tia® and Solka-Floc®, methylcellulose, croscarmellose, or crosslinked celluloses such as crosslinked sodium carboxymethylcellulose (Ac-Di-Sol®), crosslinked carboxymethylcellulose or crosslinked croscarmellose, crosslinked starches such as sodium starch glycolate, crosslinked polymers such as crospovidone, crosslinked polyvinylpyrrolidone, alginates such as alginic acid or salts of alginic acid such as sodium alginate, clays such as Veegum® HV (magnesium aluminum silicate), gums such as agar, guar, carob, karaya, pectin or tragacanth, sodium starch glycolate, bentonite, natural sponges, surfactants, resins such as cation exchange resins, citrus pulp, sodium lauryl sulfate, sodium lauryl sulfate in combination with starch, and the like.
[0343]
[0363] "Drug absorption" or "absorption" typically refers to the process of movement of a drug from the site of administration across a barrier to the blood vessel or site of action, e.g., movement of a drug from the gastrointestinal tract into the portal vein or lymphatic system.
[0344]
[0364] As used herein, an "enteric coating" is a material that remains substantially intact in the stomach and dissolves and releases the drug in the small intestine or colon. In general, enteric coatings include polymeric materials that prevent release in the low pH environment of the stomach, but ionize at a higher pH, usually a pH of 6-7, and thus dissolve sufficiently in the small intestine or colon to release the active agent therein.
[0345]
[0365] As used herein, "erosion enhancers" include substances that control the erosion of a particular substance in gastrointestinal fluids. Erosion enhancers are generally known to those of skill in the art. Exemplary erosion enhancers include, for example, hydrophilic polymers, electrolytes, proteins, peptides, and amino acids.
[0346]
[0366] "Bulking agents" as used herein include compounds such as lactose, calcium carbonate, calcium phosphate, dibasic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starch, pregelatinized starch, sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
[0347]
[0367] "Flavoring agents" and / or "sweetening agents" useful in the formulations described herein include, for example, acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana, bavarois cream, berry, blackcurrant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dextrose, eucalyptus, eugenol, fructose, fruit punch, ginger, glycyrrhetinic acid salts, licorice syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glycyrrhizinate (MagnaSweet®), maltol, mannitol, maple, marshmallow, menthol, mint, ream, mixed berry, neohesperidin DC, neotame, orange, pear, peach, peppermint, peppermint cream, Prosweet® powder, raspberry, root beer, rum, saccharin, safrole, sorbitol, spearmint, spearmint cream, strawberry, strawberry cream, stevia, sucralose, sucrose, sodium saccharin, saccharin, acesulfame potassium, talin, cylitol, Swiss cream, tagatose, tangerine, thaumatin, tutti frutti, vanilla, walnut, watermelon, wild cherry, wintergreen, xylitol, or any combination of these flavor ingredients, such as anise-menthol, cherry-anise, cinnamon-orange, cherry-cinnamon, chocolate-mint, honey-lemon, lemon-lime, lemon-mint, menthol-eucalyptus, orange-cream, vanilla-mint, and mixtures thereof.
[0348]
[0368] As used herein, "lubricants" and "glidants" are compounds that prevent, reduce or inhibit the sticking or friction of materials. Exemplary lubricants include, for example, stearic acid, calcium hydroxide, talc, sodium stearyl fumarate, hydrocarbons such as mineral oil, hydrogenated vegetable oils such as hydrogenated soybean oil (Sterotex®), higher fatty acids and their alkali metal and alkaline earth metal salts (e.g., aluminum, magnesium, zinc), stearic acid, sodium stearate, glycerol, wax, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, polyethylene glycol (e.g., PEG-4000) or methoxypolyethylene glycol such as Carbowax®, sodium oleate, glyceryl behenate, magnesium or sodium lauryl sulfate, colloidal silica such as Syloid®, Cab-O-Sil®, starch such as corn starch, silicone oil, surfactants, and the like.
[0349]
[0369] As used herein, "measurable serum concentration" or "measurable plasma concentration" refers to the serum or plasma concentration, usually measured in mg, μg, or ng, of therapeutic agent per mL, dL, or L of serum, that is absorbed into the bloodstream following administration. As used herein, measurable plasma concentrations are typically measured in ng / mL or μg / mL.
[0350]
[0370] As used herein, "pharmacodynamics" refers to the factors that determine the biological response observed relative to the concentration of a drug at a site of action.
[0351]
[0371] As used herein, "pharmacokinetics" refers to the factors that determine the achievement and maintenance of an adequate concentration of a drug at a site of action.
[0352]
[0372] As used herein, a "plasticizer" is a compound used to soften microencapsulation materials or film coatings to make them less brittle. Suitable plasticizers include, for example, polyethylene glycols such as PEG300, PEG400, PEG600, PEG1450, PEG3350 and PEG800, stearic acid, propylene glycol, oleic acid, triethylcellulose, and triacetin. In some embodiments, plasticizers can also function as dispersing or wetting agents.
[0353]
[0373] As used herein, "solubilizing agents" include compounds such as triacetin, triethyl citrate, ethyl oleate, ethyl caprylate, sodium lauryl sulfate, sodium docusate, vitamin E TPGS, dimethylacetamide, N-methylpyrrolidone, N-hydroxyethylpyrrolidone, polyvinylpyrrolidone, hydroxypropyl methylcellulose, hydroxypropyl cyclodextrin, ethanol, n-butanol, isopropyl alcohol, cholesterol, bile salts, polyethylene glycol 200-600, glycofurol, transcutol, propylene glycol, and dimethyl isosorbide.
[0354]
[0374] As used herein, "stabilizer" includes compounds such as any antioxidant, buffer, acid, preservative, etc.
[0355]
[0375] "Steady state," as used herein, is when the amount of drug administered equals the amount of drug cleared within one dosing interval, resulting in a plateau or constant plasma drug exposure.
[0356]
[0376] As used herein, the term "suspending agent" includes polyvinylpyrrolidone (e.g., polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30), vinylpyrrolidone / vinyl acetate copolymer (S630), polyethylene glycol (e.g., the polyethylene glycol can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 5400 to about 7000), sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, hydroxymethylcellulose, ... Examples of suitable cellulose acetate stearate, polysorbate 80, hydroxyethylcellulose, sodium alginate, gums such as gum tragacanth and gum acacia, guar gum, xanthan including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone and the like.
[0357]
[0377] "Surfactants" include compounds such as sodium lauryl sulfate, sodium docusate, Tween® 60 or 80, triacetin, vitamin E TPGS, sorbitan monooleate, polyoxyethylene polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, such as Pluronic® (BASF). Some other surfactants include polyoxyethylene fatty acid glycerides and vegetable oils, such as polyoxyethylene (60) hydrogenated castor oil; and polyoxyethylene alkyl ethers and alkyl phenyl ethers, such as octoxynol 10 and octoxynol 40. In some embodiments, surfactants may be included to enhance physical stability or for other purposes.
[0358]
[0378] "Thickening agents" as used herein include, for example, methylcellulose, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, hydroxypropylmethylcellulose acetate stearate, hydroxypropylmethylcellulose phthalate, carbomer, polyvinyl alcohol, alginates, acacia, chitosan, and combinations thereof.
[0359]
[0379] "Wetting agents" as used herein include compounds such as oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium docusate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, Tween® 80, Vitamin E TPGS, ammonium salts, and the like.
[0360] Dosage form
[0380] The compositions described herein can be formulated for administration to a subject by any conventional means, including, but not limited to, oral, parenteral (e.g., intravenous, subcutaneous or intramuscular), buccal, intranasal, rectal or transdermal routes of administration. As used herein, the term "subject" is used to mean an animal, e.g., a mammal, including a human or non-human. The terms "patient" and "subject" herein can be used interchangeably.
[0361]
[0381] The pharmaceutical compositions described herein comprising a compound of any of Formulae (I)-(XLIIIc) can be formulated into any suitable dosage form, such as, but not limited to, aqueous oral dispersions, liquids, gels, syrups, elixirs, slurries, suspensions and the like for oral ingestion by a patient to be treated, solid oral dosage forms, aerosols, controlled release formulations, fast dissolve formulations, effervescent formulations, lyophilized formulations, tablets, powders, pills, dragees, capsules, delayed release formulations, sustained release formulations, pulsatile release formulations, multiparticulate formulations, and immediate and controlled release mixed formulations.
[0362]
[0382] Pharmaceutical preparations for oral use can be obtained by mixing one or more solid excipients with one or more of the compounds described herein, optionally grinding the resulting mixture, adding suitable auxiliaries as necessary, and then processing the mixture of granules to obtain tablets or dragee cores.Suitable excipients include, for example, fillers such as sugars, including lactose, sucrose, mannitol or sorbitol; cellulose preparations, such as corn starch, wheat starch, rice starch, potato starch, gelatin, tragacanth gum, methylcellulose, microcrystalline cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose; or others, such as polyvinylpyrrolidone (PVP or povidone) or calcium phosphate.If necessary, disintegrants, such as cross-linked croscarmellose sodium, polyvinylpyrrolidone, agar, alginic acid, or its salts, such as sodium alginate, can be added.
[0363]
[0383] Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinylpyrridone, carbopol gel, polyethylene glycol and / or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyes or pigments can be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
[0364]
[0384] Pharmaceutical preparations that can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer such as glycerol or sorbitol. The push-fit capsules can contain the active ingredient mixed with a filler such as lactose, a binder such as starch, and / or a lubricant such as talc or magnesium stearate, and optionally a stabilizer. In soft capsules, the active compound can be dissolved or suspended in a suitable liquid, such as fatty oils, liquid paraffin, or liquid polyethylene glycol. Additionally, stabilizers may be added. All preparations for oral administration should be in dosages suitable for such administration.
[0365]
[0385] In some embodiments, the solid dosage forms disclosed herein may be in the form of a tablet (including a suspension tablet, a fast dissolving tablet, a bite-disintegrating tablet, an ultrafast disintegrating tablet, an effervescent tablet, or a caplet), a pill, a powder (including a sterile packaged powder, a dispensable powder, or an effervescent powder), a capsule (including both soft or hard capsules, such as capsules made from animal-derived gelatin or plant-derived HPMC, or "sprinkle capsules"), a solid dispersion, a solid solution, a bioerodible dosage form, a controlled release formulation, a pulsed release dosage form, a multiparticulate dosage form, a pellet, a granule, or an aerosol. In some embodiments, the pharmaceutical composition is in the form of a powder. In some embodiments, the pharmaceutical composition is in the form of a tablet, such as, but not limited to, a fast dissolving tablet. Furthermore, the pharmaceutical compositions described herein may be administered as a single capsule or in a multiple capsule dosage form. In some embodiments, the pharmaceutical composition is administered in two or three or four capsules or tablets.
[0366]
[0386] In some embodiments, solid dosage forms, such as tablets, effervescent tablets, and capsules, are prepared by mixing particles of any of the compounds of formulae (I)-(XLIIIc) with one or more pharmaceutical excipients to form a bulk blend composition. When these bulk blend compositions are referred to as homogeneous, it is meant that the particles of any of the compounds of formulae (I)-(XLIIIc) are evenly distributed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms, such as tablets, pills, and capsules. Individual unit doses may also include a film coating that disintegrates upon oral ingestion or contact with a diluent. These formulations can be manufactured by conventional pharmacological techniques.
[0367]
[0387] Traditional pharmaceutical techniques include, for example, one or a combination of the following methods: (1) dry blending, (2) direct compression, (3) milling, (4) dry or non-aqueous granulation, (5) wet granulation, or (6) fusion. See, for example, Lachman et al., The Theory and Practice of Industrial Pharmacy (1986). Other methods include, for example, spray drying, pan coating, melt granulation, granulation, fluidized bed spray drying or coating (e.g., Wurster coating), tangential coating, top spray, tabletting, extrusion, and the like.
[0368]
[0388] The pharmaceutical solid dosage forms described herein may include a compound described herein and one or more pharma- ceutically acceptable excipients, compatible carriers, binders, fillers, suspending agents, flavoring agents, sweetening agents, disintegrants, dispersing agents, surfactants, lubricants, colorants, diluents, solubilizers, wetting agents, plasticizers, stabilizers, permeation enhancers, humectants, antifoaming agents, antioxidants, preservatives, or combinations of one or more thereof. In some embodiments, a formulation of a compound of any of Formulas (I)-(XLIIIc) is film-coated using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000). In some embodiments, some or all of the particles of a compound of any of Formulas (I)-(XLIIIc) are coated. In some embodiments, some or all of the particles of a compound of any of Formulas (I)-(XLIIIc) are microencapsulated. In some further embodiments, the particles of a compound of any of Formulas (I)-(XLIIIc) are not microencapsulated or coated.
[0369]
[0389] Carriers suitable for use in the solid dosage forms described herein include, but are not limited to, acacia, gelatin, colloidal silicon dioxide, calcium glycerophosphate, calcium lactate, maltodextrin, glycerin, magnesium silicate, sodium caseinate, soy lecithin, sodium chloride, tricalcium phosphate, dipotassium phosphate, sodium stearoyl lactylate, carrageenan, monoglycerides, diglycerides, pregelatinized starch, hydroxypropyl methylcellulose, hydroxypropyl methylcellulose acetate stearate, sucrose, microcrystalline cellulose, lactose, mannitol, and the like.
[0370]
[0390] Fillers suitable for use in the solid dosage forms described herein include, but are not limited to, lactose, calcium carbonate, calcium phosphate, basic calcium phosphate, calcium sulfate, microcrystalline cellulose, cellulose powder, dextrose, dextrates, dextran, starch, pregelatinized starch, hydroxypropyl methycellulose (HPMC), hydroxypropyl methycellulose phthalate, hydroxypropyl methylcellulose acetate stearate (HPMCAS), sucrose, xylitol, lactitol, mannitol, sorbitol, sodium chloride, polyethylene glycol, and the like.
[0371]
[0391] In order to release the compound of any of formulae (I)-(XLIIIc) from the solid dosage form matrix as efficiently as possible, disintegrants are often used in the formulation, especially when the dosage form is compressed with a binder. Disintegrants help the dosage form matrix to burst by swelling or capillary action when moisture is absorbed into the dosage form. Disintegrants suitable for use in the solid dosage forms described herein include natural starches such as corn starch or potato starch, pregelatinized starches such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®, celluloses such as wood products, methyl crystalline cellulose, e.g. Avicel®, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® P100, Emcocel®, Vivacel®, Ming These include, but are not limited to, Tia® and Solka-Floc®, methylcellulose, croscarmellose, or crosslinked celluloses such as crosslinked carboxymethylcellulose (Ac-Di-Sol®), crosslinked carboxymethylcellulose or crosslinked croscarmellose, crosslinked starches such as sodium starch glycolate, crosslinked polymers such as crospovidone, crosslinked polyvinylpyrrolidone, alginates such as alginic acid or salts of alginic acid such as sodium alginate, clays such as Veegum® HV (magnesium aluminum silicate), gums such as agar, guar, carob, karaya, pectin or tragacanth, sodium starch glycolate, bentonite, natural sponges, surfactants, resins such as cation exchange resins, citrus pulp, sodium lauryl sulfate, sodium lauryl sulfate in combination with starch, and the like.
[0372]
[0392] Binders impart cohesiveness to solid oral dosage form formulations. In powder-filled capsule formulations, they aid in the formation of a plug that can be filled into soft or hard shell capsules, and in tablet formulations, they ensure that the tablet remains intact after compression and help ensure blend uniformity prior to the compression or filling step. Materials suitable for use as binders in the solid dosage forms described herein include carboxymethylcellulose, methylcellulose (e.g., Methocel®), hydroxypropyl methylcellulose (e.g., Hypromellose USP Pharmacoat-603, Hydroxypropyl methylcellulose acetate stearate (Aqoate Examples of suitable cellulose derivatives include cellulose acetate, cellulose phosphate, cellulose phosphate-soluble cellulose, cellulose phosphate-soluble cellulose, cellulose acetate ... Examples of suitable additives include, but are not limited to, husk mucilage, starch, polyvinylpyrrolidone (e.g., Polyvidone® CL, Kollidon® CL, Polyplasdone® XL-10, and Povidone® K-12), larch arabogalactan, Veegum®, polyethylene glycol, wax, sodium alginate, and the like.
[0373]
[0393] Generally, binder levels of 20-70% are used in powder-filled gelatin capsule formulations. The binder usage level in tablet formulations varies depending on whether it is direct compression, wet granulation, roller compaction, or the use of other excipients such as fillers that can act as moderate binders. Those skilled in the art can determine the binder level of their formulation, but binder usage levels up to 70% are common in tablet formulations.
[0374]
[0394] Suitable lubricants or glidants for use in the solid dosage forms described herein include, but are not limited to, stearic acid, calcium hydroxide, talc, corn starch, sodium stearyl fumarate, alkali metal and alkaline earth metal salts (e.g., aluminum, magnesium, zinc), stearic acid, sodium stearate, magnesium stearate, zinc stearate, wax, Stearowet®, boric acid, sodium benzoate, sodium acetate, sodium chloride, leucine, polyethylene glycol or methoxypolyethylene glycol (e.g., Carbowax™, PEG 4000, PEG 5000, PEG 6000, propylene glycol, sodium oleate, glyceryl behenate, glyceryl palmitostearate, glyceryl benzoate, magnesium lauryl sulfate or sodium lauryl sulfate, and the like.
[0375]
[0395] Suitable diluents for use in the solid dosage forms described herein include, but are not limited to, sugars (including lactose, sucrose, and dextrose), polysaccharides (including dextrates and maltodextrins), polyols (including mannitol, xylitol, and sorbitol), cyclodextrins, and the like.
[0376]
[0396] As used herein, the term "water-insoluble diluent" refers to calcium phosphate, calcium sulfate, starch, modified starch, and microcrystalline cellulose, and microcellulose (e.g., about 0.45 g / cm 3The present invention shows compounds commonly used in the formulation of pharmaceuticals, such as Avicel, powdered cellulose, having a density of 1000 nm, and talc.
[0377]
[0397] Suitable humectants for use in the solid dosage forms described herein include, for example, oleic acid, glyceryl monostearate, sorbitan monooleate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, quaternary ammonium compounds (e.g., Polyquat IO®), sodium oleate, sodium lauryl sulfate, magnesium stearate, sodium docusate, triacetin, vitamin E TPGS, and the like.
[0378]
[0398] Suitable surfactants for use in the solid dosage forms described herein include, for example, sodium lauryl sulfate, sorbitan monooleate, polyoxyethylene sorbitan monooleate, polysorbates, polaxomers, bile salts, glyceryl monostearate, copolymers of ethylene oxide and propylene oxide, such as Pluronic® (BASF), and the like.
[0379]
[0399] Suitable suspending agents for use in the solid dosage forms described herein include polyvinylpyrrolidins, such as polyvinylpyrrolidone K12, polyvinylpyrrolidone K17, polyvinylpyrrolidone K25, or polyvinylpyrrolidone K30, polyethylene glycols (e.g., the polyethylene glycols can have a molecular weight of about 300 to about 6000, or about 3350 to about 4000, or about 5400 to about 7000), vinylpyrrolidone / vinyl acetate copolymer (S630), sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, poly These include, but are not limited to, sorbate 80, hydroxyethylcellulose, sodium alginate, gums such as tragacanth and acacia gum, guar gum, xanthan including xanthan gum, sugars, cellulose derivatives such as sodium carboxymethylcellulose, methylcellulose, sodium carboxymethylcellulose, hydroxypropyl methylcellulose, hydroxyethylcellulose, polysorbate 80, sodium alginate, polyethoxylated sorbitan monolaurate, polyethoxylated sorbitan monolaurate, povidone, and the like.
[0380]
[0400] Suitable antioxidants for use in the solid dosage forms described herein include, for example, butylated hydroxytoluene (BHT), sodium ascorbate, and tocopherol.
[0381]
[0401] It should be understood that there is a great deal of overlap between the additives used in the solid dosage forms described herein.Therefore, the additives listed above should be taken as merely illustrative and not limiting the types of additives that can be included in the solid dosage forms described herein.The amount of such additives can be easily determined by those skilled in the art according to the specific properties desired.
[0382]
[0402] In some embodiments, one or more layers of the pharmaceutical composition are plasticized. Illustratively, plasticizers are generally high boiling solids or liquids. Suitable plasticizers can be added at about 0.01% to about 50% by weight (w / w) of the coating composition. Plasticizers include, but are not limited to, diethyl phthalate, citrate esters, polyethylene glycol, glycerol, acetylated glycerides, triacetin, polypropylene glycol, triethyl citrate, dibutyl sebacate, stearic acid, stearol, stearates, and castor oil.
[0383]
[0403] Compressed tablets are solid dosage forms prepared by compressing bulk blends of the formulations described above. In various embodiments, compressed tablets designed to dissolve in the mouth include one or more flavoring agents. In some embodiments, compressed tablets include a film surrounding the final compressed tablet. In some embodiments, the film coating can provide a delayed release of the compound of any of Formulae (I)-(XLIIIc) from the formulation. In some embodiments, the film coating aids in patient compliance (e.g., Opadry® coating or sugar coating). Film coatings, including Opadry®, typically range from about 1% to about 3% of the tablet weight. In some embodiments, compressed tablets include one or more excipients.
[0384]
[0404] Capsules can be prepared, for example, by placing a bulk blend of a formulation of any of the compounds of formulae (I)-(XLIIIc) above into a capsule. In some embodiments, the formulation (non-aqueous suspension and solution) is placed into a soft gelatin capsule. In some embodiments, the formulation is placed into a standard gelatin capsule or a non-gelatin capsule, such as a capsule containing HPMC. In some embodiments, the formulation is placed into a sprinkle capsule, which may be swallowed whole, or the capsule may be opened and the contents sprinkled on food before a meal. In some embodiments, a therapeutic dose is split into multiple (e.g., 2, 3, or 4) capsules. In some embodiments, the entire dose of the formulation is delivered in capsule form.
[0385]
[0405] In various embodiments, particles of a compound of any of Formulae (I)-(XLIIIc) and one or more excipients are dry blended and compressed into a mass, such as a tablet, having sufficient hardness to provide a pharmaceutical composition that substantially disintegrates within less than about 30 minutes, less than about 35 minutes, less than about 40 minutes, less than about 45 minutes, less than about 50 minutes, less than about 55 minutes, or less than about 60 minutes after oral administration, thereby releasing the formulation into the gastrointestinal fluids.
[0386]
[0406] In some embodiments, the dosage form may comprise a microencapsulated formulation.In some embodiments, one or more other compatible materials are included in the microencapsulated material.Exemplary materials include, but are not limited to, pH adjusters, erosion promoters, antifoaming agents, antioxidants, flavoring agents, and carrier materials such as binders, suspending agents, disintegrating agents, fillers, surfactants, solubilizers, stabilizers, lubricants, wetting agents and diluents.
[0387]
[0407] Materials useful for microencapsulation as described herein include materials compatible with any of the compounds of formulae (I)-(XLIIIc) that sufficiently isolate the compound of formulae (I)-(XLIIIc) from other incompatible excipients. Materials compatible with any of the compounds of formulae (I)-(XLIIIc) are materials that retard the release of any of the compounds of formulae (I)-(XLIIIc) in vivo.
[0388]
[0408] Exemplary microencapsulation materials useful for delaying the release of formulations comprising the compounds described herein include hydroxypropyl cellulose ethers (HPC), such as Klucel® or Nisso HPC, low-substituted hydroxypropyl cellulose ethers (L-HPC), hydroxypropyl methylcellulose ethers (HPMC), such as Seppifilm-LC, Pharmacoat®, Metolose SR, Methocel®-E, Opadry YS, PrimaFlo, Benecel MP824, Benecel MP843, methylcellulose polymers, such as Methocel®-A, hydroxypropyl methylcellulose acetates, Aqoat (HF-LS, HF-LG, HF-MS) and Metolose®, ethylcellulose (EC), and mixtures thereof, such as Ethocel®, Aqualon®-EC, Surelease®, Opadry®, and the like. Polyvinyl alcohols (PVA) such as AMB, hydroxyethylcelluloses such as Natrosol®, salts of carboxymethylcellulose (CMC) such as carboxymethylcellulose and Aqualon®-CMC, copolymers of polyvinyl alcohol and polyethylene glycol such as Kollicoat IR®, monoglycerides (Myverol), triglycerides (KLX), polyethylene glycols, modified food starches, mixtures of acrylic polymers and cellulose ethers such as Eudragit® EPO, Eudragit® L30D-55, Eudragit® FS 30D, Eudragit® L100-55, Eudragit® L100, Eudragit® S100, Eudragit® RD100, Eudragit® E100, Edragit® L12.5, Eudragit® S12.5, Eudragit® NE30D and Eudragit® NE 40D, cellulose acetate phthalate, sepifilms such as mixtures of HPMC and stearic acid, cyclodextrins, and mixtures of these materials.
[0389]
[0409] In some embodiments, plasticizers such as polyethylene glycols, e.g., PEG300, PEG400, PEG600, PEG1450, PEG3350 and PEG800, stearic acid, propylene glycol, oleic acid, and triacetin are introduced into the microencapsulation material. In some embodiments, microencapsulation materials useful for delaying the release of pharmaceutical compositions are from the USP or National Formulary (NF). In some embodiments, the microencapsulation material is Klucel. In some embodiments, the microencapsulation material is methocel.
[0390]
[0410] Microencapsulated compounds of any of Formulae (I)-(XLIIIc) can be formulated by methods known to those skilled in the art. Such known methods include, for example, spray drying, spinning disk-solvent, hot melt, spray cooling, fluidized bed, electrostatic deposition, centrifugal extrusion, rotary suspension separation, polymerization at liquid-gas or solid-gas interface, pressure extrusion, or spray solvent extraction bath. In addition to these, some chemical techniques can also be used, such as complex coacervation, solvent evaporation, polymer-polymer incompatibility, interfacial polymerization in liquid media, in situ polymerization, drying in liquid, and desolvation in liquid media. Furthermore, other methods such as roller compaction, extrusion / spheronization, coacervation, or nanoparticle coating can also be used.
[0391]
[0411] In some embodiments, particles of a compound of any of Formulae (I)-(XLIIIc) are microencapsulated prior to being formulated into one of the above forms, and in some embodiments, some or most of the particles are coated prior to further formulation by using standard coating procedures, such as those described in Remington's Pharmaceutical Sciences, 20th Edition (2000).
[0392]
[0412] In some embodiments, the solid dosage form of the compound of any of Formulae (I)-(XLIIIc) is plasticized (coated) with one or more layers. Illustratively, the plasticizer is generally a high boiling point solid or liquid. Suitable plasticizers can be added at about 0.01% to about 50% by weight (w / w) of the coating composition. Plasticizers include, but are not limited to, diethyl phthalate, citrate esters, polyethylene glycol, glycerol, acetylated glycerides, triacetin, polypropylene glycol, triethyl citrate, dibutyl sebacate, stearic acid, stearol, stearates, and castor oil.
[0393]
[0413] In some embodiments, powders containing formulations comprising any of the compounds of formulae (I)-(XLIIIc) described herein can be formulated to include one or more pharmaceutical excipients and flavoring agents. Such powders can be prepared, for example, by mixing the formulation with optional pharmaceutical excipients to form a bulk blend composition. Further embodiments also include a suspending agent and / or a wetting agent. This bulk blend is uniformly subdivided into unit dose packages or multi-dose packages.
[0394]
[0414] Further, in some embodiments, effervescent powders are also prepared according to the present disclosure. Effervescent salts have been used to disperse drugs in water for oral administration. Effervescent salts are granules or coarse powders that contain drugs in a dry mixture, usually consisting of sodium bicarbonate, citric acid, and / or tartaric acid. When the salt of the compositions described herein is added to water, the acid and base react to liberate carbon dioxide gas, thereby causing "effervescence." Examples of effervescent salts include, for example, the following ingredients: sodium bicarbonate or a mixture of sodium bicarbonate and sodium carbonate, citric acid, and / or tartaric acid. Instead of the combination of sodium bicarbonate and citric acid and tartaric acid, any acid-base combination that results in the liberation of carbon dioxide can be used, so long as the ingredients are suitable for pharmaceutical use and result in a pH of about 6.0 or higher.
[0395]
[0415] In some embodiments, the formulations described herein that include a compound of formula (I)-(XLIIIc) are solid dispersions. Methods for producing such solid dispersions are known in the art, including, but not limited to, U.S. Pat. Nos. 4,343,789, 5,340,591, 5,456,923, 5,700,485, 5,723,269, and U.S. Patent Application Publication No. 2004 / 0013734, each of which is specifically incorporated herein by reference. In some embodiments, the formulations described herein are solid solutions. Solid solutions incorporate a substance together with an active agent and other excipients, and the drug is dissolved by heating the mixture, and then the resulting composition is cooled to provide a solid blend that can be further formulated or added directly to a capsule or compressed into a tablet. Methods for producing such solid solutions are known in the art and include, but are not limited to, U.S. Pat. Nos. 4,151,273, 5,281,420, and 6,083,518, each of which is specifically incorporated herein by reference.
[0396]
[0416] Pharmaceutical solid oral dosage forms, including the formulations described herein that include any of the compounds of formulae (I)-(XLIIIc), can be further formulated to control the release of the compounds of formulae (I)-(XLIIIc). Controlled release refers to the release of any of the compounds of formulae (I)-(XLIIIc) from the dosage form in which it is incorporated, with a desired profile over an extended period of time. Controlled release profiles include, for example, sustained release, extended release, pulsed release, and delayed release profiles. In contrast to immediate release compositions, controlled release compositions allow the delivery of a drug to a subject over an extended period of time according to a predetermined profile. Such release rates can provide therapeutically effective levels of the drug over an extended period of time, thereby providing a longer duration of pharmacological response while minimizing side effects compared to conventional rapid release dosage forms. Such longer response periods provide many unique advantages that are not achieved with the corresponding short-acting immediate release formulations.
[0397]
[0417] In some embodiments, the solid dosage forms described herein can be formulated as enterically coated delayed release oral dosage forms (i.e., oral dosage forms of the pharmaceutical compositions described herein that utilize an enteric coating to affect release in the small intestine of the gastrointestinal tract). The enterically coated dosage forms can be compressed or molded or extruded tablets / formulations (coated or uncoated) that contain granules, powders, pellets, beads or particles of the active ingredient and / or other composition ingredients, which are themselves coated or uncoated. The enterically coated oral dosage forms can also be capsules (coated or uncoated) that contain solid carriers or pellets, beads or granules of the composition, which are themselves coated or uncoated.
[0398]
[0418] The term "delayed release" as used herein refers to delivery of a compound where release can be achieved at a generally predictable location in the intestinal tract distal to that which would have been achieved in the absence of the delayed release alteration. In some embodiments, the method for delayed release is by coating. Any coating can be thick enough such that the entire coating does not dissolve in gastrointestinal fluids at a pH below about 5, but dissolves at a pH of about 5 or greater. It is expected that any anionic polymer that exhibits a pH-dependent solubility profile can be used as an enteric coating in the methods and compositions described herein to achieve delivery to the lower gastrointestinal tract. In some embodiments, the polymers described herein are anionic carboxylic acid polymers. In some embodiments, the polymers and their compatible mixtures, as well as some of their properties, include, but are not limited to, the following: Shellac, also called refined lac. Shellac is a refined product obtained from the resinous secretions of insects. This coating dissolves in media with a pH>7; Acrylic polymers. The performance of acrylic polymers (mainly their solubility in biological fluids) can vary based on the degree and type of substitution. Examples of suitable acrylic polymers include methacrylic acid copolymers and ammonium methacrylate copolymers. Eudragit series E, L, S, RL, RS and NE (Rohm Pharma) are available solubilized in organic solvents, aqueous dispersions or dry powders. Eudragit series RL, NE and RS are insoluble in the gastrointestinal tract but permeable and are primarily used for colonic targeting. Eudragit series E dissolves in the stomach. Eudragit series L, L-30D and S are insoluble in the stomach and dissolve in the intestine; Cellulose derivatives. Examples of suitable cellulose derivatives are ethyl cellulose; and reaction mixtures of partial acetate esters of cellulose with phthalic anhydride. Performance may vary based on the degree and type of substitution. Cellulose acetate phthalate (CAP) dissolves at pH>6. Aquateric (FMC) is a water-based system and is a spray-dried CAP pseudolatex with particles of <1 μm. Other ingredients in Aquateric include pluronic, Tweens®, and acetylated monoglycerides. Other suitable cellulose derivatives include cellulose acetate trimellitate (Eastman); methylcellulose (Pharmacoat, Methocel); hydroxypropyl methylcellulose phthalate (HPMCP); hydroxypropyl methylcellulose succinate alginate (HPMCS) and hydroxypropyl methylcellulose acetate succinate (e.g., AQOAT (Shin Etsu)). Performance may vary based on the degree and type of substitution. For example, HPMCP such as HP-50, HP-55, HP-55S and HP-55F grades are suitable. Performance may vary based on the degree and type of substitution. For example, suitable grades of hydroxypropyl methylcellulose acetate succinate include, but are not limited to, AS-LG (LF), which dissolves at pH 5, AS-MG (MF), which dissolves at pH 5.5, and AS-HG (HF), which dissolves at higher pH. These polymers are provided as granules or as fine powders for aqueous dispersion; Polyvinyl acetate phthalate (PVAP): PVAP is soluble at pH>5 and has very low permeability to water vapor and gastric juices.
[0399]
[0419] In some embodiments, the coating can and usually does contain a plasticizer and optionally other coating excipients such as colorants, talc and / or magnesium stearate, which are well known in the art. Suitable plasticizers include triethyl citrate (Citroflex 2), triacetin (glyceryl triacetate), acetyl triethyl citrate (Citroflec A2), Carbowax 400 (polyethylene glycol 400), diethyl phthalate, tributyl citrate, acetylated monoglycerides, glycerol, fatty acid esters, propylene glycol and dibutyl phthalate. In particular, anionic carboxylic acrylic polymers usually contain 10-25% by weight of a plasticizer, in particular dibutyl phthalate, polyethylene glycol, triethyl citrate and triacetin. Conventional coating techniques such as spray coating or pan coating are used to apply the coating. The thickness of the coating must be thick enough to ensure that the oral dosage form remains intact until the desired site of topical delivery in the intestinal tract is reached.
[0400]
[0420] Colorants, antiblocking agents, surfactants, defoamers, lubricants (e.g., carnauba wax or PEG) can be added to the coating in place of plasticizers to solubilize or disperse the coating materials and improve coating performance and the coated product.
[0401]
[0421] In some embodiments, the formulations described herein that include a compound of Formula (I)-(XLIIIc) are delivered using a pulsatile dosage form. The pulsatile dosage form can provide one or more immediate release pulses at a predetermined time point after a controlled lag time or at a specific site. The pulsatile dosage form, including the formulations described herein that include a compound of any of Formulas (I)-(XLIIIc), can be administered using a variety of pulsatile dosage forms known in the art. For example, such formulations include, but are not limited to, those described in U.S. Patent Nos. 5,011,692, 5,017,381, 5,229,135, and 5,840,329, each of which is specifically incorporated herein by reference. Other pulsatile release dosage forms suitable for use with the formulations of the present invention include, but are not limited to, U.S. Patent Nos. 4,871,549, 5,260,068, 5,260,069, 5,508,040, 5,567,441, and 5,837,284, all of which are specifically incorporated herein by reference. In some embodiments, the controlled release dosage form is a pulsatile release solid oral dosage form comprising at least two particle groups (i.e., multiparticulates), each of which contains a formulation as described herein. The first particle group provides a substantially immediate dose of any of the compounds of formulae (I)-(XLIIIc) upon ingestion by a mammal. The first particle group may be uncoated or may include a coating and / or sealant. The second group of particles comprises coated particles comprising about 2% to about 75%, about 2.5% to about 70%, or about 40% to about 70% by weight of the total dose of a compound of any of Formulae (I)-(XLIIIc) in the formulation, mixed with one or more binders. The coating comprises a pharma- ceutically acceptable component in an amount sufficient to provide a delay of about 2 hours to about 7 hours after ingestion before releasing the second dose.Suitable coatings include, by way of example only, one or more differentially degradable coatings, such as pH-sensitive coatings (enteric coatings), e.g., acrylic resins (e.g., Eudragit® EPO, Eudragit® L30D-55, Eudragit® FS 30D, Eudragit® L100-55, Eudragit® LI00, Eudragit® S100, Eudragit® RD100, Eudragit® E100, Eudragit® L12.5, Eudragit® S12.5, Eudragit® NE30D, and Eudragit® NE 40D®), either alone or blended with a cellulose derivative, e.g., ethylcellulose, or non-enteric coatings of varying thickness that alter the release properties of a formulation comprising a compound of any of Formulae (I)-(XLIIIc).
[0402]
[0422] Many other types of controlled release systems known to those skilled in the art are suitable for use with the formulations described herein. Examples of such delivery systems include polymer-based systems such as polylactic acid, polyglycolic acid, polyanhydrides and polycaprolactones; non-polymer-based systems including porous matrices, sterols such as cholesterol, cholesterol esters, fatty acids, or lipids such as mono-, di-, and triglycerides; hydrogel release systems; silastic systems; peptide-based systems; wax coatings, biodegradable dosage forms, compressed tablets using conventional binders, and the like. For example, see Liberman et al., Pharmaceutical Dosage Forms, 2 Ed., Vol. 1, pp. 209-214 (1990); Singh et al., Encyclopedia of Pharmaceutical Technology, 2 ndEd., pp. 751-753 (2002); U.S. Patent Nos. 4,327,725, 4,624,848, 4,968,509, 5,461,140, 5,456,923, 5,516,527, 5,622,721, 5,686,105, 5,700,410, 5,977,175, 6,465,014, and 6,932,983, each of which is specifically incorporated herein by reference.
[0403]
[0423] In some embodiments, there is provided a pharmaceutical composition comprising particles of a compound of any of Formulae (I)-(XLIIIc) described herein and at least one dispersing or suspending agent for oral administration to a subject. The formulation may be a powder and / or granules for suspension, which upon mixing with water provides a substantially uniform suspension.
[0404]
[0424] The liquid pharmaceutical dosage form for oral administration may be an aqueous suspension selected from the group including, but not limited to, pharma- ceutically acceptable aqueous oral dispersions, emulsions, solutions, elixirs, gels, and syrups. See, e.g., Singh et al., Encyclopedia of Pharmaceutical Technology, 2 nd Ed., pp. 754-757 (2002). In addition to particles of the compound of Formulae (I)-(XLIIIc), the liquid dosage form may include additives such as: (a) a disintegrant; (b) a dispersant; (c) a wetting agent; (d) at least one preservative; (e) a thickening agent; (f) at least one sweetening agent; and (g) at least one flavoring agent. In some embodiments, the aqueous dispersion may further include a crystallization inhibitor.
[0405]
[0425] The aqueous suspensions and dispersions described herein can maintain a homogeneous state for at least 4 hours as defined in the USP Pharmacists' Pharmacopeia (2005 edition, chapter 905). Homogeneity should be determined by a consistent sampling method for determining the homogeneity of the entire composition. In some embodiments, the aqueous suspension can be resuspended into a homogeneous suspension by physical agitation lasting less than 1 minute. In some embodiments, the aqueous suspension can be resuspended into a homogeneous suspension by physical agitation lasting less than 45 seconds. In some embodiments, the aqueous suspension can be resuspended into a homogeneous suspension by physical agitation lasting less than 30 seconds. In some embodiments, no agitation is required to maintain a homogeneous aqueous dispersion.
[0406]
[0426] Examples of disintegrants for use in aqueous suspensions and dispersions include starches, e.g. natural starches such as corn starch or potato starch, pregelatinized starches such as National 1551 or Amijel®, or sodium starch glycolate such as Promogel® or Explotab®; wood products, methyl crystalline cellulose, e.g. Avicel®, Avicel® PH101, Avicel® PH102, Avicel® PH105, Elcema® P100, Emcocel®, Vivacel®, Ming Celluloses such as Tia® and Solka-Floc®, methylcellulose, croscarmellose, or crosslinked celluloses such as crosslinked carboxymethylcellulose (Ac-Di-Sol®), crosslinked carboxymethylcellulose or crosslinked croscarmellose; crosslinked starches such as sodium starch glycolate; crosslinked polymers such as crospovidone; crosslinked polyvinylpyrrolidone; alginates such as alginic acid or salts of alginic acid such as sodium alginate; clays such as Veegum® HV (magnesium aluminum silicate); gums such as agar, guar, carob, karaya, pectin or tragacanth; sodium starch glycolate; bentonite; natural sponges; surfactants; resins such as cation exchange resins; citrus pulp; sodium lauryl sulfate; sodium lauryl sulfate in combination with starch.
[0407]
[0427] In some embodiments, dispersing agents suitable for the aqueous suspensions and dispersions described herein are known in the art and include, for example, hydrophilic polymers, electrolytes, Tween® 60 or 80, PEG, polyvinylpyrrolidone (PVP; commercially known as Plasdone®), and carbohydrate-based dispersing agents, such as hydroxypropyl cellulose and hydroxypropyl cellulose ethers (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M), sodium carboxymethylcellulose, methylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose acetate stearate, amorphous cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), vinylpyrrolidone / vinyl acetate copolymers (Plasdone®, e.g., S-630), 4(1,1,3,3-tetramethylbutyl)-phenol polymers with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68®, F88®, and Fl08®, which are block copolymers of ethylene oxide and propylene oxide); and poloxamines (e.g., Tetronic 908®, also known as Poloxamine 908®, which is a tetrafunctional block copolymer derived from the sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Corporation, Parsippany, NJ.).In some embodiments, the dispersing agent is selected from the group that does not include one of the following agents: hydrophilic polymers; electrolytes; Tween® 60 or 80; PEG; polyvinylpyrrolidone (PVP), hydroxypropyl cellulose and hydroxypropyl cellulose ethers (e.g., HPC, HPC-SL, and HPC-L), hydroxypropyl methylcellulose and hydroxypropyl methylcellulose ethers (e.g., HPMC K100, HPMC K4M, HPMC K15M, and HPMC K100M, and Pharmacoat® USP 2910 (Shin-Etsu)); sodium carboxymethylcellulose; methylcellulose; hydroxyethylcellulose; hydroxypropyl methylcellulose phthalate; hydroxypropyl methylcellulose acetate stearate; amorphous cellulose; magnesium aluminum silicate; triethanolamine; polyvinyl alcohol (PVA); 4(1,1,3,3-tetramethylbutyl)-phenol polymers with ethylene oxide and formaldehyde; poloxamers (e.g., Pluronics, which are block copolymers of ethylene oxide and propylene oxide). F68®, F88®, and Fl08®); or poloxamine (e.g., Tetronic 908®, also known as Poloxamine 908®).
[0408]
[0428] Wetting agents suitable for the aqueous suspensions and dispersions described herein are known in the art and include, but are not limited to, cetyl alcohol, glycerol monostearate, polyoxyethylene sorbitan fatty acid esters (e.g., commercially available Tweens, such as Tween 20 and Tween 80 (ICI Specialty Chemicals)), and polyethylene glycols (e.g., Carbowax 3350 and 1450, and Carbopol 934 (Union Carbide)), oleic acid, glyceryl monostearate, sorbitan monolaurate, triethanolamine oleate, polyoxyethylene sorbitan monooleate, polyoxyethylene sorbitan monolaurate, sodium oleate, sodium lauryl sulfate, sodium docusate, triacetin, vitamin E TPGS, sodium taurocholate, simethicone, phosphotidylcholine, and the like.
[0409]
[0429] Suitable preservatives for the aqueous suspensions or dispersions described herein include, for example, potassium sorbate, parabens (e.g., methylparaben and propylparaben), benzoic acid and its salts, other esters of parahydroxybenzoic acid such as butylparaben, alcohols such as ethyl alcohol or benzyl alcohol, phenolic compounds such as phenol, or quaternary compounds such as benzalkonium chloride. Preservatives, as used herein, are incorporated into the dosage form in a concentration sufficient to inhibit the growth of microorganisms.
[0410]
[0430] Suitable thickening agents for the aqueous suspensions or dispersions described herein include, but are not limited to, methylcellulose, xanthan gum, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, Plasdon® S-630, carbomer, polyvinyl alcohol, alginate, acacia, chitosan, and combinations thereof. The concentration of the thickening agent depends on the agent selected and the viscosity desired.
[0411]
[0431] Examples of sweeteners suitable for the aqueous suspensions or dispersions described herein include, for example, acacia syrup, acesulfame K, alitame, anise, apple, aspartame, banana, bavarois cream, berry, blackcurrant, butterscotch, calcium citrate, camphor, caramel, cherry, cherry cream, chocolate, cinnamon, bubble gum, citrus, citrus punch, citrus cream, cotton candy, cocoa, cola, cool cherry, cool citrus, cyclamate, cylamate, dextrose, eucalyptus, eugenol, fructose, fruit punch, ginger, glycyrrhetinic acid salts, liquorice syrup, grape, grapefruit, honey, isomalt, lemon, lime, lemon cream, monoammonium glycyrrhizinate (MagnaSweet®), maltol, mannitol, maple, marshmallow. , menthol, mint cream, mixed berry, neohesperidin DC, neotame, orange, pear, peach, peppermint, peppermint cream, Prosweet® powder, raspberry, root beer, rum, saccharin, safrole, sorbitol, spearmint, spearmint cream, strawberry, strawberry cream, stevia, sucralose, sucrose, sodium saccharin, talc, Swiss cream, tagatose, tangerine, thaumatin, tutti frutti, vanilla, walnut, watermelon, wild cherry, wintergreen, xylitol, or any combination of these flavor ingredients, such as anise-menthol, cherry-anise, cinnamon-orange, cherry-cinnamon, chocolate-mint, honey-lemon, lemon-lime, lemon-mint, menthol-eucalyptus, orange-cream, vanilla-mint, and mixtures thereof. In some embodiments, the aqueous liquid dispersion can include a sweetening or flavoring agent at a concentration ranging from about 0.001% to about 1.0% by volume of the aqueous dispersion, hi some embodiments, the aqueous liquid dispersion can include a sweetening or flavoring agent at a concentration ranging from about 0.005% to about 0.5% by volume of the aqueous dispersion.Additionally, in some embodiments, the aqueous liquid dispersion may include a sweetening or flavoring agent at a concentration ranging from about 0.01% to about 1.0% by volume of the aqueous dispersion.
[0412]
[0432] In addition to the additives listed above, the liquid formulation may also contain inert diluents commonly used in the art, such as water or other solvents, solubilizers, and emulsifiers.Exemplary emulsifiers include ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, sodium lauryl sulfate, sodium docusate, cholesterol, cholesterol esters, taurocholic acid, phosphotidylcholine, oils such as cottonseed oil, peanut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethylene glycol, fatty acid esters of sorbitan, or mixtures of these substances.
[0413]
[0433] In some embodiments, the pharmaceutical compositions described herein may be self-emulsifying drug delivery systems (SEDDS). An emulsion is a dispersion of one immiscible phase in another, usually in the form of droplets. Generally, emulsions are created by vigorous mechanical dispersion. In contrast to emulsions or microemulsions, SEDDS spontaneously form emulsions when added to excess water without external mechanical dispersion or agitation. The advantage of SEDDS is that only gentle mixing is required to distribute the droplets throughout the solution. Furthermore, water or aqueous phase can be added immediately prior to administration, which ensures stability of potentially unstable or hydrophobic active ingredients. Thus, SEDDS provides an effective delivery system for oral and parenteral delivery of hydrophobic active ingredients. SEDDS may provide improved bioavailability of hydrophobic active ingredients. Methods for making self-emulsifying dosage forms are known in the art and include, but are not limited to, U.S. Pat. Nos. 5,858,401, 6,667,048, and 6,960,563, each of which is specifically incorporated herein by reference.
[0414]
[0434] It should be understood that there is overlap between the above-listed additives used in the aqueous dispersion or suspension described herein, since a given additive is often classified differently by different practitioners in the field or is commonly used for any of several different functions.Therefore, the above-listed additives should be taken as merely illustrative, and do not limit the types of additives that can be included in the formulation described herein.The amount of such additives can be easily determined by those skilled in the art according to the specific properties desired.
[0415] Intranasal preparations
[0435] Intranasal formulations are known in the art and are described, for example, in U.S. Patent Nos. 4,476,116, 5,116,817, and 6,391,452, each of which is specifically incorporated herein by reference. Formulations containing any of the compounds of formula (I)-(XLIIIc) prepared by these and other techniques well known in the art are prepared in saline solution using benzyl alcohol or other suitable preservatives, fluorocarbons, and / or other solubilizing or dispersing agents known in the art. See, for example, Ansel, HC et al., Pharmaceutical Dosage Forms and Drug Delivery Systems, Sixth Ed. (1995). In certain embodiments, these compositions and formulations are prepared using suitable non-toxic pharma- ceutically acceptable ingredients. These ingredients are known to those skilled in the preparation of nasal dosage forms, and some of these can be found in REMINGTON: THE SCIENCE AND PRACTICE OF PHARMACY, 21st edition, 2005, a standard reference in this field. The selection of suitable carriers depends largely on the exact nature of the desired nasal dosage form, e.g., solution, suspension, ointment or gel. Nasal dosage forms generally contain a large amount of water in addition to the active ingredient. Small amounts of other ingredients, such as pH adjusters, emulsifiers or dispersants, preservatives, surfactants, gelling agents or buffers, and other stabilizers and solubilizers, may also be present. The nasal dosage form may be isotonic with nasal secretions.
[0416]
[0436] For administration by inhalation, any of the compounds of formulae (I)-(XLIIIc) described herein may be in the form of an aerosol, mist, or powder. The pharmaceutical compositions described herein are conveniently delivered in the form of an aerosol spray presentation from a pressurized pack or nebulizer using a suitable propellant, such as dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide, or other suitable gas. In the case of a pressurized aerosol, the dosage unit can be determined by providing a valve that delivers a fixed, metered amount. By way of example only, gelatin capsules and cartridges for use in an inhaler or insufflator can be formulated to contain a powder mix of the compounds described herein and a suitable powder base, such as lactose or starch.
[0417] Oral Preparations
[0437] Oral formulations containing any of the compounds of formula (I)-(XLIIIc) can be administered using various formulations known in the art. For example, such formulations include, but are not limited to, those described in U.S. Pat. Nos. 4,229,447, 4,596,795, 4,755,386 and 5,739,136, each of which is specifically incorporated herein by reference. In addition, the oral dosage forms described herein can further include a biodegradable (hydrolyzable) polymeric carrier that also serves to adhere the dosage form to the oral mucosa. The oral dosage form is manufactured to gradually erode over a period of time, and any of the compounds of formula (I)-(XLIIIc) is delivered substantially throughout that period. As will be appreciated by those skilled in the art, delivery of oral drugs avoids the disadvantages encountered with oral drug administration, such as slow absorption, degradation of the active agent by fluids present in the digestive tract, and / or first-pass inactivation in the liver. With respect to the biodegradable (hydrolyzable) polymeric carrier, it will be understood that virtually any such carrier can be used so long as the desired drug release profile is not compromised and the carrier is compatible with any of the compounds of formula (I)-(XLIIIc) and any other ingredients that may be present in the oral dosage unit. In general, the polymeric carrier comprises a hydrophilic (water-soluble and water-swellable) polymer that adheres to the wet surface of the oral mucosa. Examples of polymeric carriers useful herein include acrylic acid polymers and copolymers, such as those known as "carbomers" (Carbopol®, available from BF Goodrich, for example, is one such polymer). Other ingredients that may also be incorporated into the oral dosage forms described herein include, but are not limited to, disintegrants, diluents, binders, lubricants, flavoring agents, coloring agents, preservatives, and the like. For buccal or sublingual administration, the compositions may take the form of tablets, lozenges, or gels formulated in a conventional manner.
[0418] Transdermal formulations
[0438] The transdermal formulations described herein can be administered using various devices described in the art.For example, such devices include, but are not limited to, those described in U.S. Patent Nos. 3,598,122, 3,598,123, 3,710,795, 3,731,683, 3,742,951, 3,814,097, 3,921,636, 3,972,995, 3,993,072, 3,993,073, 3,996,934, 4,031,894, 4,060,084, 4,072,095 ... Nos. 069,307, 4,077,407, 4,201,211, 4,230,105, 4,292,299, 4,292,303, 5,336,168, 5,665,378, 5,837,280, 5,869,090, 6,923,983, 6,929,801, and 6,946,144, each of which is specifically incorporated herein by reference in its entirety.
[0419]
[0439] The transdermal dosage forms described herein may incorporate certain pharma- ceutically acceptable excipients conventionally used in the art. In some embodiments, the transdermal formulations described herein include at least three components: (1) a formulation of a compound of any of Formulae (I)-(XLIIIc); (2) a penetration enhancer; and (3) an aqueous adjuvant. In addition, the transdermal formulations may include additional components, such as, but not limited to, gelling agents, cream and ointment bases. In some embodiments, the transdermal formulations may further include a woven or nonwoven backing to enhance absorption and prevent removal of the transdermal formulation from the skin. In some embodiments, the transdermal formulations described herein may maintain a saturated or supersaturated state to facilitate diffusion into the skin.
[0420]
[0440] Suitable formulations for transdermal administration of the compounds described herein may use transdermal delivery devices and transdermal delivery patches, which may be lipophilic emulsions or buffered aqueous solutions dissolved and / or dispersed in a polymer or adhesive. Such patches may be constructed for continuous, pulsatile, or on-demand delivery of the drug. Additionally, transdermal delivery of the compounds described herein may be achieved by means of iontophoretic patches and the like. Additionally, transdermal patches may provide controlled delivery of any of the compounds of formula (I)-(XLIIIc). Absorption rate may be slowed by using a rate-controlling membrane or by trapping the compound within a polymer matrix or gel. Conversely, absorption enhancers may be used to enhance absorption. The absorption enhancer or carrier may include an absorbent pharma- ceutically acceptable solvent to aid in penetration into the skin. For example, the transdermal device is in the form of a bandage that includes a backing member, a reservoir containing the compound with an optional carrier, a rate-controlling barrier that delivers the compound to the host's skin at a controlled, predetermined rate over an optional extended period of time, and a means for securing the device to the skin.
[0421] Injectable preparations
[0441] Formulations containing any of the compounds of formulae (I)-(XLIIIc) suitable for intramuscular, subcutaneous or intravenous injection may include physiologically acceptable sterile aqueous or non-aqueous solutions, dispersions, suspensions or emulsions, and sterile powders for reconstitution into sterile injectable solutions or dispersions. Examples of suitable aqueous and non-aqueous carriers, diluents, solvents or vehicles include water, ethanol, polyols (e.g., propylene glycol, polyethylene glycol, glycerol cremophor, etc.), suitable mixtures thereof, vegetable oils (e.g., olive oil), and injectable organic esters such as ethyl oleate. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions, and by the use of surfactants. Formulations suitable for subcutaneous injection may also contain additives such as preservatives, wetting agents, emulsifying agents, and dispensing agents. Prevention of microbial growth can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol, phenol, sorbic acid, etc. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, etc. Prolonged absorption of the injectable pharmaceutical form can be brought about by the use of agents delaying absorption, such as aluminum monostearate and gelatin.
[0422]
[0442] For intravenous injection, the compounds described herein can be formulated in aqueous solutions, such as physiologically compatible buffers, such as Hanks' solution, Ringer's solution, or physiological saline buffer. For transmucosal administration, a penetrant suitable for the barrier to be permeated is used in the formulation. Such penetrants are generally known in the art. For other parenteral injections, suitable formulations can include, for example, aqueous or non-aqueous solutions containing physiologically compatible buffers or excipients. Such penetrants are generally known in the art.
[0423]
[0443] Parenteral injections may include bolus injection or continuous infusion. Injectable preparations may be provided in unit dosage form, for example in ampoules or in multi-dose containers with added preservatives. The pharmaceutical compositions described herein may be in a form suitable for parenteral injection as sterile suspensions, solutions, or emulsions in oily or aqueous vehicles and may contain formulatory agents such as suspending, stabilizing, and / or dispersing agents. Pharmaceutical compositions for parenteral administration include aqueous solutions of the active compound in water-soluble form. Additionally, suspensions of the active compound may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils, such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compounds to allow for the preparation of highly concentrated solutions. Alternatively, the active ingredient may be in powder form for constitution with a suitable vehicle, eg, sterile pyrogen-free water, before use.
[0424] formulation
[0444] In certain embodiments, delivery systems for pharmaceutical compounds can be used, such as liposomes and emulsions. In certain embodiments, the compositions provided herein can also include a mucoadhesive polymer selected from, for example, carboxymethylcellulose, carbomer (acrylic acid polymer), poly(methyl methacrylate), polyacrylamide, polycarbophil, acrylic acid / butyl acrylate copolymer, sodium alginate, and dextran.
[0425]
[0445] In some embodiments, the compounds described herein can be administered topically and can be formulated into a variety of topically administrable compositions, such as solutions, suspensions, lotions, gels, pastes, medicated sticks, balms, creams, or ointments, etc. Such pharmaceutical compounds can contain solubilizers, stabilizers, isotonicity agents, buffers, and preservatives.
[0426]
[0446] The compounds described herein may also be formulated into rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG, etc. In suppository forms of the composition, a low melting wax, such as, but not limited to, a mixture of fatty acid glycerides, optionally combined with cocoa butter, is first melted.
[0427] Examples of Dosage Methods and Treatment Regimens
[0447] The compounds described herein can be used in the preparation of a medicament for the inhibition of menin or a homolog thereof, or in the treatment of a disease or condition that would benefit, at least in part, from the inhibition of menin or a homolog thereof. Additionally, a method of treating a disease or condition described herein in a subject in need of such treatment comprises administering to said subject a therapeutically effective amount of a pharmaceutical composition containing at least one compound of any of formulas (I)-(XLIIIc) described herein, or a pharma- ceutically acceptable salt, pharma-ceutically acceptable N-oxide, pharma-ceutically active metabolite, pharma-ceutically acceptable prodrug, or pharma-ceutically acceptable solvate thereof.
[0428]
[0448] The compositions containing the compounds described herein can be administered for preventive and / or therapeutic treatment. In therapeutic applications, the compositions are administered to a patient already suffering from a disease or condition in an amount sufficient to cure or at least partially arrest the symptoms of the disease or condition. Amounts effective for this use will depend on the severity and course of the disease, disorder or condition, previous treatments, the patient's health condition, weight, response to the drug, and the judgment of the treating physician. It is believed to be well within the skill of one of ordinary skill in the art to determine such therapeutically effective amounts by routine experimentation, including but not limited to dose escalation clinical trials.
[0429]
[0449] In prophylactic applications, compositions containing the compounds described herein are administered to patients susceptible to or otherwise at risk of a particular disease, disorder, or condition. Such an amount is defined as a "prophylactically effective amount or dose." In this use, the exact amount also depends on the patient's health status, weight, and the like. It is considered well within the skill of one of ordinary skill in the art to determine such prophylactically effective amounts by routine experimentation (e.g., dose escalation clinical trial). When used in patients, the amount effective for this use will depend on the severity and course of the disease, disorder, or condition, previous treatments, the patient's health status, response to the drug, and the judgment of the treating physician.
[0430]
[0450] If the patient's condition does not improve, the compounds may be administered chronically, i.e., for an extended period of time, including the patient's life, at the physician's discretion, to ameliorate or otherwise control or limit the symptoms of the patient's disease or condition.
[0431]
[0451] If the patient's condition improves, at the physician's discretion, the compound may be given continuously, or the administered drug dosage may be temporarily reduced or discontinued for a period of time (i.e., a "drug holiday"). The length of the drug holiday can vary from 2 days to 1 year, including, by way of example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10 days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100 days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300 days, 320 days, 350 days, or 365 days. The dose reduction during the drug holiday can be 10% to 100%, including, by way of example only, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95% or 100%.
[0432]
[0452] Once the patient's condition has improved, a maintenance dose is administered as needed. Thereafter, the dosage or frequency of administration, or both, can be reduced as a function of symptoms to a level at which the improved disease, disorder, or condition is maintained. However, patients may require intermittent treatment on a long-term basis upon recurrence of symptoms.
[0433]
[0453] The amount of a given drug corresponding to such an amount for the above improvements will vary depending on factors such as the particular compound, the disease or condition and its severity, the characteristics of the subject or host requiring treatment (e.g., body weight), and the like, but can nevertheless be routinely determined depending on the particular circumstances surrounding the case, including, for example, the particular drug administered, the route of administration, the condition being treated, and the subject or host being treated. In general, however, doses used for adult treatment will usually be in the range of 0.02 to 5000 mg / day, or about 1 to 1500 mg / day. The desired dose may conveniently be presented in a single dose or as divided doses administered simultaneously (or over a short period of time), or at appropriate intervals, e.g., as two, three, four or more subdoses per day.
[0434]
[0454] The pharmaceutical compositions described herein may be in unit dosage form suitable for single administration of a precise dose. In unit dosage form, the formulation is divided into unit doses containing an appropriate amount of one or more compounds described herein. The unit dosage may be in the form of a package containing a discrete amount of the formulation. Non-limiting examples are packaged tablets or capsules, and powders in vials or ampoules. Aqueous suspension compositions may be packaged in single-dose non-reclosable containers. Alternatively, multi-dose reclosable containers may be used, which typically include a preservative in the composition. By way of example only, parenteral injection preparations may be provided in unit dosage form, including but not limited to ampoules, or in multi-dose containers with added preservative.
[0435]
[0455] The foregoing ranges are only suggestive, since there are many variables with respect to any particular treatment regime, and substantial deviations from these recommendations are common. Such dosages may vary depending on many variables, including, but not limited to, the activity of the compound being used, the disease or condition being treated, the method of administration, the requirements of the particular subject, the severity of the disease or condition being treated, and the judgment of the physician.
[0436]
[0456] Toxicity and therapeutic efficacy of such treatment regimens can be assessed by standard pharmaceutical procedures in cell cultures or experimental animals, including, but not limited to, LD 50 (i.e., the dose that is lethal to 50% of the population) and ED 50 (i.e., the dose that is therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is known as the therapeutic index, and the LD 50 and ED 50 The therapeutic index can be expressed as a ratio between ED and ED. Compounds that exhibit large therapeutic indices are preferred. Data obtained from cell culture assays and animal studies can be used in formulating a range of dosages for use in humans. The dosages of such compounds herein are determined based on the ED with minimal toxicity. 50 The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
[0437] Combination therapy
[0457] The menin-MLL inhibitor compositions described herein can also be used in combination with other well-known therapeutic agents that are selected for their therapeutic value against the condition to be treated. Generally, in embodiments in which the compositions described herein and combination therapies are used, the other agents do not need to be administered in the same pharmaceutical composition, and may have to be administered by different routes due to different physical and chemical properties. The determination of the method of administration, and if possible, whether to administer in the same pharmaceutical composition, is well within the knowledge of a skilled clinician. Initial administration can be performed according to established protocols known in the art, and then the dosage, method of administration, and time of administration can be modified by a skilled clinician based on the effects observed.
[0438]
[0458] In certain instances, it may be appropriate to administer at least one menin-MLL inhibitor compound described herein in combination with another therapeutic agent. By way of example only, if nausea is one of the side effects experienced by a patient when administered one of the menin-MLL inhibitor compounds described herein, it may be appropriate to administer an anti-nausea agent in combination with the initial therapeutic agent. Alternatively, by way of example only, the therapeutic effectiveness of one of the compounds described herein may be enhanced by administration of an adjuvant (i.e., an adjuvant may have minimal therapeutic benefit by itself, but when combined with another therapeutic agent (e.g., one described herein), the overall therapeutic benefit to the patient is enhanced). Alternatively, by way of example only, the benefit experienced by the patient may be increased by administering one of the compounds described herein with another therapeutic agent that also has a therapeutic benefit and is included in the treatment regimen. In either case, regardless of the disease, disorder, or condition being treated, the overall benefit experienced by the patient may be merely additive of the two therapeutic agents, or the patient may experience a synergistic benefit.
[0439]
[0459] The particular choice of compounds to be used will depend on the diagnosis of the attending physician, their judgment of the patient's condition, and the appropriate treatment protocol. Compounds may be administered simultaneously (e.g., simultaneously, substantially simultaneously, or within the same treatment protocol) or sequentially, depending on the nature of the disease, disorder, or condition, the patient's condition, and the actual choice of compounds to be used. The determination of the order of administration of each therapeutic agent in a treatment protocol and the number of repeated administrations is well within the knowledge of a skilled physician after evaluation of the disease being treated and the patient's condition.
[0440]
[0460] It is known to those skilled in the art that therapeutically effective dosages may vary when drugs are used in combination therapy.Methods for experimentally determining therapeutically effective doses of drugs and other agents for use in combination therapy regimens are described in the literature.For example, the use of metronomic therapy (i.e., providing low doses frequently to minimize toxic side effects) has been widely described in the literature.Combination therapy also includes periodic therapy that starts and stops at different times to assist in the clinical management of patients.
[0441]
[0461] For the combination therapy described herein, the dosage of the co-administered compound will of course vary depending on the type of co-drug used, the specific drug used, the disease or condition being treated, etc. Furthermore, when co-administered with one or more biologically active agents, the compounds provided herein can be administered simultaneously with the biologically active agents or sequentially. When administered sequentially, the attending physician will determine the appropriate order for administering, for example, the protein in combination with the biologically active agent.
[0442]
[0462] In either case, the multiple therapeutic agents (e.g., one of which is a compound of Formula (I)-(XLIIIc) described herein) can be administered in any order or simultaneously. If administered simultaneously, the multiple therapeutic agents can be provided in a single combined form or in multiple forms (e.g., as a single pill or as two separate pills). One of the therapeutic agents may be given in multiple doses, or both may be given as multiple doses. If not simultaneous, the time between multiple doses can vary from more than 0 weeks to less than 4 weeks. In addition, the combination methods, compositions, and formulations are not limited to the use of only two agents, and the use of multiple therapeutic combinations is also envisioned.
[0443]
[0463] It is understood that the dosage regimen for treating, preventing or ameliorating the pathology that is sought to be alleviated may vary according to various factors.These factors include the disorder that the subject suffers from, as well as the subject's age, weight, sex, diet and medical condition.Therefore, the dosage regimen actually used may vary widely and therefore may deviate from the dosage regimen described herein.
[0444]
[0464] The agents constituting the combination therapy disclosed herein may be in combined dosage form or in separate dosage forms intended for substantially simultaneous administration. The agents constituting the combination therapy may also be administered sequentially, with each therapeutic compound being administered by a regimen requiring two-step administration. A two-step administration regimen may require sequential administration of active agents or spaced administration of individual active agents. The time between the multiple administration steps may range from minutes to hours, depending on the properties of each agent, such as their potency, solubility, bioavailability, plasma half-life, and kinetic profile. Circadian variations in target molecule concentrations may also determine optimal dose intervals.
[0445]
[0465] In addition, the compounds described herein may also be used in combination with procedures that may provide additive or synergistic benefits to patients.By way of example only, patients are expected to find therapeutic and / or prophylactic benefits in the methods described herein, and the pharmaceutical compositions of the compounds described herein and / or combinations with other therapeutic agents are combined with genetic testing to determine whether the individual is a carrier of a mutant gene known to be correlated with a particular disease or condition.
[0446]
[0466] The compounds and combination therapies described herein can be administered before, during or after the onset of a disease or condition, and the timing of administration of the composition containing the compound can vary. Thus, for example, the compounds can be used as prophylactics and can be administered continuously to a subject at risk of developing a condition or disease to prevent the onset of the disease or condition. The compounds and compositions can be administered to a subject when symptoms are present or as soon as possible after onset. Administration of the compounds can begin within 48 hours of onset of symptoms, within 6 hours of onset of symptoms, or within 3 hours of onset of symptoms. The initial administration can be by any practical route, such as intravenous injection, bolus injection, infusion over 5 minutes to about 5 hours, pill, capsule, transdermal patch, buccal delivery, and the like, or a combination thereof. The compounds should be administered as soon as practicable after the onset of a disease or condition is detected or suspected, for the period of time required to treat the disease, for example, about 1 month to about 3 months. The length of treatment can vary from subject to subject, and the length can be determined using known criteria. For example, the compound or a formulation containing the compound can be administered for at least 2 weeks, for about 1 month to about 5 years, or for about 1 month to about 3 years.
[0447] Exemplary Therapeutic Agents for Use in Combination with Menin-MLL Inhibitor Compounds Described herein
[0467] If a subject has or is at risk for diabetes, the menin-MLL inhibitor compounds can be used in any combination with one or more of the following therapeutic agents: insulin, insulin lispro, humalog, insulin aspart, novolog, insulin glulisine, apidr, regular insulin (Humulin R, Novolin R), rapid acting zinc insulin (Semilente), isophane insulin, intermediate acting insulin (Humulin N, Novolin N), insulin zinc (Lente), long-acting insulin zinc insulin (ultralente), insulin glargine (Lantus), insulin detemir (Levemir), and insulin degludec (Tresiba); biguanides, metformin (Glucophage), phenformin, buformin; thiazolidinediones, rosiglitazone (Avandia), pioglitazone (Actos), and troglitazone (Rezulin); lyn kinase activators; sulfonylureas, tolbutamide, acetohexamide, tolazamide, chlorpropamide, glipizide, glyburide or glibenclamide, glimepiride, gliclazide, glyclopyramide, and gliquidone; meglitinides, repaglinide, nateglinide; alpha-glucosidase inhibitors, miglitol, acarbose, and voglibose; glucagon-like peptides. (GLP) agonists, exenatide (Exendin-4, Byetta), liraglutide (Victoza), taspoglutide, lixisenatide (Lyxumia), semaglutide (Ozempic), and dulaglutide (Trulicity); dipeptidyl peptidase-4 (DPP-4) inhibitors, virgliptin (Galvus), sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin, septagliptin, teneligliptin, gemigliptin, Zemiglo; and SGLT-2 inhibitors, dapagliflozin, canagliflozin, empagliflozin, and remogliflozin.
[0448] Kits / Products
[0468] Kits and products are also described herein for use in the therapeutic applications described herein.Such kits include carriers, packages or containers that are compartmentalized to accommodate one or more containers, such as vials, tubes, etc., each container containing one of the individual elements used in the methods described herein.Suitable containers include, for example, bottles, vials, syringes and test tubes.Containers can be formed from a variety of materials, such as glass or plastic.
[0449]
[0469] The products provided herein include packaging materials. Packaging materials for use in packaging pharmaceutical products are well known to those skilled in the art. For example, see U.S. Patent Nos. 5,323,907, 5,052,558 and 5,033,252. Examples of pharmaceutical packaging materials include, but are not limited to, blister packs, bottles, tubes, inhalers, pumps, bags, vials, containers, syringes, bottles, and any packaging material suitable for the selected formulation and intended administration and treatment method. A wide range of formulations of the compounds and compositions provided herein are contemplated as a variety of therapeutic agents for any disease, disorder or condition that would benefit from the inhibition of menin or in which menin is a mediator or contributor to the symptoms or causation.
[0450]
[0470] For example, the container can contain one or more compounds described herein, optionally in a composition or in combination with another agent disclosed herein. The container optionally has a sterile access port (e.g., the container can be an intravenous solution bag or a vial with a stopper pierceable by a hypodermic injection needle). Such a kit optionally contains a compound with an identifying description or label or instructions for its use in the methods described herein.
[0451]
[0471] The kit typically includes one or more additional containers, each containing one or more of various materials (e.g., reagents, optionally in concentrated form, and / or devices) that are desirable from a commercial and user standpoint for use of the compounds described herein. Non-limiting examples of such materials include, but are not limited to, buffers, diluents, filters, needles, syringes, carriers, packages, containers, vials, and / or tube labels listing the contents, and / or instructions for use and inserts containing the instructions for use. A set of instructions is also typically included.
[0452]
[0472] The label may be on or associated with the container. The label may be on the container if letters, numbers, or other characters forming the label are affixed, molded, or etched into the container itself. The label is associated with the container if it is present in a container or carrier that also holds the container, for example, as a package insert. The label may be used to indicate that the contents are to be used for a particular therapeutic application. The label may also indicate how to use the contents, such as in the methods described herein.
[0453]
[0473] In certain embodiments, the pharmaceutical compositions can be provided in a pack or dispenser device that can contain one or more unit dosage forms containing the compounds provided herein. The pack can, for example, comprise metal or plastic foil, such as a blister pack. The pack or dispenser device can be accompanied by instructions for administration. The pack or dispenser can also bear a notice associated with the container in a form prescribed by a government agency regulating the manufacture, use, or sale of pharmaceuticals, which notice reflects the approval by the agency of the drug form for human or veterinary administration. Such notice can be, for example, labeling approved by the US Food and Drug Administration for prescription drugs or an approved product insert. Compositions containing the compounds provided herein formulated in a compatible pharmaceutical carrier can also be prepared, placed in an appropriate container, and labeled for treatment of an indicated condition. EXAMPLES
[0454] Working Example
[0474] The following specific and non-limiting examples should be construed as merely illustrative and do not limit the present disclosure in any way. Without further elaboration, it is believed that a person skilled in the art can utilize the present disclosure to the fullest extent based on the description herein. All publications cited herein are incorporated by reference in their entirety. When a URL or other such identifier or Internet address is referenced, it is understood that such identifiers may change and specific information on the Internet may come and go, but equivalent information may be found by searching the Internet. Reference thereto evidences that such information is available and generally distributed.
[0455]
[0475] The compounds described herein have been prepared or can be prepared according to the synthetic methods described in U.S. Pat. No. 11,084,825 or WO 2022 / 133064, or some variation thereof, the contents of which are incorporated herein by reference in their entireties.
[0456] Further exemplary compounds
[0476] Other compounds described herein have been prepared or can be prepared according to the synthetic methods described herein, or some variations thereof. The compounds can be prepared from readily available starting materials using the following general methods and procedures. It will be understood that where typical or recommended process conditions (i.e., reaction temperatures, times, molar ratios of reactants, solvents, pressures, etc.) are given, other process conditions can also be used unless otherwise stated. Optimum reaction conditions may vary with the particular reactants or solvents used, but such conditions can be determined by one skilled in the art by routine optimization procedures.
[0457]
[0477] The following compounds were or can be prepared from readily available starting materials using the general methods and procedures described herein and are shown in Table 1.
[0458] [Table 1]
[0459] [Table 2]
[0460] [Table 3]
[0461] [Table 4]
[0462] [Table 5]
[0463]
[0478] The following additional compounds have been made or can be prepared from readily available starting materials using the general methods and procedures described herein and are shown in Table 2 below.
[0464] [Table 6]
[0465] [Table 7]
[0466] The following additional compounds have been made or can be prepared from readily available starting materials using the general methods and procedures described herein and are shown below. [ka]
[0467] Example 101: Menin-MLL In Vitro Inhibitory Activity
[0479] Menin-MLL IC of the compounds disclosed herein 50 is determined as described below.
[0468] 1. Preparation of Cells
[0480] MLL-rearranged MOLM13 cell lines and MLL germline HL60 growing in log phase cultures were counted and resuspended at a concentration of 10,000 cells / 100 μL (100,000 cells / mL) in RPMI 10% FBS containing medium with Pen / Strep. A total of 100 μL was seeded into each well of a round-bottom 96-well non-tissue culture treated plate (Corning). Thus, each well had 10,000 MOLM13 or HL60 cells on day 1.
[0469] Compound dilution
[0481] Each compound was diluted in DMSO to a final concentration of 5 mM. 15 mL Falcon tubes were used for dilutions. These 5 mM stocks were stored in multiple 50 μL aliquots in 2 mL light-proof Eppendorf tubes to prevent repeated freeze-thaw cycles of the entire stock.
[0470]
[0482] The following concentrations were determined for each compound: 0.01 μM, 0.03 μM, 0.1 μM, 0.3 μM, 0.5 μM, 1 μM, 3 μM and 5 μM.
[0471]
[0483] First, a 2x working stock was made for each desired concentration using standard RPMI 10% FBS media as the diluent.
[0472]
[0484] Specifically, working stocks of 0.02 μM, 0.06 μM, 0.2 μM, 0.6 μM, 1 μM, 2 μM, 6 μM and 10 μM (i.e., 2× the desired concentrations above) were made from the 5 mM stock.
[0473]
[0485] 100 μL of each working stock dilution was added to each well containing 100 μL of seeded cells, thereby achieving a 1× drug concentration. A similar strategy was used for the DMSO control arm.
[0474]
[0486] IC of Menin-MLL inhibition 50 was determined using methods known to those skilled in the art.
[0475] Example 102: Restoration of glycemic control in diabetic obese rats This example describes the development of diabetic Zucker diabetic obese rats (ZDF rats, genotype ZDF-Lepr fa / Crl; Charles River). Carnicelli et al., 2005, Charles River.
[0476] Control and test compounds were stored at 4° C. and prepared weekly as needed. The vehicle for the positive control pioglitazone was 0.25% carboxymethylcellulose and 1% Tween® 80 in reverse osmosis deionized water. The vehicle for Compound 10 was 10% DMSO, 10% Solutol HS 15, and 80% (10% hydroxypropyl-β-cyclodextrin in 50 mM citrate buffer at pH 3.0).
[0477] Body weight and non-fasting glucose were measured for 24 ZDF rats (and 8 reserve ZDF rats) on day -3. LabDiet 5008 was provided ad libitum throughout the study, as was water, except during designated procedures. To minimize the effects of blood glucose and body stress, all animals, including the reserve, were sham-dosed once daily by oral gavage with phosphate buffered saline (pH 7.2) (5 mL / kg dose) beginning on days -5 to -1 of the study.
[0478] Vehicle, control, and test compounds were administered by oral gavage on days 1-16 according to the following design.
[0479] [Table 8]
[0480]
[0487] Nonfasting blood glucose was measured on days -3, 1, 8, and 14. On day 15, an oral glucose tolerance test was performed. Animals were weighed and placed in clean cages without food. Access to water was provided throughout the procedure. Animals were fasted for 5 hours and blood glucose was measured. Animals were gavaged with 2 g / kg (10 mL / kg) glucose. Blood glucose was measured by tail snip. A second drop of blood from the animals was placed on a handheld glucometer (Abbott Alpha Trak) at the following times relative to glucose administration: 0 (before glucose administration), 15, 30, 60, 90, and 120 minutes. Food was returned to the cage after the final blood glucose measurement. On day 17, a 4-hour fasting glucose was measured. Serum samples were used to measure insulin by ELISA. Analysis was performed on days 1-3 of each collection. On day 17, a terminal blood draw of approximately 8 mL per animal was obtained to measure blood glucose.
[0481]
[0488] As shown in Figures 1A and 1B, compound 10 significantly reduced glucose in the non-fasted (Figure 1A) and fasted (Figure 1B) states compared to vehicle and control. As shown in Figures 2A and 2B, compound 10 significantly reduced insulin in the non-fasted (Figure 2A) and fasted (Figure 2B) states compared to vehicle and control. As shown in Figures 3A and 3B, compound 10 significantly reduced insulin resistance (HOMA, homeostasis model assessment of insulin resistance; Turner et al., 1993, Current Topics in Diabetes Research12: 66-75; Turner et al., 1979, Metabolism. 28(11): 1086-96) in the non-fasted (Figure 3A) and fasted (Figure 3B) states compared to vehicle and control.
[0482]
[0489] In the oral glucose tolerance test in Figures 4A and 4B, compound 10 provided significant glucose control after 15 days of administration. Figure 4A provides the blood glucose and Figure 4B provides the blood glucose area under the curve data. Even after 14 days of non-administration on day 29, compound 10 provided significant glucose control after 15 days of administration as shown in Figures 5A-5B. Figure 5A provides the blood glucose and Figure 5B provides the blood glucose area under the curve data. Also, in Figures 6A and 6B, on day 29, compound 10 increased insulin and glucose lowering despite no treatment for 2 weeks. The results were statistically superior to the control. Figure 6A provides insulin at 4 hours fasting and Figure 6B provides glucose at 4 hours fasting. In Figure 7, compound 10 shows an increase in C-peptide after 2 weeks of treatment. C-peptide is the product of insulin synthesis and indicates insulin levels.
[0483] Example 103: Restoration of glycemic control in streptozotocin-induced rats
[0490] This example provides the ability of compound 10 to restore glycemic control to streptozotocin (STZ)-induced type II diabetes in Wistar Han rats. Fahmy et al., 2017, World J. Pharm. Med. Res. 3(3):37-39.
[0484]
[0491] Control and test compounds were stored at 4°C and prepared weekly as needed. The vehicle for the positive control pioglitazone was 0.25% carboxymethylcellulose and 1% Tween® 80 in reverse osmosis deionized water. The vehicle for compound 10 was 10% DMSO, 10% Solutol HS 15, and 80% (10% hydroxypropyl-β-cyclodextrin in 50 mM citrate buffer at pH 3.0). The vehicle for pretreatment with streptozotocin was 0.1 M sodium citrate, pH 4.5.
[0485]
[0492] On day -3, 24 Wistar Han rats (plus 8 reserve Wistar Han rats) were given body weight and non-fasting glucose. Starting on day -42, D12451 Research Diet was given ad libitum throughout the study, as was water, except during designated procedures. To minimize the effects of blood glucose and body stress, all animals, including the reserves, were given a sham dose of phosphate buffered saline (pH 7.2) (5 mL / kg) by gavage once daily on days -5 to -1 of the study. Glucose (200 g / L) 20% in drinking water was given ad libitum for 24 hours after streptozotocin injection on days -14 and -7.
[0486]
[0493] On days -14 and -7, streptozotocin was administered intraperitoneally at 30 mg / kg / day once daily. Starting on day 1, control and test compounds were administered on the following schedule:
[0487] [Table 9]
[0488]
[0494] Nonfasting blood glucose was measured on days -7 to -1, and on days 1, 8, and 14. On day 15, an oral glucose tolerance test was performed. Animals were weighed and placed in clean cages without food. Access to water was provided throughout the procedure. Animals were fasted for 5 hours and blood glucose was measured. Animals were gavaged with 2 g / kg (10 mL / kg) glucose. Blood glucose was measured by venipuncture. A second drop of blood from the animals was placed on a handheld glucometer (Abbott Alpha Trak) at the following times relative to glucose administration: 0 (just before glucose administration), 15, 30, 60, 90, and 120 minutes. Food was returned to the cage after the final blood glucose measurement. On day 17, a 4-hour fasting glucose was measured. Serum samples were used to measure insulin by ELISA. Analysis was performed on days 1 to 3 of each collection. On day 17, a terminal blood draw of approximately 8 mL per animal was obtained to measure blood glucose.
[0489]
[0495] In a streptozotocin-induced diabetes model, compound 10 provided a rapid reduction in non-fasting glucose upon dosing compared to vehicle and control, as shown in Figure 8. Compound 10 significantly reduced insulin in non-fasting conditions, as shown in Figure 9. Compound 10 provided a maintenance or reduction in insulin in non-fasting (Figure 10A) and fasting (Figure 10B) conditions, as shown in Figures 10A and 10B.
[0490]
[0496] In the oral glucose tolerance test in Figures 11A and 11B, compound 10 provided significant glucose control after 15 days of administration. Figure 11A provides the blood glucose and Figure 11B provides the blood glucose area under the curve data. The reduction was statistically significant compared to vehicle and control.
[0491] Example 104: Restoration of glycemic control in Zucker diabetic obese rats
[0497] This example demonstrates that compound 10 maintains long-term glycemic control in the Zucker diabetic obese rat model of type 2 diabetes mellitus (T2DM) after short-term treatment.
[0492]
[0498] Rats were dosed daily with Compound 10, liraglutide or vehicle for 28 days and monitored for an additional 28 days after dosing. Compound 10 was well tolerated by all animals throughout the study.
[0493]
[0499] As shown in FIG. 12, administration of compound 10 resulted in a significant reduction in HbA1C on day 21, with an absolute reduction in HbA1C relative to vehicle reaching 3.5% compared to liraglutide (1.7% on day 29), and the reduction was maintained throughout the study, including after treatment. The high dose group of compound 10 showed a strong reduction in 4-hour fasting blood glucose during treatment up to day 29. In both compound 10 treatment groups, in contrast to vehicle and liraglutide-treated animals, an oral glucose tolerance test (OGTT) on day 25 showed improved glycemic control. In addition, insulin levels, HOMA-IR, HOMA-B, OGTT, HbA1C, and C-peptide levels are measured on day 57 in all groups. Taken together, these data demonstrate the novel long-acting nature of compound 10 as an oral treatment for T2DM in maintaining glycemic control after short-term dosing.
[0494] Example 105: Restoration of glycemic control in streptozotocin-induced and Zucker diabetic obese rats
[0500] This example demonstrates that compound 10 restores glycemic control in Zucker diabetic obese (ZDF) rats and streptozotocin-induced rat (STZ) models of T2DM, with long-term glycemic control in ZDF rats for 2 weeks after dosing.
[0495]
[0501] ZDF rats were administered Compound 10, vehicle or pioglitazone daily for 16 days and monitored for an additional 2 weeks post-treatment up to day 29. The STZ rat model was induced by pre-treating animals with a high fat diet containing low doses of streptozotocin on days -14 and -7, followed by treatment starting on day 0 and continuing until day 16. ZDF and STZ rats were monitored for fasting blood glucose levels, oral glucose tolerance test (OGTT), insulin and C-peptide levels, HOMA-IR (homeostasis model assessment of insulin resistance), blood lipid levels, and body weight as outlined below for each model. ZDF rats were analyzed for OGTT on day 29 and serum insulin and C-peptide on day 31 for measurements 15 days post-treatment.
[0496]
[0502] ZDF rat model-3 treatment groups: 1. Vehicle; 2. Compound 10 (175 mg / kg); and 3. Pioglitazone (30 mg / kg); n=10 / group. Days 0-16, once daily dosing → Days 16-29, drug washout. Rats were monitored throughout the dosing and washout periods for the following parameters: body weight, fasting blood glucose, blood insulin, C-peptide, and OGTT.
[0497]
[0503] STZ rat model-3 treatment groups: 1. Vehicle; 2. Compound 10 (175 mg / kg); and 3. Pioglitazone (30 mg / kg); n=10 / group. Pretreatment with STZ 14 days prior to dosing. Dosed once daily from days 0 to 16. Throughout the dosing period, rats were monitored for the following parameters: body weight, blood glucose levels, and OGTT.
[0498]
[0504] As shown in FIG. 13, compound 10 significantly lowers blood glucose levels and significantly alters serum insulin and C-peptide levels in ZDF rats.
[0499]
[0505] As shown in FIG. 14, compound 10 maintains a significant effect on blood glucose, insulin and C-peptide levels during drug washout (ie, 2 weeks after the last dose).
[0500]
[0506] As shown in FIG. 15, compound 10 potently reduces blood glucose levels in STZ-induced rats.
[0501]
[0507] As shown in FIG. 16, compound 10 increases insulin sensitivity in ZDF rats.
[0502]
[0508] As shown in FIG. 17, compound 10 significantly lowers blood lipid levels and reduces body weight in treated ZDF rats.
[0503]
[0509] In conclusion, administration of compound 10 significantly reduced fasting and non-fasting blood glucose levels (about 50%), significantly reduced serum insulin and C-peptide levels (p<0.05), and reduced HOMA-IR (p<0.001) in ZDF rats after 2 weeks of administration. Furthermore, compound 10 showed long-term glycemic control in the ZDF model, as evidenced by the reduction in glucose levels in the oral glucose tolerance test on day 15 (54% AUC reduction, p<0.001) and on day 29 of the drug washout period (40% AUC reduction, p<0.05, about 2 weeks after the last administration), demonstrating sustained glycemic control. Surprisingly, compound 10 reduced blood glucose levels by OGTT in STZ animals (41% AUC reduction, p<0.05), but not pioglitazone. Significant reductions in blood lipid levels (p<0.01) and body weight were observed in both models. Taken together, the data demonstrate the novel and significant potential of compound 10 as an oral, long-acting therapeutic agent for T2DM.
[0504] Example 106: Reduction of HbA1c in Zucker diabetic obese rats
[0510] This example demonstrates that compound 10 achieves sustained glycemic control after short-term treatment in the Zucker diabetic obese rat model of type 2 diabetes mellitus (T2DM).
[0505]
[0511] Zucker diabetic obese (ZDF) rats were dosed daily with Compound 10, liraglutide or vehicle for 28 days (n=10 / group) and monitored for an additional 28 days after the last dose. Fasting blood glucose, insulin, C-peptide levels, HbA1c, oral glucose tolerance test (OGTT), and body weight were monitored during and after treatment.
[0506]
[0512] ZDF rat model-5 treatment groups: 1. Vehicle; 2. Compound 10 (40 mg / kg); 3. Compound 10 (85 mg / kg); 4. Compound 10 (170 mg / kg); and 5. Liraglutide (0.2 mg / kg); n=10 / group. The dose (40 mg / kg) for group 2 was increased to 200 mg / kg from day 17 for the remainder of the dosing period. Days 0-28, once daily dosing → Days 28-56, drug washout. Rats were monitored throughout the dosing and washout periods for the following parameters: body weight, fasting blood glucose, blood insulin, C-peptide, OGTT, and HbA1C.
[0507]
[0513] As shown in FIG. 18, compound 10 is shown to gradually increase body weight and fasting blood glucose levels over time, likely due to very high food intake.
[0508]
[0514] As shown in FIG. 19, compound 10 significantly reduces HbA1c and controls blood glucose levels in a 4-week administration study in ZDF rats.
[0509]
[0515] As shown in FIG. 20, compound 10 exhibits sustained glycemic control over a four week dosing period.
[0510]
[0516] As shown in FIG. 21, compound 10 maintains a significant reduction in HbA1c even two weeks after the last dose.
[0511]
[0517] In conclusion, the medium and high dose groups of Compound 10 showed a reduction in fasting blood glucose levels similar to liraglutide. On day 29 (i.e., one day after treatment was stopped), the high dose group of Compound 10 showed a sustained and significant reduction in fasting blood glucose. Compound 10 administration reduced HbA1c levels by day 21 of administration. The absolute amount was 3.5% lower than the vehicle group (i.e., a 33% decrease from vehicle) and 1.8% lower than the liraglutide group (i.e., a 20% decrease from vehicle) on day 29, and remained reduced throughout the study period, including after administration. All Compound 10 dose groups showed improved glycemic control by oral glucose tolerance test (OGTT) on day 25 compared to the vehicle treatment group, with the high dose treatment group showing an improved response compared to liraglutide. Fasting insulin and c-peptide levels were elevated in animals treated with Compound 10 until the last day of dosing, an effect that persisted well up to 2 weeks after the last dose. Compound 10 induced significant reductions in HbA1c at all doses tested, an effect that persisted 15 days after the last dose.
[0512]
[0518] It is understood that the examples and embodiments described herein are for illustrative purposes only, and that various modifications or changes in light thereof will be suggested to those skilled in the art and are to be included within the spirit and scope of the present disclosure and the scope of the appended claims. All publications, patents, and patent application publications cited herein are hereby incorporated by reference in their entirety for all purposes.
[0513]
[0519] At least some of the chemical names of the compounds described herein are generated on an automated basis by using commercially available chemical naming software programs and may not have been independently verified. Where the indicated chemical name and the indicated chemical structure differ, the indicated chemical structure controls. In chemical structures where a chiral center exists in a chemical structure but no specific stereochemistry is indicated for the chiral center, both enantiomers associated with the chiral chemical structure are encompassed by the chemical structure.
Claims
1. A pharmaceutical composition for use in reducing glycated hemoglobin (HbA1c), comprising: Formula (I) 【Chemistry 1】 or a pharma- ceutically acceptable salt thereof, wherein: A is carbon or nitrogen; Cy is a substituted or unsubstituted 【Chemistry 2】 and Q is -N(H)-; Z is -CR 5a = or -N=; X is -NR 3a Or -C(R 3b ) 2 - and Y is a single bond, -NR 3a - or - C(R 3b ) 2 - and W is -C(O)- or S(O) 2 - and R 1 and R 2 One of them is Cy 2 -N(H)C(O)-C(R 6a ) = C(R 6b ) (R 6C ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a ) = C(R 6b ) (R 6C ) and the other is hydrogen; Cy 2 is an optionally substituted group selected from phenyl, pyridyl, or a 4- to 7-membered heterocycloalkyl ring having one nitrogen heteroatom; Each R 3a and R 3b is hydrogen; Each R 4a and R 4b is independently hydrogen, fluoro or methyl; Each R is independently hydrogen or C 1~6 an optionally substituted group selected from an aliphatic, phenyl, an 8-10 membered bicyclic aryl ring, a 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups on the same nitrogen together with their intervening atoms form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 5a is hydrogen; Each R 6a and R 6b are independently hydrogen or C 1~6 is alkyl; or R 6a and R 6b come together to form a bond; R 6c is hydrogen, or a substituted or unsubstituted C 1~6 is alkyl; m is 1, 2 or 3; and n is 1, 2, 3 or 4 Pharmaceutical compositions.
2. -X-W-Y is N(H)-C(O)-N(H)-, -N(H)-C(O)-CH 2 --, --CH 2 -C(O)-N(H)-, -N(H)-S(O) 2 -N(H)-, -N(H)-S(O) 2 -CH 2 --, --CH 2 -S (O) 2 The pharmaceutical composition of claim 1, which is -N(H)- or -N(H)-C(O)-.
3. The compound has the formula (XXIIIa), (XXIIIb), (IVa) or (IVb): 【Chemistry 3】 2. The pharmaceutical composition of claim 1, wherein p is 0, 1, 2 or 3, or a pharma- ceutically acceptable salt thereof.
4. Cy is 【Chemistry 4】 and In the formula, R 7 teeth, 【Chemistry 5】 The pharmaceutical composition according to any one of claims 1 to 3,
5. The compound has the formula (XXIVa) or (XXIVb) 【Chemistry 6】 or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3; R 7 teeth, 【Chemistry 7】 The pharmaceutical composition of claim 1 ,
6. The compound has the formula (VIIa), (VIIb), (VIIc), (VIIIa), (VIIIb), (VIIIc), (XXVIa), (XXVIb) or (XXVIc) 【Chemistry 8】 【Chemistry 9】 【Chemistry 10】 2. The pharmaceutical composition of claim 1, wherein the compound is
7. i) R 6a is hydrogen; R 6b is hydrogen; and R 6c is hydrogen; or ii) R 6a is hydrogen; R 6b is hydrogen; and R 6c is methyl or ethyl; or iii) R 6a is hydrogen; Each R 6b is hydrogen; and R 6c is —CH 2 NMe 2 ; or iv) R 6a and R 6b are joined together to form a single bond; and R 6c is methyl; The pharmaceutical composition according to any one of claims 1 to 6.
8. R 6a and R 6b Each of is hydrogen; 6c The pharmaceutical composition of any one of claims 1 to 7, wherein is substituted or unsubstituted alkyl.
9. The compounds have formulas (IXa), (IXb), (IXc), (Xa), (Xb), (Xc) (XIa), (XIb), (XIc), (XIIa ), (XIIb), (XIIc), (XIIIa), (XIIIb), (XIIIc), (XIVa), (XIVb) or (XIVc) 【Chemistry 11】 【Chemistry 12】 【Chemistry 13】 【Chemistry 14】 【Chemistry 15】 【Chemistry 16】 2. The pharmaceutical composition of claim 1, wherein the compound is
10. The compound has formula (XVI) or formula (XVII) 【Chemistry 17】 【Chemistry 18】 2. The pharmaceutical composition of claim 1, wherein the compound is
11. The compound may be represented by formula (XXVIIa), (XXVIIb), (XXVIIc), (XXVIIIa), (XXVIIIb), (XXVIIIc), (XXIXa), (XXIXb), (XXIXc), (XLa), (XLb), (XLc), (XLIa), (XLIb), (XLIc), (XLIIa), (XLIIb), (XLIIc), (XLIIIa), (XLIIIb) or ((XLIIIc) 【Chemistry 19】 【Chemistry 20】 【Chemistry 21】 【Chemical 22】 【Chemistry 23】 【Chemistry 24】 【Chemistry 25】 2. The pharmaceutical composition of claim 1, wherein the compound is
12. The compound is 【Chemistry 26】 or a pharma- ceutically acceptable salt thereof.
13. The compound is Compound 10. 【Chemistry 27】 or a pharma- ceutically acceptable salt thereof.
14. The pharmaceutical composition of claim 1, wherein the compound is any one of the compounds selected from the following: 【Table 1】 【Table 2】 【Table 3】 【Table 4】 【Table 5】 【Table 6】 【Table 7】
15. The pharmaceutical composition of claim 1, which reduces HbA1c by at least 0.5% within one month after administration.
16. The pharmaceutical composition of claim 1, which reduces HbA1c by 1% to 3.5% between the 21st and 29th days after administration.
17. The pharmaceutical composition of claim 1, wherein at least a 1% reduction in HbA1c is maintained sustained even after administration of the drug is discontinued.
18. The pharmaceutical composition of claim 1, wherein at least a 50% increase in C-peptide is maintained after administration of the drug is discontinued.
19. The pharmaceutical composition of claim 1, wherein treatment results in a reduction in cholesterol levels by at least 30% or a reduction in triglyceride levels by at least 50%.
20. The pharmaceutical composition of claim 1, which causes a reduction in HbA1c within 4 weeks of administration.
21. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition also lowers blood glucose levels.
22. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition also increases serum insulin.
23. The pharmaceutical composition described in claim 1, which also increases serum C-peptide levels.
24. A pharmaceutical composition for use in improving glycemic control, comprising: Formula (I) 【Chemistry 28】 or a pharma- ceutically acceptable salt thereof, wherein: A is carbon or nitrogen; Cy is a substituted or unsubstituted 【Chemical 29】 and Q is -N(H)-; Z is -CR 5a = or -N=; X is -NR 3a or -C(R 3b ) 2 -; Y is a single bond, -NR 3a - or -C(R 3b ) 2 -; W is -C(O)- or -S(O) 2 -; one of R 1 and R 2 is Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6C ) or CH 2 -Cy 2 -N(H)C(O)-C(R 6a )=C(R 6b )(R 6C ); the other is hydrogen; Cy 2 is an optionally substituted group selected from phenyl, pyridyl, or a 4-7 membered heterocycloalkyl ring having one nitrogen heteroatom; Each R 3a and R 3b is hydrogen; each R 4a and R 4b is independently hydrogen, fluoro, or methyl; each R is independently hydrogen or an optionally substituted group selected from a C 1-6 aliphatic, phenyl, an 8-10 membered bicyclic aryl ring, a 4-7 membered saturated or partially unsaturated heterocycle having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, and a 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R groups on the same nitrogen together with their intervening atoms form a 4-7 membered saturated, partially unsaturated, or heteroaryl ring having, in addition to the nitrogen, 0-3 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 5a is hydrogen; each R 6a and R 6b is independently hydrogen or C 1-6 alkyl; or R 6a and R 6b together form a bond; R 6c is hydrogen or substituted or unsubstituted C 1-6 alkyl; m is 1, 2 or 3; and n is 1, 2, 3 or 4 Pharmaceutical compositions.
25. The pharmaceutical composition of claim 24, wherein -X-W-Y is N(H)-C(O)-N(H)-, -N(H)-C(O)-CH2-, -CH2-C(O)-N(H)-, -N(H)-S(O)2-N(H)-, -N(H)-S(O)2-CH2-, -CH2-S(O)2-N(H)- or -N(H)-C(O)-.
26. The compound of claim 25, wherein the compound has the formula (XXIIIa), (XXIIIb), (IVa) or (IVb): 【Chemistry 30】 25. The pharmaceutical composition of claim 24, wherein p is 0, 1, 2 or 3, or a pharma- ceutically acceptable salt thereof.
27. Cy is 【Chemistry 31】 and In the formula, R 7 is 【Chemistry 32】 25. The pharmaceutical composition of claim 24, wherein
28. The compound has formula (XXIVa) or (XXIVb) 【Chemical 33】 or a pharma- ceutically acceptable salt thereof, wherein p is 0, 1, 2 or 3; R 7 is 【Chemical 34】 25. The pharmaceutical composition of claim 24, wherein 29. The compound of claim 29, wherein the compound has the formula (VIIa), (VIIb), (VIIc), (VIIIa), (VIIIb), (VIIIc), (XXVIa), (XXVIb) or (XXVIc). 【Chemistry 35】 【Chemical 36】 【Chemical 37】 25. The pharmaceutical composition of claim 24, wherein the compound is
30. i) each of R 6a , R 6b and R 6c is hydrogen; or ii) each of R 6a and R 6b is hydrogen; and R 6c is methyl or ethyl; or iii) each of R 6a and R 6b is hydrogen; and R 6c is —CH 2 NMe 2 ; or iv) R 6a and R 6b form a bond; and R 6c is methyl; 25. The pharmaceutical composition of claim 24.
31. The pharmaceutical composition of claim 24, wherein each of R 6a and R 6b is hydrogen; and R 6c is substituted or unsubstituted alkyl.
32. The compounds have formulas (IXa), (IXb), (IXc), (Xa), (Xb), (Xc) (XIa), (XIb), (XIc), (XIIa ), (XIIb), (XIIc), (XIIIa), (XIIIb), (XIIIc), (XIVa), (XIVb) or (XIVc) 【Chemical 38】 【Chemical 39】 【Chemistry 40】 【Chemistry 41】 【Chemistry 42】 【Chemistry 43】 25. The pharmaceutical composition of claim 24, wherein the compound is
33. The compound has formula (XVI) or formula (XVII) 【Chemistry 44】 【Chemistry 45】 25. The pharmaceutical composition of claim 24, wherein the compound is 34. The compound of claim 34, wherein the compound is represented by the formula (XXVIIa), (XXVIIb), (XXVIIc), (XXVIIIa), (XXVIIIb), (XXVIIIc), (XXIXa), (XXIXb) or (XXIXc), (XLa), (XLb), (XLc), (XLIa), (XLIb), (XLIc), (XLIIa), (XLIIb), (XLIIc), (XLIIIa), (XLIIIb) or (XLIIIc). 【Chemistry 46】 【Chemistry 47】 【Chemistry 48】 【Chemistry 49】 【Chemistry 50】 【Chemistry 51】 【Chemistry 52】 25. The pharmaceutical composition of claim 24, wherein the compound is 35. The compound comprising: 【Chemistry 53】 or a pharma- ceutically acceptable salt thereof. The compound is compound 10. 【Chemical 54】 or a pharma- ceutically acceptable salt thereof.
37. The pharmaceutical composition of claim 24, wherein the compound is any one of the compounds selected from the following: 【Table 8】 【Table 9】 【Table 10】 【Table 11】 【Table 12】 【Table 13】 【Table 14】
38. The pharmaceutical composition described in claim 24, which also lowers blood glucose levels in fasting or non-fasting states.
39. The pharmaceutical composition of claim 24, which also reduces insulin resistance.
40. The pharmaceutical composition described in claim 24, which also increases serum C-peptide levels.
41. The pharmaceutical composition of claim 24, which also increases serum insulin.
42. The pharmaceutical composition of claim 24, which also lowers serum triglycerides.
43. The pharmaceutical composition of claim 24, which also lowers serum cholesterol.
44. The pharmaceutical composition of claim 24, wherein the improvement in glycemic control is sustained even after administration.
